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Chapter 1
General introduction 
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INTRoDUCTIoN
The management and, consequently, the outcome of acute coronary syndromes (ACS) due 
to coronary heart disease have improved impressively over the last decades (1), but ACS or 
myocardial infarction or heart attack in mother tongue, a different condition than cardiac 
arrest, still remains the most important cause of re-hospitalisation, repeat interventions, 
heart failure and death worldwide (1-3). It is estimated that each year, 30,000 people in 
the Netherlands suffer from myocardial infarction, and is in fact a major public health care 
burden. Next to ischaemic heart disease (IHD), thanks to modern medicine, more and 
more patients with congenital heart disease (CHD) reach adulthood, but nonetheless re-
quire lifelong professional care (4, 5). Imaging techniques are essential in these two groups 
of patients for establishing diagnosis, guiding therapy and predicting outcomes. While 
echocardiography remains the first line diagnostic imaging test, with improved functional 
assessment in evaluating ischaemic and congenital heart disease, cardiac magnetic reso-
nance (CMR) and computed tomography (CT) provide valuable information. 
Early reperfusion of the ischaemic myocardium caused by an occluded coronary artery, 
in patients with atherosclerosis, is the cornerstone in the treatment of patients with 
ST-segment elevation myocardial infarction (STEMI). A primary percutaneous coronary 
intervention (pPCI) – defined as an emergent percutaneous catheter intervention in the 
setting of STEMI, without previous fibrinolytic treatment - is the preferred reperfusion 
therapy (6). However a large proportion of patients experience a “no-reflow” phenom-
enon, caused by distal atherothrombotic embolisation, reperfusion injury, ischaemic 
injury or patient characteristics (7). Despite the opening of an infarct related artery, mi-
crovascular obstruction (MO) could persist (8). Although prompt myocardial reperfusion 
with a pPCI has reduced mortality and morbidity, the benefits of pPCI are blunted by 
MO, which prevents full recovery of distal flow (9). No-reflow can be assessed with angi-
ography and ST-segment resolution, and since the 1980’s also with contrast-enhanced 
magnetic resonance imaging (MRI) (10). Magnetic resonance imaging reveals the 
presence and extent of MO, location of the infarction, the size of the infarction (IS%LV), 
oedema and its consequences on regional and global left ventricular (LV) function. The 
reproducibility of these measurements are excellent (11). The technique has become an 
established imaging tool in investigating ischaemic and congenital heart disease. Due 
to end-user driven, technical developments over the past twenty years, it is possible to 
image the beating heart (12). In Figures 1 and 2, an example of the heart visualised with 
MRI is depicted. If used properly with the right sequence protocols, it provides excel-
lent spatial and temporal resolution to investigate cardiac diseases. Moreover, due to 
developments in electrocardiogram (ECG) gating and the introduction of breath-hold 
sequences, disturbing motion artefacts are less likely to occur. As IHD is a consequence 
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of coronary artery disease (CAD) which by itself is importantly triggered by hyperten-
sion, and the prevalence of congenital heart disease (CHD), and the adult population 
with CHD (GUCH) is expected to rise, the contribution of dedicated imaging techniques 
to reduce the impact on these disease on the populations is essential and needs further 
improvement. Many of the quantification techniques investigated in this thesis, can be 
both applied in IHD and CHD.
Late gadolinium enhancement imaging is an important part of infarct size determination, 
and in the evaluation of prognosis in patients with STEMI. This T1-weighted technique (T1 
relaxation describes the recovery of the z-component (Mz) of the magnetisation following 
an RF pulse) is the cornerstone of myocardial tissue characterisation. It is able to dem-
Figure 1. An MRI image of a patient with acute 
myocardial infarction. The compartments of a 
human heart are depicted. Abbreviations: RL: 
right lung, LL: left lung, RA: right atrium, LV: left 
ventricle
Figure 2. An MRI image of a patient with 
acute myocardial infarction. The com-
partments of a human heart are depict-
ed. Abbreviations: RL: right lung, LL: left 
lung, RV: right ventricle, LV: left ventricle, 
RA: right atrium, LA: left atrium, Aod: de-
scending aorta.
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onstrate the presence and extent of myocardial scarring. In brief, a gadolinium-chelate 
contrast agent is administered into an antebrachial vein and diffuses into the extracellular 
myocardial compartment. The gadolinium-chelate accumulates in myocardial scar tissue. 
With T1-weighted imaging the accumulated gadolinium is depicted as a hyperintense sig-
nal (bright) (13). The normal myocardium has a hypointense signal or appears as black. In 
STEMI, a disease due to an occluded coronary artery, the non-vascularised myocardium is 
in a region of ischaemia, lacks oxygen and becomes necrotic. During this process, starting 
from the endocardial border where the oxygen supply is first compromised, myocardial 
muscle cells become necrotic over time. With T1-weighted sequences, end-users are able 
to depict necrotic myocardial tissue. In this necrotic tissue, a dark rim is frequently seen 
and is associated with obstruction of the small arteries, the so-called MO. Figure 3 depicts 
MRI images of a patient with myocardial necrosis. 
Moreover MRI techniques may be applied in resistant hypertension. Hypertension is a known 
risk factor for IHD. There are numerous classes of anti-hypertensive drugs. In case of therapy 
resistant hypertension renal denervation is being used as an experimental therapy to lower 
blood pressure. However, the long term safety of the first generation radiofrequency devices 
used in renal denervation are unknown. MRI can be used to assess vessel patency over time.
Furthermore, MRI may be applied in patients with CHD. The quantification of left and 
right ventricular function is equally important in patients with CHD as in those with 
IHD. Perhaps, especially in the field of CHD, focus on the right side of the heart is of 
eminent importance. Congenital heart disease is a common type of birth defect with a 
prevalence of 8.0 per 1000 births (14). The most common heart defects are ventricular 
septal defect (VSD, 34%), atrial septal defect (ASD, 13%), persistent ductus arteriosus 
(10%), pulmonary stenosis (8%), tetralogy of Fallot (ToF, 5%), coarctation of the aorta 
Figure 3. An MRI (late gadolinium en-
hancement) image of a patient with 
acute myocardial infarction. Notice the 
hyperenhanced, bright signal of the left 
ventricular muscle. The black areas are 
associated with obstruction of the small 
vessels. Abbrevations: RL: right lung, LL: 
left lung, RV: right ventricle, LV: left ven-
tricle, RA: right atrium, LA: left atrium, 
Aod: descending aorta. 
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(CoA, 5%), transposition of the great arteries (TGA, 5%), aortic stenosis (4%) (15). The 
incidence of Wolff-Parkinson-White Syndrome is estimated around 1-3 per 1000 births. 
The population of adult patients with CHD is rapidly expanding due to advances in 
paediatric cardiology and cardiothoracic surgery over the past decades. This results in 
a growing number of adults with CHD with an estimation of 35,000 in the Netherlands 
(16). Although survival has improved, morbidity is substantial. The most common com-
plications in adults with CHD are arrhythmias and heart failure. The risks differ amongst 
the various congenital lesions. While echocardiography remains the first line imaging 
modality with improved functional assessment and emerging techniques to visualise 
the right ventricle (17), CMR is also able to image the right side of the heart and subtle 
changes can be depicted. With emerging sequences, MRI provides excellent possibili-
Figure 5. An example of the heart ex-vivo. Notice 
the white fibrotic area. 
Figure 4. An MRI (late gadolinium en-
hancement) image of a Yorkshire pig 
with a posterolateral myocardial infarc-
tion due to occlusion of the left circum-
flex artery. Notice the white area, with a 
dark rim. 
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ties to image the beating heart. For example, cine gradient echo (GRE) sequences are 
applied to evaluate LV and RV function and dimensions, to measure velocities and flow, 
and to evaluate valvular stenosis or regurgitation. Furthermore, the sequence is useful in 
detection of the Qp/Qs ratio in intracardiac shunting lesions to decide whether there will 
be an indication for therapy, and to visualise conduits in patients with transposition of 
the great arteries (TGA). A four dimensional (4D) flow sequence, to quantify myocardial 
blood flow, is a new kid on the block and is recently introduced.
In this thesis, we apply several MRI techniques in patients with IHD and CHD.
The specific aims of this thesis were to:
• Reduce infarct size and obstruction of the small vessels with bivalirudine and post-
condtioning in patients with STEMI. LV function, infarct size and MO will be measured 
with CMR as surrogate endpoints. 
• Evaluate the hypothesis that MO and infarct size as expressed as a percentage of the 
LV are independent predictors of major adverse cardiovascular events and death in 
patients with STEMI undergoing pPCI. Moreover we evaluate the hypothesis that MO 
and infarct size are predictors for adverse LV remodeling.
• Validate magnetic resonance angiography (MRA) against invasive ultrasound tech-
niques (IVUS), to measure the renal arteries in patients with high blood pressure. 
MRA will be used to evaluate safety of renal denervation, an experimental treatment 
to lower blood pressure.
• Describe the effects of VEGF165A microsphere therapy, an experimental therapy in 
an animal model with a reperfused myocardial infarction. In a second experimental 
study, our aim was to induce diastolic dysfunction in a swine model. We evaluate 
the impact of induction of hypertension, DM and hypercholesterolemia in animal 
experiment, using quantitative MRI techniques.
• Validate a four dimensional (4D) flow sequence to quantify myocardial blood flow 
against echocardiography and 2D phase contrast MRI sequences in patients with 
CHD.
• Count complications in patients with CHD, and describe the complications of pace-
maker therapy in a challenging group of patients with CHD.
Part 2: VALIDATIoN oF NoVeL MRI seQUeNCes AND ITs APPLICATIoN 
Resistant hypertension, or high blood pressure not controlled by medication, is a con-
dition that is associated with the occurrence of IHD (18) and diastolic heart failure. In 
chapter 2, renal artery measurements are validated against intravascular ultrasound 
to select patients for renal denervation out of patients with resistant hypertension. 
The cause of resistant hypertension is multifactorial. Chronic activation of the sympa-
thetic nervous system plays a central role in blood pressure elevation. Reduction of renal 
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sympathetic afferent and efferent activity by catheter-based denervation might lower 
blood pressure. In this thesis, MRA is used to select eligible patients with appropriate 
renal artery anatomy for renal denervation (RDN), a novel experimental procedure to 
disrupt renal artery nerves, in cases of uncontrolled hypertension (19). Figure 6 depicts 
an example of a renal artery as measured by MRI. In chapter 2, intra observer and inter 
observer reproducibility of renal artery dimensions are studied. In chapter 3, short term 
safety of RDN procedures is evaluated with MRA. With emerging sequences, MRI is an 
excellent and unique tool for the diagnosis and follow-up of CHD. Chapter 4 describe 
the research performed in visualisation of blood velocities through the heart and the 
large vessels (Figure 7), the so-called four dimensional flow (4D flow). Four dimensional 
flow MRI refers to phase contrast MR sequence with flow-encoding in all three spatial 
directions, and to the dimension of time along the cardiac cycle. It is a straightforward 
acquisition, and it enables retrospective calculation of blood flow through any plane. 
Four-dimensional flow MRI has enabled more comprehensive access to intra- and extra-
Figure 6. A magnetic resonance angiography 
image of a patient referred for renal denervation. 
Abbreviations: L: liver, S: spleen, Ath: aorta thora-
calis, RRA: right renal artery, RL: right kidney, LR: 
left kidney, Aab: aorta abdominalis.
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cardiac blood fl ow, with typical spatial resolution of 1.5×1.5×1.5 to 3×3×3 mm3, typical 
temporal resolution of 30–40 ms, and acquisition times of 5 to 25 min (20). We evaluated 
4D ﬂow data, and assessed its accuracy for the detection and grading of aortic and 
pulmonary valve regurgitation using transthoracic echocardiography as a reference. 
Part 3: CARDIAC MAGNeTIC ResoNANCe IMAGING IN IsCHAeMIC HeART 
DIseAse TRIALs
The MRI characteristics of an experimental therapy in an animal model with a reperfused 
myocardial infarction are studied. In chapter 5 we describe the eff ects of VEGF165A 
microsphere therapy. Magnetic resonance imaging is used as an endpoint in this study 
(Figures 4 and 5). Chapter 6 covers the application of MRI in diastolic heart disease, a 
condition is known as impaired relaxation of the heart chambers. Predicting the risk 
of heart failure and death after myocardial infarction with use of MRI, and its use in 
cardiovascular trials, has recently become a subject of great interest. In chapter 7 to 
8, in an international meta-analysis of individual patient data, we describe a study that 
evaluated the predictive value of infarct size, MO and LVEF in patients with STEMI on 
the medium term occurrence of cardiac death and major adverse cardiovascular events 
(MACE). In studies of myocardial reperfusion, both in experimental models and in pa-
tients, the realisation that reperfusion injury could exacerbate the eff ects of myocardial 
infarction also came to the fore early on, and the role of MO consequent to reperfusion 
injury has been extensively recognised (21). In chapter 9, we describe in detail how to 
setup a study to investigate the eff ect of postconditioning, an experimental treatment 
of acute myocardial infarction in humans (Figure 8) (22). 
Figure 7. Published with permission from col-
league Saru; an 4D fl ow crossection image of the 
heart. Abbreviations: Ao = aorta ascendens, LV = 
Left ventricle, RV = right ventricle. 
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Part 4: oUTCoMe sTUDIes IN CoNGeNITAL HeART DIseAse
The improved survival in patients with CHD is hampered in the long term in a substantial 
number of patients by sinus node dysfunction, atrial arrhythmias such as atrial fibrilla-
tion and atrioventricular blocks. Many require pacemaker therapy and are subject to 
lifelong need for re-interventions and follow-up (23). In chapters 10 and 11, we inves-
tigated pacemaker therapy in adults with congenital heart disease. In a large cohort, 
peri procedural and late pacemaker complications were studied. Knowledge regarding 
pacemaker therapy is lacking in patients with CHD due to its small population. Therefore 
we set up a multicentre study. 
Figure 8. example of coronary angiography im-
age in a patient with atherosclerosis, landmark 
during primary PCI or dotter treatment (a stent 
could be placed in the occluded artery) during 
myocardial infarction to limit infarct size, the left 
coronary artery is depicted
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Measured by Magnetic Resonance 
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AbsTRACT
Rationale and Objectives - Magnetic resonance angiography (MRA) is a well-established 
modality for the assessment of renal artery stenosis. Using dedicated quantitative 
analyses, MRA can become a useful tool for assessing renal artery dimensions in patients 
referred for renal sympathetic denervation (RDN) and for providing accurate measure-
ments of vascular response after RDN. The purpose of this study was to test the repro-
ducibility of a novel MRA quantitative imaging tool and to validate these measurements 
against intravascular ultra- sound (IVUS).
Materials and Methods - In nine patients referred for renal denervation, renal artery 
dimensions were measured. Bland–Altman analysis was used to assess the intraobserver 
and interobserver reproducibility.
Results - Mean lumen diameter was 5.8 ± 0.7 mm, with a very good intraobserver and 
interobserver variability of 0.7% (reproducibility: bias, 0 mm; standard deviation [SD], 
0.1 mm) and 1.2% (bias, 0 mm; SD, 0.1 mm), respectively. Mean total lumen volume was 
1035.3 ± 403.6 mm3 with good intraobserver and interobserver variability of 2.9% (bias, 
9.7 mm3; SD, 34.0 mm3) and 2.8% (bias, 11.4 mm3; SD, 42.4 mm3). The correlation (Pearson 
R) between mean lumen diameter measured with MRA and IVUS was 0.750 (P = .002).
Conclusions - Using a novel MRA quantitative imaging tool, renal artery dimensions 
can be measured with good reproducibility and accuracy. MRA-derived diameters and 
volumes correlated well with IVUS measurements.
Keywords: Renal artery; percutaneous renal sympathetic denervation; magnetic reso-
nance angiography; intravascular ultrasound.
Validation of renal artery dimensions 31
INTRoDUCTIoN
Percutaneous renal sympathetic denervation (RDN) is currently being studied as a po-
tential treatment to lower sympathetic nerve activity in a broad spectrum of diseases (1, 
2). At present, more than 53 devices are available to disrupt renal afferent and efferent 
nerves traveling along the renal arterial wall. Besides the fact that initial promising, but 
noncontrolled studies on clinical efficacy in patients with therapy-resistant hypertension 
were recently challenged by a negative randomized controlled trial, data on long-term 
safety are mainly limited to the use of the first-generation radiofrequency devices (3-5). 
The currently available data on the incidence of renal artery stenosis, mostly derived 
from duplex ultrasound findings, are showing a low rate of adverse events, both at short 
and longer term follow-up (4-6). Published data from computed angiography (CTA) or 
magnetic resonance angiography (MRA) report only binary outcomes (7), precluding 
firm conclusion on the true vascular response to RDN itself. As new renal denervation 
systems are being introduced, there is a need for dedicated volumetric noninvasive 
imaging tools to accurately assess renal artery integrity at the medium to long term (8). 
Furthermore, balloon-based RDN devices require accurate sizing to avoid complications 
due to oversizing (9). The aim of the present study was to evaluate a new software tool 
allowing automated vessel segmentation for quantitative renal artery lumen dimension 
assessment. Intraobserver and interobserver reproducibility were studied, and MRA-
derived measurements were validated with intravascular ultrasound (IVUS).
MATeRIALs AND MeTHoDs
Patient selection
Nine consecutive patients underwent both MRA and preprocedural IVUS at the time of 
the renal denervation procedure. Because of an early trifurcation in the vessel in one 
patient, automated segmentation with MRA was not successful in one artery. For the 
MRA analyses, 17 vessels were used. For the correlation analyses between MRA and IVUS, 
MRA vessel length was determined and manually adjusted on the basis of the length of 
the IVUS pullback with either the ostium or bifurcation as landmark. Because of a lack of 
IVUS measurement in 1 vessel and a lack of visualization of either bifurcation or ostium, a 
total of 16 arteries in which both MRA and IVUS data were available were used for valida-
tion of MRA against IVUS measurements. The study was approved by the hospital ethics 
committee and conforms to the declaration of Helsinki. All patients provided written 
informed consent before inclusion.
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Magnetic Resonance Angiography Acquisition
MRA was performed on a 1.5T MRI scanner (Discovery MR450; GE Medical systems, Mil-
waukee, WI). Patients were positioned in supine position, and an eight-channel cardiac 
coil was placed on the thorax and upper abdomen. A dedicated RDN-MRI protocol was 
used. As part of this MRI protocol, a three-dimensional (3D) Vasc Fast time of flight (TOF) 
spoiled gradient-echo sequence was used to acquire images of the renal vasculature, 
after a test bolus procedure. Images were acquired during a breath-hold. The following 
parameters were used: field of view, 46 cm 41.4 cm; matrix, 320 x 192, upsampled to 
512 x 512; number of excitations, 0.75; pixel size, 0.89 x 0.89 mm; flip angle, 17 ; slice 
thickness, 1.6 mm; location per slab, 28 upsampled to 56 with ZIP2; repetition time, 3.2 
milliseconds; echo time, 1.2 milliseconds; band- width, 83.33 Hz. Approximately, 20 sec-
onds was the duration of the breath-hold, depending on the locations per slab. A power 
injector (Medrad Spectris, Warrendale, PA) was used to inject gadobutrol (Gadovist 1.0 
mmol/mL; Bayer, Mijdrecht, The Netherlands). Gadovist was injected, around 18 seconds 
before acquisition, with a dose of 0.1 mmol/kg into an antecubital vein followed by 15 
mL of saline at a rate of 2.5 mL/s to visualize the renal arteries.
MRA Analysis
Renal arteries were analyzed with CAAS MRA version 1.0 (Pie Medical Imaging B.V, 
Maastricht, The Netherlands). The segmentation was initialized by placing four delimiter 
points on the volumetric rendered contrast-enhanced MRA view; root delimiter point at 
the thoracic aorta, abdominal aorta, and finally two points distal of the bifurcation of the 
renal artery (Supplementary Figure 1). Ray tracing was used to extract the 3D position 
of the user-defined delimiter points within the rendered volume. The acquired position 
was centralized within the lumen by image processing techniques. The 3D segmenta-
tion used a deformable model algorithm (10) that iteratively optimized the location of 
the surface to- ward the luminal border based on image gradients while simultaneously 
maintaining local smoothness of the 3D segmented surface. After segmentation, the 
center lines of the 3D segmentation were extracted as the minimum path of maximal 
inscribed spheres from the root delimiter point to the distal delimiter points (11). Within 
this process, the diameter of the spheres resembled the minimum diameter along the 
center line of the 3D segmentation (Supplementary Figure 2). The ostium and bifurca-
tion of the renal arteries were automatically detected, by generation of a polygon of 
confluence (POC) (12). The center line splits in the POC from the proximal main vessel 
splits in the renal artery and the bifurcation of the renal artery. Outside the POC, the 
cross-sectional area was defined perpendicular to the lumen wall along each position 
of the center line. Based on the cross-sectional area, the lumen diameter was defined 
as the equivalent diameter on the basis of the assumption of circularity. For analysis, 
the arteria renal was selected, which is the single vessel segment between the ostial 
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POC and the bifurcation POC. In case of failure of this method, only the bifurcation of 
the renal artery was selected manually. The automatically segmented arteries were in-
spected, and borders were manually corrected if necessary in the stretched multi- planar 
rendering and perpendicular view. Vessel length of the renal arteries was defined as the 
distance between the automatically defined ostium and bifurcation of the renal artery 
(Fig 1). Minimal lumen diameter, mean lumen diameter, and total lumen volume were 
based on semiautomatic segmentation. To compare and validate MRA with IVUS, images 
were matched and MRA dimensions were measured again with use of IVUS references. 
IVUS-derived borders were used as a reference. To be able to validate the MRA volu-
metric measurements with IVUS, the segment of interest was matched by using either 
the ostium or bifurcation of the renal artery as a landmark. MRA borders were adjusted 
according to the vessel length measured with IVUS. In this way, we were able to validate 
the volume measurements of the renal artery segment between MRA and IVUS.
IVUs Acquisition
Renal arteries were examined with an IVUS system with automatic pullback at 0.5 mm/s 
(Atlantis SR Pro Imaging Catheter; Boston Scientific, Natick, MA) before renal denervation 
in all vessels. Spatial resolution was 100 μm. A total dose of 200 μg of nitrates was locally 
administered before invasive imaging to prevent catheter-induced spasm. Retrieved 
IVUS images were digitally stored and analyzed offline.
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Figure 1 
(a) Example  renal artery  measured with MRA. (b) Typical longitudinal cross-section of an analyzed renal 
artery. Blue lines represent renal artery borders. The pink line can be manually moved to mea- sure  
luminal dimensions at  a  specific cross  section. Orange lines represents reference lines for stenosis 
measurements. MRA, magnetic resonance angiography. 
 
 
 
 
 
 
 
 
 
Figure 1. (a) Example renal artery measured 
with MRA. (b) Typical longitudinal cross-
section of an analyzed renal artery. Blue lines 
represent renal artery borders. The pink line 
can be manually moved to mea- sure lumi-
nal dimensions at a specific cross section. 
Orange lines represents reference lines for 
stenosis measurements. MRA, magnetic res-
onance angiography.
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IVUs Analysis
Volumetric analysis of the region of interest was performed at 0.5-mm fixed intervals 
throughout the segment between the renal artery ostium and the first major bifurcation 
using dedicated software (QCU-CMS, LKEB, Leiden University, The Netherlands). In cases 
where the guiding catheter was located deeper than the anatomic renal artery ostium 
or that the first major bifurcation was not visualized, IVUS analysis was per- formed in 
the entire pullback. In analyzed frames, the lumen contour was segmented with the help 
of a semiautomatic algorithm, using manual corrections where necessary (Fig 2). As in 
MRA, mean diameter was calculated in each frame by the lumen area, as the equivalent 
diameter based on the assumption of circularity.
statistical Analysis
Continuous data with normal distribution are presented as mean standard deviation 
(SD). Bland–Altman plots were drawn to assess intraobserver and interobserver vari-
ability of MRA and IVUS measurements. Intraobserver and interobserver variability was 
calculated as the absolute value of the difference between two measurements divided 
by the average value of the pairs of interest. Associations of MRA measurements with 
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Figure 2.   lntravascular ultrasound renal  artery.  Black  line represents intravascular ultrasound 
catheter. White band is guidewire artifact.  Red  line represents the lumen  area. Green  line 
represents the external elastic membrane. ROl, region of interest. 
Figure 2. lntravascular ultrasound renal artery. 
Black line represents intravascular ultrasound 
catheter. White band is guidewire artifact. Red 
line represents the lumen area. Green line repre-
sents the external elastic membrane. ROl, region 
of interest.
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IVUS measurements were estimated with the Pearson correlation coefficient. Paired t 
tests were performed to test significant differences between the means values for MRA 
and IVUS measurements. Statistical analyses were per- formed using the IBM SPSS Sta-
tistics, version 20.0.01 (SPSS, Chicago, IL). Bland–Altman plots were made with GraphPad 
PrisM version 4.00 (GraphPad Software Inc, La Jolla, CA).
ResULTs
segmentation Algorithm and Renal Artery Dimensions
In nine patients, 17 renal arteries were analyzed to study intra- observer and interob-
server reproducibility. In three renal arteries by observer 1 and in 3 renal arteries by 
observer 2, the bifurcation was selected manually. The segmentation was not possible in 
two matched renal arteries. Minimum lumen diameter, mean lumen diameter, and total 
lumen volume measured by MRA and IVUS are summarized in Table 1 and Supplemen-
tary Tables 1 and 2.
Intraobserver Reproducibility MRA
Mean minimum lumen diameter was 5.1 ± 0.8 mm. Bias of minimum lumen diameter 
was 0 mm; standard deviation (SD) of bias, 0.1 mm (95% limits of agreement, 0.1 to 0.1 
mm). Intraobserver variability was 0.8%. Mean lumen diameter was 5.8 ± 0.7 mm. Bias 
of mean lumen diameter was 0 mm; SD of bias, 0.1 mm (95% limits of agreement) -0.1 
to 0.1 mm). Intraobserver variability was 0.7%. Mean vessel length was 39.4 ± 12.3 mm. 
Bias of vessel length was 0.1 mm; SD of bias, 1.2 mm (95% limits of agreement, -2.2 
to 2.4 mm). Intraobserver variability was 2.5%. Mean total lumen volume was 1035.3 ± 
403.6 mm3. Bias of total lumen volume was -9.7 mm3; SD of bias, 34.0 mm3 (95% limits 
of agreement, -76.4 to 57.0 mm3). Intraobserver variability was 2.9%. Bland-Altman plots 
are shown in Figure 3.
Table 1. Renal Artery Dimensions After Adjustments with IVUS Ref
Parameter
MRA, 
Mean ± SD; 
n = 14 
MRA 
Range
IVUS,
Mean ± SD;
n = 14
IVUS 
Range P value
Minimum lumen diameter (mm) 5.2 ± 0.7 4.1-6.4 5.2 ± 0.7 4.2-6.7 0.947
Mean lumen diameter (mm) 5.8 ± 0.7 4.6-7.1 5.9 ± 0.6 4.7-7.0 0.485
Total lumen volume (mm3) 861.9 ± 407.3 406.2-1687.2 902.9 ± 369.4 471.3-1527.5 0.248
IVUS, intravascular ultrasound; MRA, magnetic resonance angiography; SD, standard deviation. A paired t 
test is used to test differences between the mean values for MRA and IVUS
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Interobserver Reproducibility MRA
Mean minimum lumen diameter was 5.0 mm ± 0.8 mm. Bias of minimum lumen 
diameter was 0.1 mm; SD of bias, 0.3 mm (95% limits of agreement, -0.5 to 0.7 mm). 
Inter-observer variability was 3.2%. Mean lumen diameter was 5.7 ± 0.7 mm. Bias of 
mean lumen diameter was 0 mm; SD of bias, 0.1 mm (95% limits of agreement, -0.2 to 
0.3 mm). Interobserver variability was 1.2%. Mean vessel length was 39.8 ± 12.0 mm. Bias 
of vessel length was -0.9 mm; SD of bias, 2.8 mm (95% limits of agreement, -6.4 to 4.6 
mm). Interobserver variability was 2.8%. Mean total lumen volume was 1041.0 ± 397.1 
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Figure 3.  Bland-Altman plots  of minimum lumen diameter (a), mean lumen  diameter (b),  vessel  
length (c),  and  total  lumen  volume  (d) of the renal arteries measured by mag- netic  resonance  
angiography. Dotted  lines show 95% limits of agreement. 
Figure 3. Bland-Altman plots of minimum lumen diameter (a), mean lumen diameter (b), vessel length (c), 
and total lumen volume (d) of the renal arteries measured by mag- netic resonance angiography. Dotted 
lines show 95% limits of agreement.
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mm3. Bias of total lumen volume was -11.4 mm3; SD of bias, 42.4 mm3 (95% limits of 
agreement, -94.5 to 71.7 mm3). Interobserver variability was 2.8%. Bland-Altman plots 
are shown in Figure 4.
Validation of MRA Dimensions Against IVUs
Mean vessel length measured with MRA was 32.3 ± 11.4 and measured with IVUS 32.8 ± 
11.4. Mean minimum lumen diameter was 5.2 ± 0.7 mm. Bias of minimum lumen diam-
eter was 0 mm; SD, 0.5 mm (95% limits of agreement, -0.9 to 0.9 mm). Minimum lumen 
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Figure 4.   lnterobserver  variability magnetic resonance angiography (MRA). Bland-Altman plots  of 
mini- mum lumen diameter (a), mean lumen  diameter (b),  vessel  length (c), and  total  lumen  volume  
(d) of the   renal   arteries  measured   by MRA. Dotted  lines show  95%  limits of agreement. 
Figure 4. lnterobserver variability magnetic resonance angiography (MRA). Bland-Altman plots of mini- 
mum lumen diameter (a), mean lumen diameter (b), vessel length (c), and total lumen volume (d) of the 
renal arteries measured by MRA. Dotted lines show 95% limits of agreement.
38 Chapter 2 
diameter measured by MRA was correlated with minimum lumen diameter measured 
by IVUS (R value, 0.771; P = .001). Mean lumen diameter was 5.8 ± 0.6 mm. Bias of mean 
lumen diameter was -0.1 mm; SD, 0.5 mm (95% limits of agreement, -1.1 to 0.9 mm). 
Mean lumen diameter measured by MRA was correlated with mean lumen diameter 
measured by IVUS (R value, 0.750; P = .002). Mean total lumen volume was 882.4 ± 383.6 
46
Figure 5 
 
Figure 5.   Bland-Altman  plots   of minimum     lumen     diameter    (a), mean lumen diameter (b), and  
total lumen   volume   (c)  in  mm3   of  the renal   arteries measured  by  mag- netic   resonance 
angiography and intravascular ultrasound. Dotted lines show 95% limits of agreement 
Figure 5. Bland-Altman plots of minimum lumen diameter (a), mean lumen diameter (b), and total lumen 
volume (c) in mm3 of the renal arteries measured by mag- netic resonance angiography and intravascular 
ultrasound. Dotted lines show 95% limits of agreement
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mm3. Bias of total lumen volume was -40 mm ; SD, 126.7 mm3 (95% limits of agreement 
-289.4 to 207.5 mm3 ). Total lumen volume measured by MRA was correlated with the 
IVUS measurement (R value, 0.951; P < .001). Bland-Altman and correlation plots are 
shown in Figures 5 and 6.
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Figure 6
Figure 6.   Correlation of MRA dimensions with IVUS. Correlation of minimum  lumen  diameter (a), 
correlation of mean lumen  diameter (b), correlation of total lumen volume (c). MRA, magnetic 
resonance angiography; IVUS, intravascular ultrasound. 
Figure 6. Correlation of MRA dimensions with IVUS. Correlation of minimum lumen diameter (a), correla-
tion of mean lumen diameter (b), correlation of total lumen volume (c). MRA, magnetic resonanc  angiog-
raphy; IVUS, intravascular ultrasound.
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DIsCUssIoN
Our study demonstrates that quantitative MRA can measure the renal artery dimen-
sions (vessel length, minimum lumen diameter, mean lumen diameter, and renal 
artery volumes) reproducibly and with good intraobserver and interobserver variability. 
Intraobserver variability using semiautomatic MRA analysis was excellent for minimum 
lumen diameter and mean lumen diameter (0.8% and 0.7%, respectively). For vessel, 
length and total lumen volume was slightly higher but were still well (2.5% and 2.9%, 
respectively). Interobserver variability was excellent for minimum lumen diameter and 
mean lumen diameter (3.2% and 1.2%, respectively) and good for vessel length and total 
lumen volume (2.8% and 2.8%, respectively).
MRA Technique
Automatic analysis of MRA and CTA (13-15) has been developed over the last years. The 
described quantitative MRA software requires minimal of user interaction to select the 
vessel segment of interest. By standardizing marker points for ostium and bifurcation 
identification, the used algorithm achieves excellent reproducibility which is important 
when baseline and follow-up imaging have to be compared. As well as CTA, renal duplex 
ultrasound, and invasive renal angiography, MRA is widely used for the detection of RAS 
(16). The advantage of MRA is that it does not require the use of ionizing radiation or 
iodinated contrast material that are required by CTA (17, 18), nor is MRA hampered by a 
higher body mass as may the case with duplex ultrasound. Various magnetic resonance 
imaging techniques have been developed to visualize the aorta and its branches, in-
cluding ‘‘black blood’’ sequences, 2D and 3D TOF methods, phase-contrast techniques, 
and 3D contrast-enhanced methods using a gadolinium-based agent (19). The most 
commonly used sequences are the 2D TOF MRA and 3D contrast-enhanced methods. 
Nevertheless, the quality of the images in MRA depends on proper breath-hold and 
accurate timing of the contrast bolus. MRA cannot be performed in patients with im-
planted devices or claustrophobia.
Validation with IVUs
To the best of our knowledge, this is the first study validating MRA measurements of the 
renal arteries against IVUS measurements. Because of difficulties in engaging the tip of 
the IVUS catheter beyond the first large renal artery bifurcation (53% of the cases) and 
inability to fully visualize the ostium of the renal artery due to engagement of the tip of 
the guiding catheter (47%), IVUS pullback length was on average 5.9 mm shorter than 
the length of renal artery as assessed by MRA. To be able to validate the MRA volumetric 
measurements with IVUS, the segment of interest was matched by using either the 
ostium or bifurcation of the renal artery as a land mark. In this way, we were able to 
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validate the volume measurements of the renal artery segment between MRA and IVUS. 
Quantitative MRA renal artery measurements correlated well with IVUS, with a Pearson 
R > 0.5 for all measurements. MRA slightly underestimated vessel dimensions compared 
with IVUS, but the mean differences were small and not significant. One potential cause 
could have been the use of perprocedural intra-arterial nitrates directly before the IVUS 
pullback.
Clinical Applicability
Noninvasive quantitative measurements of renal artery dimension might be useful in 
preprocedural planning. The significance of the proper assessment of luminal dimen-
sions has been demonstrated by recent data showing that oversizing with balloon-based 
RDN devices significantly increases the risk of intimal dissections of the renal artery as 
detected by OCT. Particularly, the measurement of minimum lumen diameter can be 
helpful in helping the treating physician in selecting the proper device and especially in 
selecting the balloon size to avoid oversizing (9). MRA may thus be important to the se-
lection of patients for RDN procedure. Quantitative MRA analyses might allow accurate 
follow- up of renal arteries after renal artery interventions, allowing precise estimates 
of the vascular lumen and possible stenoses. The latter supports the use of MRA over 
duplex ultrasound, which is known to be highly operator dependent and which has a 
diagnostic accuracy in detecting stenosis that ranges from 60% to 90% (20). MRA, in 
contrast, has a sensitivity of 93% and specificity of 91% to detect renal artery stenosis 
compared with digital subtraction arteriography with invasive measurements (21). Cur-
rent rates of stenosis after RDN depend strongly on the definitions and the methods of 
follow-up. For example, the Symplicity HTN-3 trial (which used the Medtronic Symplicity 
Flex RDN system) showed that the occurrence of RAS (defined as >70%) was low (1 of 
332 [0.3%]) within 6 months after renal denervation. Conversely, an emerging number 
of case reports have been published on RAS related to RDN (22-24), and recent data on 
the use of optical coherence tomography after RDN showed dissections in up to 35% 
of the arteries (9). In our study, MRA measurements demonstrated a low intraobserver 
variability of 0.8% for minimum lumen diameter, 2.9% for total lumen volume, and low 
interobserver variability of 3.2% for minimum lumen diameter, and 2.8% for total lumen 
volume. This allows the assessment of changes well in the range of a 10–40% change 
in luminal dimensions that might be clinically relevant at the long term. This dedicated 
quantitative analyses software requires minimal user input and might help to examine 
subtle changes renal artery integrity after RDN. The presented technology could help 
to achieve a more ac- curate evaluation of renal artery integrity at the medium- and 
long-term after renal artery interventions, especially in an era with an emerging number 
of newer generation devices.
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Limitations
Our study has several limitations. First, interstudy variability was not tested by perform-
ing repeated MRAs. Second, as we were unable to treat small renal arteries with the 
current generation devices used in our site, patients with a renal artery diameter <4 
mm were not included in this study. Our results might therefore not be applicable to 
arteries <4 mm. A total dose of 200 μg of nitrates was locally administered before IVUS 
to prevent catheter-induced spasm. This might change the artery size and might be an 
explanation for the small differences in renal artery dimensions. The slice thickness of 
1.6 mm without overlap is a limitation of the acquisition but inherent to breath-hold 
period of 20 seconds used in our protocol. Different MRA protocols and interstudy 
repeatability of the renal artery dimension were not tested as we were interested in the 
segmentation algorithm. Another contrast-agent injection on a second day would also 
have been more invasive. A double dose (0.2 mmol/kg) of contrast agent for CE-MRA 
might have an impact on signal intensity (25). We opted for a single dose of contrast 
agent because kidney perfusion was part of the MRI protocol, which requires another 
0.1 mmol/kg of contrast agent.
CoNCLUsIoNs
Renal artery dimensions acquired with MRA can be quantified with good reproducibil-
ity, and these measurements correlated well with IVUS measurements. The software is a 
promising tool to assess changes in renal artery dimension after renal artery interven-
tion and for the selection of the proper device before the procedure.
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AbsTRACT
Aims - renal sympathetic denervation (RDN) is being studied as a therapeutic option 
for patients with therapy resistant hypertension. It remains unclear if the procedure af-
fects the renal arteries in such a way that luminal narrowing might occur at the mid- to 
longer-term. 
Methods & results - In a prospective cohort of 27 patients referred for RDN, quantitative 
magnetic resonance angiography (MRA) was used to assess 52 vessels at baseline, 6-, 
and 12 months post treatment with one out of four different devices. No renal artery 
stenosis was seen at 6 or 12 months. The average mean lumen area was 26,6±7,3mm2 at 
baseline versus 25,0±7.1 and 25,0±6.1 at 6 and 12 months respectively resulting in a late 
loss of 1.6 mm2 at 6 months and 1,9 mm2 at 12 months. No differences were observed in 
the arterial response to RDN with the four different systems used. There was no correla-
tion between post procedural dissections, edema or thrombi as detected with invasive 
imaging and luminal narrowing at follow-up. 
Conclusions - Quantitative MRA of patients treated with RDN revealed no significant 
change in renal artery dimensions up to 12 months follow-up. The lack of a change in re-
nal artery luminal dimensions was irrespective of the arterial response to the individual 
devices used.
Keywords: renal artery, renal artery denervation, MRA, hypertension
CoNDeNseD AbsTRACT
It remains unclear if percutaneous renal sympathetic denervation (RDN), a potential 
treatment for therapy resistant hypertension, might cause luminal narrowing at mid- to 
longer-term. A total of 52 vessels, treated with one out of four different RDN devices, 
were analyzed with quantitative magnetic resonance angiography (MRA) at baseline, 
6 months and 12 months. Renal artery dimension did not change over time. No differ-
ences were observed in the arterial response to RDN with the four different systems 
used. There was no correlation between post procedural arterial damage as detected 
with invasive imaging and luminal narrowing at follow-up. 
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INTRoDUCTIoN
Controlling blood pressure in hypertensive patients remains a challenge for all physi-
cians and treatment targets are usually not achieved despite multiple antihypertensive 
drugs. (1) Percutaneous renal sympathetic denervation (RDN) is currently being studied 
as a potential treatment option in patients with therapy resistant hypertension. The 
indication spectrum is currently even being expanded towards several new indications 
(2-5). At present, over 53 devices are available to dismantle afferent and efferent renal 
nerves in the renal arterial wall. Although the body of evidence supporting the efficacy 
of several of both the 1st and 2nd generation devices is growing, long-term safety data 
is limited(6-8) and mostly restricted to duplex ultrasound findings, showing a low rate 
of adverse events, both at short and longer term follow-up (7, 9). A limited number of 
computed tomography angiography (CTA) or magnetic resonance angiography (MRA) 
follow-up observations revealed an absence of renal artery stenosis at 6 months. (10). 
However, recent high resolution intravascular imaging findings performed directly post 
procedure, demonstrated signs of small thrombi and/or dissections in almost 50% of the 
treated arteries, illustrating that binary outcome parameters of stenosis might not be 
sufficient. (11) The aim of the present study is to accurately assess renal artery integrity 
at the medium to long-term using recently validated quantitative Magnetic Resonance 
Angiography software in patients treated with 4 different RDN devices. (12, 13)
MeTHoDs
Patient selection
We present a prospective study in which a total of 29 patients with therapy resistant 
hypertension, vasospastic angina and/or heart failure underwent RDN at the Erasmus 
Medical Center, Rotterdam, the Netherlands, between December 2012 and Febru-
ary 2014. RDN was performed by one out of four different systems: Symplicity Flex™ 
(Medtronic, Minneapolis, MN), Paradise™ (Recor Medical, Palo Alto, CA), Oneshot™ (Co-
vidien, Campbell, CA), and Vessix V2™ (Boston Scientific, Natick, MA). Two patients were 
excluded because of the implantation of a non-MRI compatible pacemaker at 3 months 
(n=1) and 1 because of a missed follow-up scan (n=1). A total of 27 patients and 52 
vessels were used for the final analyses at baseline and 6 months follow-up (in 2 patients 
only 1 vessel could be analysed at baseline because of insufficient contrast density). For 
the 12 months analyses, 33 vessel remained (MRA imagine quality was insufficient at 
12 months follow-up (N=14), CTA at 12 months follow-up instead of MRA (N=1) and no 
follow-up MRA of 12 months follow-up post at the time of this research (N=4)). 
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Denervation procedure. 
All patients were preloaded with 300mg aspirin, if naïve, and advised to continue with 
aspirin for at least 1 month. Pre-procedurally, 100IU heparin/kg were administered to 
achieve an active clotting time>250s. A total of 200mcg nitrates was locally adminis-
tered before invasive imaging. Procedures were performed according to device-specific 
instructions for use. Additional peri-procedural invasive imaging was performed in 
19 out of the 52 vessels used for the final analysis in the present study. Targeted renal 
arteries were examined with an intravascular ultrasound (IVUS) system with automatic 
pullback at 0.5 mm/s (Boston Scientific, Natick, MA) and optical coherence tomography 
(OCT) using the Illumien or C7XR system and Dragonfly or Dragonfly Duo catheter (all 
Lightlab/St Jude, Minneapolis, MN) as previously described. (11)
IVUs and oCT image acquisition 
Targeted renal arteries were examined with an IVUS system with automatic pullback at 
0.5 mm/s (Boston Scientific, Natick, MA) pre- and post-RDN. Retrieved IVUS images were 
stored and analyzed offline. OCT was performed after RDN. Images were acquired using 
the Illumien or C7XR system and Dragonfly or Dragonfly Duo catheter (all Lightlab/St 
Jude, Minneapolis, MN). The catheter was positioned distally to the examined segment 
(distal to the first major bifurcation) and automatically pulled back at 20mm/sec, acquir-
ing images at 100m/sec, with simultaneous iso-osmolar contrast (Iodixanol 370, Visi-
paque™, GE Health Care, Ireland) administration at a flow rate of 4-6ml/sec, depending 
on artery size. The protocol used for detection of edema, thrombus or dissection using 
both IVUS and OCT has been published previously. (11)
Magnetic resonance angiography acquisition
Magnetic resonance angiography was performed on a 1.5-T MRI scanner (Discovery 
MR450, GE Medical systems, Milwaukee, Wisconsin, USA) at baseline and 6 and 12 
months follow-up according to a dedicated RDN imaging protocol. Patients were 
positioned in supine position and an 8-channel cardiac coil was placed on the thorax 
and upper-abdomen. As part of this MRI protocol, a 3D Vasc Fast TOF Spoiled Gradient 
Echo sequence was used to acquire images of the renal vasculature, after a test-bolus 
procedure. Images were acquired during a breath hold. The following parameters were 
used: field of view: 46 cm * 41.4 cm, matrix; 320 * 192, upsampled to 512 * 512, number 
of excitations; 0.75, pixel size; 0.89 * 0.89 mm, flip angle; 17 degrees, slice thickness; 
1.6 mm, location per slab; 28 upsampled to 56 with ZIP2, repetition time; 3.2 ms, echo 
time; 1.2 ms, bandwidth; 83.33 Hz. The duration of the breathhold was approximately 
20 seconds, depending on the locations per slab. A power injector (Medrad Spectris, 
Warrendale, Pennsylvania, U.S.A.) was used to inject gadobutrol (Gadovist 1.0 mmol/
ml, Bayer, Mijdrecht, the Netherlands). Gadovist was injected, around 18 seconds before 
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acquisition, with a dose of 0.1 mmol/kg ml into an antecubital vein followed by 15 ml of 
saline at a rate of 2.5 ml/s to visualize the renal arteries. 
Magnetic resonance angiography analysis
Quantitative magnetic resonance angiography was performed using dedicated imaging 
software CAAS MRA (Version 1.0, Pie Medical Imaging B.V, Maastricht, the Netherlands) 
according to a predefined algorithm. (13) The automatically segmented arteries were in-
spected and borders were manually corrected if necessary in the stretched multi-planar 
rendering and perpendicular view. Vessel length (mm), minimum lumen diameter (mm) 
mean lumen diameter (mm), minimum lumen area (mm2), mean lumen area (mm2), 
percent diameter stenosis and percent area stenosis were based on semi-automatic 
segmentation (Figure 1). One of the investigators (LZ) performed all of the analyses 
blinded to individual patients characteristics and treatment time.
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Figure 1: case example of a renal artery analysis with the use of CAAS quantitative MRA software. Baseline, 6 
months follow-up and 12 months follow-up are depicted.  
Baseline 6 months follow-up 12 months follow-up
Vessel Length, mm 36,8 35,2 36,8
Minimum lumen diameter, 
mm
4,5 4,3 4,0
Mean lumen diameter, mm 5,2 5,3 5,3
Minimum lumen area, 
mm2
15,6 14,5 12,8
Mean lumen area, mm2 21,6 23,0 22,4
Baseline 6 months follow-up 12 months follow-up
Vessel Length, mm 36,8 35,2 36,8
Minimum lumen diameter, mm 4,5 4,3 4,0
Mean lumen diameter, mm 5,2 5,3 5,3
Minimum lumen area, mm2 15,6 14,5 12,8
Mean lumen area, mm2 21,6 23,0 22,4
Figure 1. Case example of a renal artery analysis with the use of CAAS quantitative MRA software. Baseline, 
6 months follow-up and 12 months follow-up are depicted. 
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statistical analysis
Statistical analyses were performed by using SPSS (version 21.0, SPSS Inc, Chicago Ill). 
Baseline, categorical variables are reported as either counts of percentages and com-
pared using the Chi Squared test. Continuous variables are reported as mean ±SD and 
were compared using a linear mixed model. All continuous variables were normally 
distributed. Categorical variables were reported as either percentages or frequencies. A 
P value < 0.05 was considered statistically significant. Between-device differences were 
examined using analysis of variance (ANOVA). When there was a significant difference 
between groups, the Bonferroni test was used as a post hoc comparison. Since our data 
included multiple observations per patient, crossed random effects modeling was used 
to account for the correlation between observations. (14) Luminal dimensions over time 
were assessed using crossed random effects with two random effects. The first random 
effect was the period (either 6 or 12 months), the second random effect was related to 
the fact whether either 1 or both vessels were assessed in each individual patients. 
ResULTs
Patient demographics and baseline characteristics are depicted in Table 1. Mean age at 
the time of intervention was 64±11 years and 56% of the patients were male. Diabetes 
was present in 26% and 70% of the patients had hypercholesterolemia. Baseline renal 
function was preserved in all patients with a baseline eGFR of 82.5±28.0ml/min/1.73m2. 
Mean office blood pressure (BP) was 176±21/93±17mmHg. Mean ambulatory BP was 
144±14/81±13 mmHg. There was no significant difference between any of the baseline 
characteristics in patients treated with the four different devices used for RDN (table 1). 
Quantitative MRA at baseline an follow-up revealed no renal artery stenosis at either 6 or 
12 months. The average mean lumen area was 26,6±7,3mm2 at baseline versus 25,0±7.1 
and 25,0±6.1 at 6 and 12 months respectively resulting in a late loss of 1.6 mm2 at 6 
months and 1,9 mm2 at 12 months (Table 2). There was no significant increase in the 
area or diameter stenosis over time. By using three different cut-offs for diameter and 
area stenosis (>25%, >50% and >70%), no trend was observed towards an increased 
number of patients with renal artery stenosis over time (Figures 2 and 3). Only 5 out of 
52 vessels showed an absolute increase in percent diameter stenosis > 25% at 6 months. 
If comparing baseline versus 12 months, no vessels were identified with a >25% increase 
in percent diameter stenosis. An absolute increase of > 50% in percent diameter stenosis 
was not observed at either time point in any of the patients. Comparing the differences 
in late loss in vessels treated with balloon (ReCor Paradise, BSc Vessix and Covidien 
OneShot) versus the MDT Symplicity Flex non-balloon based system did not results in 
any significant differences (P=NS for all) (Figure 4). Intravascular imaging using optical 
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Figure 2: % diameter stenosis subdivided in 3 categories 
Figure 2. % diameter stenosis subdivided in 3 categories
Table 2. Quantitative renal artery imaging results at baseline, 6 months and 12 months follow-up (vessel 
analyses)
Variables Baseline 
N=52 
(mean±SD)
6 Months 
follow-up
N=52 
(mean±SD)
12 months 
follow-
up N=33 
(mean±SD) 
P-value
Baseline –
6 months 
follow-up
P-value
Baseline –
12 months 
follow-up
Vessel length, mm 40,3±12,6 40,3±12,7 39,2±12,1 ,693 ,878
Minimum lumen diameter, mm 4,9±0,8 4,7±0,8 4,8±0,7 ,044 ,124
Mean lumen diameter, mm 5,7±0,8 5,6±0,7 5,6±0,7 ,086 ,004
Minimum lumen area, mm2 19,7±6,6 17,9±5,8 18,3±5,6 ,051 ,114
Mean lumen area, mm2 26,6±7,3 25,0±7,1 25,0±6,1 ,088 ,003
Percent diameter stenosis 14,9±9,0 13,2±8,4 12,9±8,4 ,159 ,130
Percent area stenosis 26,9±14,9 23,9±14,4 23,4±14,6 ,175 ,152
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Figure 3. % area stenosis subdivided in 3 categories
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coherence tomography directly post procedure revealed dissections in 6/19 vessels 
(32%) and thrombus in 13/19 vessels (68%). There was no correlation between these 
post procedural signs of vascular traumata and luminal narrowing at 6 or 12 months. 
Renal function slightly decreased over time. Mean baseline eGFR was 82.4ml/min and 
decreased to 77 ml/min/1.73m2at 6 months and 74.9 ml/min/1.73m2at 12 months (p-
value=0.013). Although there was no correlation between late-loss and change in renal 
function at 6 or 12 months, a clear correlation was seen between contrast volume using 
peri-procedural and renal function decline over time. No new cases of renal impairment 
(eGFR<60ml/min) were observed.
DIsCUssIoN 
Using quantitative MRA software we demonstrated an absence of renal artery stenosis 
at 6 and 12 months post procedure. More specifi cally, no decrease in renal artery dimen-
sions post RDN could be found at either 6 or 12 months, irrespective of the device used. 
The present study adds to previous observations reporting on the safety of RDN 
because of 3 reasons. At fi rst, recent studies with a focus on follow-up of renal arteries 6 
month after RDN used duplex ultrasound or occasionally CTA or MRA, and only focused 
on binary outcomes, namely the presence of stenosis or not. Using recently validated 
dedicated quantitative MRA software we were able to more accurately report on the 
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true vascular response of RDN.(13) Second, our study was not limited to the use of a 
single RDN device. Instead, the vascular response to treatment with both balloon and 
non-balloon based devices as well as radiofrequency versus ultrasounds devices was as-
sessed. Third, we were able to extend the safety findings reported at 6 months to 1 year.
The need for a more precise method to assess renal artery dimensions was driven 
by the findings from several recent studies assessing the direct consequences of RDN 
on renal artery integrity.(11, 15, 16) Using dedicated intravascular imaging techniques 
like IVUS and OCT a significant proportion of renal arteries proved to be left with dis-
sections, thrombus and edema, mostly not directly visible on standard post procedural 
angiography. Although in the vast majority of the cases these findings were not linked 
to direct clinical consequences, the effect on long-term vascular integrity and perhaps 
even renal function remains elusive. The importance however of a careful assessment 
of long-term vascular safety has been recently underlined by the report of a European 
expert consensus document on future trial design in renal denervation. (17) 
In a recently published validation study we demonstrated that renal artery dimension 
can be accurately measured using CAAS MRA, with a good intraobserver and interob-
server variability and a good correlation as compared to intravascular ultrasound. (13) 
Quantitative MRA facilitates non-invasive assessment of small changes in renal artery 
luminal dimensions and allowed us to study the correlation between peri-procedural re-
nal artery damage and long-term luminal narrowing. Although we hypothesized that a 
small albeit significant change in luminal dimensions could be due to the cases in which 
the arterial lumen integrity was lost due to small dissections, thrombi and edema, we 
were not able to demonstrate a correlation. Additionally, no differences were observed 
between luminal narrowing at follow-up and the use of either of the individual RDN 
devices used. 
In our study renal function slightly deteriorated over time. Although the technology 
has been previously hypothesized to improve renal function in patients with renal failure, 
the impact of the treatment on renal function over time has been disputed. While some 
single arm studies reported on an improvement in renal function, others demonstrate 
that renal function might slightly deteriorate over time. (18, 19) We further hypothesized 
that luminal narrowing might be responsible for a decrease in renal function. However, 
no correlation was found between the change in luminal dimensions at both 6 and 12 
months follow-up and the change in eGFR. Further scrutinizing the pathophysiology of 
the renal function decline in our cohort revealed a clear correlation with contrast vol-
ume used during the procedure. Due to the learning curve in the initial cases performed 
at our site together with the use of OCT imaging to assess renal artery integrity contrast 
usage was substantially higher in the initial cases. It appears therefore unlikely that the 
RDN procedure itself causes a significant change in renal function over time. 
Follow-up of renal artery dimensions 57
Limitations
The sample size of our study was relatively small, which implicates that the conclusions 
on the inter-device differences should be interpreted with caution. Unfortunately, sev-
eral follow-up scans could not be analyzed adequately due to the suboptimal quality 
of several MRA’s with suboptimal harmonization of contrast delivery and scan time and 
movement- and breathing artefacts due to the need for a 20-second breath hold. Also, 
at the time of this study, not all patients reached the 12 months follow-up (N=2). Further 
research should focus on a lager study cohort and extended follow-up duration. 
CoNCLUsIoN
Quantitative MRA of patients treated with percutaneous renal denervation revealed 
no significant decrease in renal artery dimensions at both 6 and 12 months follow-up. 
The lack of a decrease in renal artery luminal dimensions was irrespective of the arterial 
response to the individual devices used.
Funding : None. 
Take home message
Renal artery luminal dimension did not change after treatment with one out of four 
different renal denervation devices when measured using dedicated quantitative MRA 
software. There was no correlation between post procedural arterial damage as detected 
with invasive imaging and luminal narrowing at follow-up.
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AbsTRACT 
Over the past 10 years there has been intense research in the development of volumetric 
visualization of intracardiac flow by cardiac magnetic resonance (CMR). This volumetric 
time resolved technique called CMR 4D flow imaging has several advantages over stan-
dard CMR. It offers anatomical, functional and flow information in a single free-breathing, 
ten-minute acquisition. However, the data obtained is large and its processing requires 
dedicated software. We evaluated a cloud-based application package that combines 
volumetric data correction and visualization of CMR 4D flow data, and assessed its ac-
curacy for the detection and grading of aortic valve regurgitation using transthoracic 
echocardiography as reference. Between June 2014 and January 2015, patients planned 
for clinical CMR were consecutively approached to undergo the supplementary CMR 
4D flow acquisition. Fifty four patients (median age 39 years, 32 males) were included. 
Detection and grading of the aortic valve regurgitation using CMR 4D flow imaging 
were evaluated against transthoracic echocardiography. The agreement between 4D 
flow CMR and transthoracic echocardiography for grading of aortic valve regurgitation 
was good (K = 0.73). To identify relevant, more than mild aortic valve regurgitation, CMR 
4D flow imaging had a sensitivity of 100 % and specificity of 98 %. Aortic regurgitation 
can be well visualized, in a similar manner as transthoracic echocardiography, when 
using CMR 4D flow imaging.
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INTRoDUCTIoN
In the management of valvular heart disease assessment of transvalvular flow by cardiac 
magnetic resonance (CMR) can provide valuable incremental information to echocar- 
diography, either as an alternative imaging modality in patients with poor acoustic 
windows, complex anatomy or for quantification of transvalvular flow. By current CMR 
practices, valvular flow patterns are measured across two-dimensional cross-sections, 
which are manually placed in the position of interest. Over the past 10 years there has 
been intense research in the development of volumetric visualization of intracardiac 
flow by CMR (1). So-called CMR 4D flow imaging offers volumetric anatomical, functional 
and flow information during the entire cardiac cycle. It has several potential advantages 
over standard planar methods (2), including the ability to visualize complex flow pat-
terns, select any plane when evaluating these CMR 4D flow datasets, without being 
limited to preselected planes and with the possibility to adapt the point of evaluation 
to the structural displacement throughout the cardiac cycle. Because all data is acquired 
during an uninterrupted ten-minute free-breathing scan, CMR 4D flow imaging is easy 
to perform and more comfortable for the patient. There are however a number of practi-
cal drawbacks that have prevented CMR 4D flow imaging from reaching the stage of 
widespread clinical implementation. While data acquisition was lengthy in the past, 
parallel imaging techniques (3, 4) have reduced the scan time to ten minutes or less. 
However, processing of the large data and correcting for eddy currents and gradient 
field distortions require dedicated software (5). Previously published experiences were 
achieved by using in-house developed software for volumetric data pre-processing (6-
10). In this proof of concept study we evaluated the feasibility and performance of a 
cloud-based application that combines data pre-processing, including volumetric eddy 
currents correction, and visualization of CMR 4D flow data, and assessed its accuracy 
for the detection and grading of aortic valve regurgitation using echocardiography as 
reference.
MeTHoDs
study population
Between June 2014 and January 2015 adult patients planned for clinical contrast-
enhanced CMR were consecutively approached to undergo the supplemental CMR 4D 
flow examination, and prospectively included in the study principles of the Declaration 
of Helsinki and approved by the institutional Medical Ethics Committee. All participants 
gave written informed consent.
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Cardiac MR examination
The acquisition was performed using a 1.5 T or 3.0 T whole body scanners (Discovery 
MR450 and Discovery MR750, 45 mT/m, 200 T/ms, GE Medical Systems, Milwaukee, WI, 
USA) with a software version DV24.0, using dedicated 32-channel phased-array cardiac 
surface coils. Depending on the clinical request a variety of CMR examinations were 
performed including multi-planar cine steady-state free precession acquisitions, flow vi-
sualization using phase contrast sequence, contrast-enhanced angiography or delayed 
enhancement imaging.
CMR 4D flow data acquisition
The CMR 4D flow data was acquired immediately, or shortly after the bolus injection of 
0.1-0.2 mmol/kg gadolinium-based contrast agent (Gadovist 1 mmol/ml, Bayer, Mijdre-
cht, The Netherlands), depending on the clinical indication for contrast administration. 
The sequence was prescribed in the axial plane, with a matrix of 192 x 144 and 2.8 mm 
slices interpolated to 1.4 mm slices, while the entire thorax was included in the field 
of view during a free-breathing, ECG gated scan. Patients were also asked to breath 
regularly during the acquisition. The median views per segment was 4 and the median 
repetition time was 3.9 ms, resulting in a temporal resolution of 63 ms. When necessary, 
the views per segment and temporal resolution were adapted to limit the scan duration 
to approximately ten minutes (Table 2). Following recommendations from literature, the 
velocity encoding value was set at 250 cm/s, which is a good compromise for the 4D flow 
to allow acquiring low and high velocities simultaneously (11).
Remote CMR 4D flow data correction, reconstruction and analysis
Because CMR 4D flow imaging is a phase contrast sequence, similar to planar flow 
acquisitions, magnitude images for anatomic information as well as images containing 
flow information may be reconstructed from the data. These large unreconstructed raw 
data sets (approximating 5 Gb per patient) were uploaded to a dedicated web-based 
software application (Arterys Inc., San Fran- cisco, CA, USA) for data correction, visualiza-
tion of the anatomical and flow components, and evaluation of the aortic regurgitation. 
As previously described (6), images were reconstructed for each cardiac temporal phase 
with a combined auto calibrating parallel imaging compressed sensing algorithm (L1-
SPIRIT). Data was processed using large servers (Amazon Inc., Seattle, WA, USA). They are 
equipped with high frequency processors (Intel Xeon E5-2670, Intel Corporation, Santa 
Clara, CA, USA) and high- performance graphics processing units (NVIDIA Corporation, 
Santa Clara, CA, USA). The user logged into the application via internet connection from 
any type of computer or other device. Before the data sets were analyzed, the user could 
semi-automatically correct the images for encoding errors related to gradient field 
distortions and eddy currents. This approach is based on defining a threshold to identify 
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regions with static tissue. These were then used to estimate eddy current induced vary-
ing phase offset errors, which were subsequently subtracted from the entire image (12). 
Once the post-processing was complete and eddy currents correction performed the 
software facilitated interactive, real-time, manual navigation through the imaging vol-
ume using perpendicular multi- planar reformations and volume rendered reconstruc-
tions. The data could be reformatted into planes representing specific regions of interest 
(Fig. 1; Video 1). Flow could be displayed by color-coding of the velocity information 
or by vector rendering to display flow direction. For a red color on the color scale, a 
threshold of 150 cm/s was set.
evaluation of aortic valve function by CMR 4D flow imaging
The aortic valve was localized within the three dimensional anatomical dataset and 
displayed on three cross-sectional views that are perpendicular to each other. Using the 
cine display mode with superposition of flow onto the anatomy, the data was screened 
for the presence of reversed flow from the aortic valve during diastole. Identification of 
suspected aortic regurgitation was then evaluated using a temporally frame-by-frame 
approach. Because the velocity-based color- coded display of flow lacks directional 
information, the vector arrow display was used for confirmation (Fig. 1). Aortic valve 
regurgitation was defined as mild, moderate or severe. The grading criteria were 
adapted from echocardiographic recommendations (13, 14) using only the parameters 
available for both echocardiography and CMR 4D flow imaging: the ratios between the 
width of regurgitant jet and of the left ventricle outflow tract, and between the length 
of the regurgitant jet and of the left ventricle and the presence of reversal flow during 
diastole at the level of the descending aorta (Table 3). Two blinded readers (RGC and KN 
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Figure 1 
 
Figure 1:  Aortic valve visualization with CMR 4D  flow imaging. Short (a)  and long-axis (b)  cross-sectional 
views of the  left  ventricular outflow tract depicting systolic flow across the aortic valve. Because velocity-
based color-coding lacks directional information, superimposed vectors display is used for confirmation of flow 
direction (c). The color scale can be manually modified as in this example where low velocities are displayed in 
dark blue color and equal or higher than 150 cm/s are displayed in red color. lv left ventricle, ao aorta 
Figure 1. Aortic valve visualization with CMR 4D flow imaging. Short (a) and long-axis (b) cross-sectional 
views of the left ventricular outflow tract depicting systolic flow across the aortic valve. Because velocity-
based color-coding lacks directional information, superimposed vectors display is used for confirmation 
of flow direction (c). The color scale can be manually modified as in this example where low velocities are 
displayed in dark blue color and equal or higher than 150 cm/s are displayed in red color. lv left ventricle, 
ao aorta
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with 4 and 7 years of CMR experience, respectively) independently assessed each case 
and graded aortic regurgitation. A joint consensus reading served to solve discordant 
interpretations.
evaluation of aortic valve function by echocardiography
Two-dimensional transthoracic Doppler echocardiography was performed using a com-
mercially available system (IE33, Philips Medical Systems, Best, The Netherlands). The 
gain settings were adapted to the patient’s characteristics to obtain the best quality of 
color Doppler. Because usually in aortic regurgitation the velocities are higher than 2 
m/s, it is not possible to correct for aliasing phenomenon even by changing the aliasing 
velocity settings. Thus practically aliasing is always present. We set the aliasing velocity 
at 1.2 m/s. Blinded to the CMR 4D flow imaging results, echocardiography images were 
independently evaluated by two cardiologists (AvdB and JR-H with 15 and 23 years of 
echocardiography experience, respectively), followed by a consensus reading. The pres-
ence of aortic regurgitation was graded using the same criteria as described above for 
the CMR 4D flow imaging. Because our paper focusses on the technical validation of 4D 
flow imaging we only considered parameters that could be assessed by both techniques.
statistical analysis
Statistical analysis was performed using SPSS (version 21 IBM, Armonk, NY, USA) and 
MedCalc (version 13.0; MedCalc Software, Ostend, Belgium). Categorical variables were 
reported as totals and percentages and continuous variables with a normal distribution 
as means ± standard deviations (SDs), or if data was skewed, as median with interquar-
tile range. The diagnostic characteristics of CMR 4D flow imaging were evaluated against 
echocardiography by using C-statistics, including sensitivity, specificity, positive predic-
tive value, negative predictive value with their corresponding 95 % confidence intervals 
(CIs), accuracy and Cohen’s kappa agreement test.
ResULTs
Out of 59 eligible patients, the scan failed in five because of insufficient data storage 
capacity on the MR scanner, leaving 54 patients for inclusion in the study. Median age 
of the population was 39 years (range 18-76), 32 were males and 46 % were known with 
congenital heart disease (Table 1). 69 % were scanned on 1.5 T and 31 % on 3.0 T MR 
scanner. No patients were excluded due to poor image quality of CMR 4D flow imaging 
or echocardiography. The median time between echocardiography and CMR 4D flow 
acquisition was 2 months.
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Performance of CMR 4D flow imaging
The correction and visualization of the CMR 4D flow data and interpretation of aortic 
regurgitation required 10-15 minutes per patient. The agreement between CMR 
4D flow imaging and echocardiography for the grading of regurgitation was good 
(K = 0.73; Table 4). Representative case examples are shown in Figs. 2, 3 and Video 2. 
Table 1. Baseline characteristics of the study population
Characteristic
Age (years)a 39 ± 15
Male gender 32 (59)
Body mass index (kg/m2)a 24.7 ± 5.2
Heart rate (beats/min)b 66 (48 - 208)
Sinus rhythm 51 (94)
Systolic blood pressure (mmHg)a 124 ± 14
Diastolic blood pressure (mmHg)a 77 ± 10
Clinical history
Congenital heart disease 25 (46.2)
Aortic valve stenosis (corrected) 4 (7.4)
Atrial septum defect 2 (3.7)
Bicuspid aortic valve 7 (12.9)
Coarctation – corrected 1 (1.8)
Marfan syndrome 1 (1.8)
Pulmonary valve stenosis – corrected 3 (5.5)
Tetralogy of Fallot – corrected 1 (1.8)?
Turner Syndrome 4 (7.4)
Ventricular septal defect (closed) 1 (1.8)
Cardiomyopathies (CMP) 26 (48.1)
Anthracyclines induced CMP 1 (1.8)
Amyloidosis 1 (1.8)
Dilated CMP 4 (7.4)
Hypertrofic CMP 13 (24)
Non-compaction CMP 4 (7.4)
Sarcoidosis 3 (5.5)
Other 3 (5.5)
Heart transplant 1 (1.8)
Hypertension 1 (1.8)
Post-cardiac arrest 1 (1.8)
Unless otherwise specified, data are numbers of patients, with percentages
in parentheses
a Data are means ± standard deviations
b Medians with minimum and maximum values
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By CMR 4D flow imaging all four patients with moderate and 9 out of 15 patients with 
mild regurgitation were correctly identified. One case of mild regurgitation by echo-
cardiography was interpreted as moderate by CMR 4D flow, and in 1 out of 35 cases 
CMR 4D flow identified mild regurgitation while echocardiography showed none. For 
the detection of any regurgitation, CMR 4D flow imaging demonstrated specificity of 97 
% (95 % Cl: 85-99 %), sensitivity of 74 % (Cl: 49-91 %), positive predictive value of 93 % 
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Figure 2:  Aortic regurgitation by echocardiography and CMR 4D  flow imaging. Case example of a 19-year-old 
man after balloon dilatation of the aortic valve for congenital aortic stenosis. Panel a Parasternal long  axis  view  
of  aortic  valve  in  diastole,  showing  moderate regurgitation (asterisk) demonstrated with color-flow 0oppler 
echocardiography.  Panels b and  c  Corresponding  CMR  4D   flow images showing the moderate aortic 
regurgitation. Asterisk regurgitant jet, Iv left ventricle, ao aorta 
Figure 2. Aortic regurgitation by echocardiography and CMR 4D flow imaging. Case example of a 19-year-
old man after balloon dilatation of the aortic valve for congenital aortic stenosis. Panel a Parasternal long 
axis view of aortic valve in diastole, showing moderate regurgitation (asterisk) demonstrated with color-
flow 0oppler echocardiography. Panels b and c Corresponding CMR 4D flow images showing the moderate 
aortic regurgitation. Asterisk regurgitant jet, Iv left ventricle, ao aorta
Table 2. Imaging parameters of the CMR 4D flow acquisition
Imaging parameter Value
Repetition time (ms)c 3.9
Echo time (ms)c 1.5
Flip angle (degrees) 15
Acquired matrix size 192 x 160 x 78
Reconstructed matrix 256 x 256 x 156
Acquired spatial resolution (mm) 1.77 x 2.12 x 2.80
Reconstructed spatial resolution (mm) 1.33 x 1.33 x 1.40
Views per segmenta 4 (3-5)
Temporal resolution (ms)b 62.8 (51 - 65)
Velocity encoding 250 x 250 x 250
Sampling Poisson
Accelerationc 2.0 x 2.0 
Median scanning duration (min.s)b 8:52 (7.37 – 9:50)
A Medians with minimum and maximum values
B Medians with interquartile range in parenthesis
C Medians
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(Cl: 68-99 %) negative predictive value of 87 % (Cl: 73-96 %), accuracy of 88 % and K = 
0.74. To identify clinically relevant, more than mild regurgitation, CMR 4D flow imaging 
had sensitivity of 100 % (Cl: 40-100 %), specificity of 98 % (Cl: 89-100 %), positive predic-
tive value of 80 % (Cl: 29-97 %) and negative predictive value of 100 % (Cl: 92-100 %), 
accuracy of 98 % and excellent agreement with echocardiography K = 0.88.
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Figure 3
Fig. 3  Mild aortic regurgitation and intracardiac shunt. A 47-year-old man post aortic valvotomy and Ross 
procedure for congenital aortic stenosis. Panel a Three chamber view with color-flow Doppler 
echocardiography showing a small aortic regurgitant jet (asterisk). Panel b Doppler echocardiography imaging, 
apical four chamber view, zoomed in on the basal septum and the right atrium; color flow through a typical 
Gerbode defect (arrows). Panels C and D CMR 4D  flow imaging with corresponding views of the mild aortic 
regurgitation and the subvalvular, ventriculo-atrial jet, respectively. Iv left ventricle, ao aorta, ra right atrium, rv 
right ventricle 
Figure 3. Mild aortic regurgitation and intracardiac shunt. A 47-year-old man post aortic valvotomy and 
Ross procedure for congenital aortic stenosis. Panel a Three chamber view with color-flow Doppler echo-
cardiography showing a small aortic regurgitant jet (asterisk). Panel b Doppler echocardiography imaging, 
apical four chamber view, zoomed in on the basal septum and the right atrium; color flow through a typi-
cal Gerbode defect (arrows). Panels C and D CMR 4D flow imaging with corresponding views of the mild 
aortic regurgitation and the subvalvular, ventriculo-atrial jet, respectively. Iv left ventricle, ao aorta, ra right 
atrium, rv right ventricle
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DIsCUssIoN
In this study we report the first experiences with a cloud- based software application 
for pre- and post-processing CMR 4D flow data. We investigated its performance for the 
evaluation of aortic valve regurgitation. The novelty of storage capacity of the MR scan-
ner caused difficulties, reconstruction and evaluation was successful in all other cases. 
For the detection and grading of aortic regurgitation, CMR 4D flow imaging correlated 
well with echocardiog- raphy and all patients with clinically relevant aortic regurgitation 
were correctly identified. There were two cases of overestimation, one mild aortic regur-
gitation graded as moderate with 4D flow and another one not visible with echocardiog-
raphy which was graded as mild with 4D flow. There were also five mild regurgitations 
on echo, missed with 4D flow. We consider that CMR 4D flow is feasible and correlates 
well, but the population is not of sufficient size to conclude if there is systematic over- or 
underestimation. Out of the 5 underestimated regurgitations, two were scanned at 3.0 
T and three at 1.5 T and from the two overestimated regurgitations one was scanned at 
1.5 T and one at 3.0 T. Under the limitations of modest number of patients, we did not 
observe any indication that field strength was associated with accuracy.
Table 3. Aortic regurgitation grading criteria
Grade Ratio between the width of 
the regurgitant jet and the left 
ventricle outflow tract
Ratio between the length of 
the regurgitant jet and the left 
ventricle outflow tract
Diastolic reversal flow in the 
descending aorta
Mild <25% <25% Absent
Moderate 25-64% 25-50% Trace
Severe More than 65 More than 50% Present holodiastolic
Adapted from echocardiographic recommendations for the assessment of native aortic valve regurgitation, 
only parameters available for both methods were used; the ratios between the width of regurgitant jet and 
of the left ventricle outflow tract and between the length of the regurgitant jet and of the left ventricle and 
the presence of reversal flow during diastole at the level of the descending aorta (13,14) 
Table 4. Agreement between CMR 4D flow imaging and echocardiography
CMR 4D flow imaging Echocardiography
None Mild Moderate Total
None 34 5 0 39
Mild 1 9 0 10
Moderate 0 1 4 5
Total 35 15 4 54
The correlation between the two methods, when assessing the aortic regurgitation, was kappa = 0.73. 
When using a threshold of mild aortic regurgitation the correlation kappa = 0.74 and when using a thresh-
old of moderate aortic regurgitation was kappa = 0.88.
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ln 2012, Hsiao et al. [6] used non-commercially avail- able in-house software with a 
similar computational algorithm for data processing with color-speed overlay as in our 
paper, to evaluate valve regurgitation and intracardiac shunts with CMR 4D flow imag-
ing against color Doppler echocardiography. The results are similar to our findings, good 
agreement (K = 0.76) was achieved when applying a threshold of at least mild regurgita-
tion, and also a substantial agreement (K = 0.69) when using a threshold of more than 
mild regurgitation. The minor differences in agreement between both studies may be 
explained by the fact that in our study vector arrow overlay was used to help indicate 
the direction of the flow.
Clinical utility of CMR 4D flow imaging
Echocardiography has been the primary imaging technique for the care of patients with 
structural heart disease, offering advantages in ease of performance, safety and cost. 
How- ever, in complex disease and after surgery echocardiography alone is frequently 
insufficient. CMR offers an alternative imaging option that is helpful in a number of 
specific applications, e.g. imaging of myocardial perfusion or scar, flow quantification, 
or when echocardiography cannot be performed adequately due to technical reasons, 
such as insufficient acoustic window. By the current standard of care, CMR measures flow 
using two-dimensional, velocity- encoded sequences, and it displays flow perpendicular 
to a manually selected plane. It can be a lengthy process that requires good cooperation 
from the patient. Potential advantages of CMR 4D flow protocol are that anatomical, 
functional and flow information are obtained during a free- breathing acquisition of 
7-10 minutes, which is more comfortable for the patient and easier to perform. Without 
a need to specify beforehand, or expert assistance during the examination, flow can be 
measured anywhere and in any direction within the great vessels of the thorax after 
the data has been acquired. While 2D sequences acquire flow information in a static 
plane, CMR 4D flow imaging allows for dynamic alignment of the plane of interest to the 
position of moving structures (e.g. valve annulus) (15). Three-dimensional visualization 
of flow is also helpful for assessment of regurgitation jets that change direction during 
the heart cycle. However, clinical application of CMR 4D flow imaging is met by several 
technical challenges. Accurate representation of flow requires several pre-processing 
steps to correct for eddy currents and for magnetic field inhomogeneity. Experienced 
centers often rely on in-house developed solutions. To our knowledge this is the first 
report on the performance of a cloud-based software that applies volumetric eddy 
currents correction and direct, interactive flow visualization of CMR 4D flow data in a 
single tool package by internet connection, with remote processing of transferred raw 
datasets on high-performance workstations.
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study limitations
This is a relatively small, single-center study. As a proof of concept we limited the analy-
sis to the qualitative evaluation of aortic valve regurgitation. Because demonstration 
of technical feasibility for flow visualization was the aim of this study, only parameters 
available for both echocardiography and CMR 4D flow imaging were used for assess-
ment of the regurgitation severity. The prevalence of aortic regurgitation was 35 %, 
though none of the patients had severe regurgitation. Future studies should expand 
into quantitative analyses, as well as a wider range of valve pathologies. Future work 
is needed to determine optimal technical parameters for quantification of stenosis, 
regurgitation, shear stress, pressure gradients and other flow field derived metrics. To 
improve the contrast to noise ratio, we performed the CMR 4D flow acquisition after 
clinically indicated intravenous contrast agent administration. Future work may focus of 
determining diagnostic accuracy with- out the use of contrast agent.
CoNCLUsIoN
In this study we showed that the use of a cloud-based reconstruction application with 
advanced eddy currents correction, integrated with interactive imaging evaluation tools 
allowed for remote visualization and interpretation of CMR 4D flow data and is sufficient 
for gross visualization of aortic valve regurgitation.
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AbsTRACT
VEGF165A microsphere therapy for myocardial infarction suppresses acute cytokine 
release and in- creases microvascular density but does not improve cardiac function. 
Am J Physiol Heart Circ Physiol 309: H396 –H406, 2015. First published May 29, 2015; 
doi:10.1152/ajpheart.00698.2014.—Angiogenesis induced by growth factor-releasing 
microspheres can be an off-the-shelf and immediate alternative to stem cell therapy 
for acute myocardial infarction (AMI), independent of stem cell yield and comorbidity-
induced dysfunction. Reliable and prolonged local delivery of intact proteins such 
as VEGF is, however, notoriously difficult. Our objective was to create a platform for 
local angiogenesis in human-sized hearts, using polyethylene-glycol/polybutylene-
terephthalate (PEG-PBT) microsphere-based VEGF165A delivery. PEG-PBT microspheres 
were biocompatible, distribution was size dependent, and a regimen of 10 X 106 15-
µ.m microspheres at 0.5 X 106/min did not induce cardiac necrosis. Efficacy, studied in 
a porcine model of AMI with reperfusion rather than chronic ischemia used for most 
reported VEGF studies, shows that microspheres were retained for at least 35 days. Acute 
VEGF165A release attenuated early cytokine release upon reperfusion and produced 
a dose-dependent increase in microvascular density at 5 wk following AMI. However, 
it did not improve major variables for global cardiac function, left ventricular dimen-
sions, infarct size, or scar composition (collagen and myocyte content). Taken together, 
controlled VEGF165A de- livery is safe, attenuates early cytokine release, and leads to 
a dose-dependent increase in microvascular density in the infarct zone but does not 
translate into changes in global or regional cardiac function and scar composition. 
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INTRoDUCTIoN
STEM CELL THERAPY for acute myocardial infarction (AMI), sought after to facilitate cardiac 
repair, has shown promise to improve cardiac function and patient outcome (1). However, 
outcome parameters vary widely (2) and are not always reported well (3). Rather than trans-
differentiation of stem cells into cardiomyocytes, the postulated mechanism of stem cell 
action is through paracrine factors, inducing antiapoptotic effects, immunomodulation, 
and regional angiogenesis (4). Improved angiogenesis or maintenance of the preexisting 
mi- crovascular bed is a prerequisite for, not only cardiac regeneration, but also cardiac 
healing through improved or maintained perfusion. It allows for access of leukocytes and 
facilitates scar-stabilizing processes such as fibrosis and debridement. Autologous stem 
cell therapy, however, is delayed hours to days because of cell harvesting and cell culture 
steps, and quality and viability may vary with comorbidities (5, 6). In addition, it has been 
suggested that early post-AMI regional inflammation may impair stem cell function. This 
implies that stem cell therapy depends heavily on quality of the cells and, importantly, 
cannot be used immediately following a primary percutaneous coronary intervention 
(pPCI), which is the preferred AMI treatment. This leaves acute and reperfusion- induced 
injury such as no reflow untreated. Microsphere (MSP) therapy, releasing angiogenic or 
other therapeutic factors, could be an off-the-shelf alternative to stemcells. It would make 
it independent from comorbidity-induced This timing is of particular importance, as de-
livery of therapeutic agents before the occurrence of no-reflow-induced perfusion deficits 
should allow optimal distribution of MSPs and widens its therapeutic potential beyond 
angiogenesis to prolonged local delivery of other pharmaceuticals.
We used an amphiphilic biomaterial composed of polyethylene glycol and polybutyl-
ene terephthalate (PEG-PBT) with adjustable release kinetics (PolyActive). It is designed 
especially for stable protein delivery (7-11) and can theoretically harbor more than one 
growth factor per MSP for simultaneous release. Adjustable release kinetics of MSPs 
allows control of diffusion, and, subsequently, sequential release of multiple growth fac-
tors is possible when a mixture of growth factor- specific MSPs with dedicated release 
characteristics is given. PolyActive MSP delivery keeps proteins intact, protects them 
against proteolytic degradation, and has shown excellent bio- compatibility in implants 
(12). PolyActive can be stored as an off-the-shelf therapy without loss of activity.
Many studies of growth factor-induced angiogenesis have been performed in the past, 
but these models invariably used chronic ischemia through permanent occlusion of a 
coronary artery. However, the clinical reality in Western Europe is that patients suffering 
an AMI are referred for pPCI where possible, to relieve ischemia by immediate reperfu-
sion. We therefore studied the efficacy of MSP-induced angiogenesis using VEGF165A 
as a model drug in a setting similar to that used for pPCI by using a translational animal 
model of ischemia- reperfusion.
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MATeRIALs AND MeTHoDs
source of VeGF165A
Growth factor VEGF165A, used for both cell culture studies and preparation of loaded 
MSPs, was sourced from one supplier (Peprotech, Rocky Hill, NJ). Growth factor for cell 
culture studies was diluted from fresh stock.
Preparation of VeGF165A-Loaded PolyActive MsPs 
Monodisperse formulations of placebo, high-dose (-0.3 pg), and low-dose (-0.1 pg) 
VEGF165A-loaded PolyActive MSPs (OctoPlus, Leiden, The Netherlands) were prepared 
by a double-emulsion (water in oil in water) method. VEGF165A aqueous solution (0.5% 
wt/vol) was emulsified by high shear mixing (Ultra-Turrax) into a solution of PolyActive, 
a copolymer of PEG-PBT with compositions 1000PEGT80PBT20 or 1500PEGT77PBT23 
(Polyvation, Groningen, The Netherlands) in dichloromethane (10% wt/vol). This emul-
sion was pushed through a membrane (Nanomi, Oldenzaal, The Nether- lands) with a 
uniform pore size specific for each desired MSP size, using nitrogen into a 0.5% solution 
of polyvinyl alcohol (13–23 kDa; Sigma, Zwijndrecht, The Netherlands), resulting in a 
suspension of uniformly sized microdroplets. Extraction and evaporation of the organic 
solvent resulted in formation of hardened MSPs. After the washing and final sieving 
through an absolute 20-µ.m sieve to remove aggregated samples, suspended MSPs 
were frozen in water for injection and stored at -80°C until use.
MsP size Distribution and surface Characteristics
Size distribution and the number of MSPs per milliliter were determined by Coulter coun-
ter analysis (Coulter Counter Multisizer 3; Beckman Coulter, Mijdrecht, The Netherlands). 
MSP shape and surface characteristics were studied by scanning electron microscopy 
(Jeol JSM6610LV at 5 KV). Hydrated MSPs were dried through graded ethanol series fol-
lowed by a chemical drying step using hexamethyldisilazane (Sigma). Fully dried MSPs 
were mounted using double-sided conductive carbon tape and sputter coated (gold) 
before examination.
In Vitro Release Kinetics of VeGF165A MsPs
Because small increments in systemic VEGF levels are difficult to determine (13), release 
kinetics of drug-laden MSPs were only deter- mined in vitro. Release kinetics were as-
sessed by placing 10 X 106 MSP in a gently and continuously swirled extraction medium 
at 37°C (PBS + 0.05% Tween20) that precludes aggregation of proteins and stabilizes 
them for later analysis (14). Total VEGF165A release was measured at <1 min (mimicking 
acute release), 2.5 h (mimicking early reperfusion), then every day for 14 days followed 
by 21, 28, and 35 days postincubation. These time points were selected to mimic timing 
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of the efficacy study described below. Eluted VEGF165A was measured by ELISA ac-
cording to manufacturer’s instructions for human VEGF165A (R&D Systems, Abingdon, 
Oxfordshire, United Kingdom). Absorbance was measured at 450 nm with a microplate 
photometer and converted to concentration using a standard calibration curve. MSP size 
was measured before and after the release kinetics studies by Coulter counter analysis.
In Vitro Angiogenic VeGF165A efficacy
To study the lower threshold of VEGF165A efficacy in cardiac network formation, 
cultured human cardiac microvascular endothelial cells (HCMVECs; Lonza, Breda, The 
Netherlands) were starved for 20 h [0.5% heat-inactivated FBS in basal endothelial cell 
growth medium (EBM2)] (Lonza) for synchronization. Starved cells were isolated by con-
temporary trypsinization and centrifugation, and 2.6 X 104 cells/cm2 were resuspended 
into EBM2 + 0.5% heat-inactivated FBS. According to the manufacturer’s instructions, 
microslides for angiogenesis (IBIDI, Martinsried, Germany) were filled with 10 µ.l growth 
factor-reduced MatriGel (BD Biosciences, Breda, The Netherlands) per well. Then 50 µ.l 
of cell suspension with incremental VEGF165A (Peprotech; 0, 30, or 100 ng/g) was added 
to every well (n 5), and equal distribution was ascertained. Angiogenesis was subse-
quently allowed for 18 h at 37°C under hypoxic (PO2: 2%) cell culture conditions and 
photographically documented. Total tube length and number of junctions were quanti-
fied (Angiosys 1.0; TCS Cellworks, Buckingham, Buckinghamshire, United Kingdom) for 
statistical analysis.
In Vivo size Finding for MsP Retention, safety, and biocompatibility
The MSP size generally used for determination of myocardial blood flow is 15 µ.m, as it 
is retained by the organ without inducing arteriolar obstruction (15). However, because 
biomaterials can show specific behavior, we decided to test both smaller (12 µ.m) and 
larger (17 µ.m) MSPs to confirm retention and determine potential arteriolar obstruction 
with PolyActive MSPs. These experiments were per- formed in 5– 6-mo-old Yorkshire-
Landrace swine of either sex (34.2 ± 0.9 kg). All animal experiments were conducted 
in compliance with the Guide for the Care and Use of Laboratory Animals and after 
written approval of the Animal Ethics Committee of the Erasmus MC. In short, swine 
were sedated with an intramuscular injection of midazolam (1 mg/kg) and ketamine 
(20 mg/kg). Following an intra- venous ear catheter placement, anesthesia was induced 
with an intra- venous injection of 600 mg pentobarbital. Animals were intubated and 
mechanically ventilated (O2:N2 1:3, vol:vol). Anesthesia was maintained with pentobar-
bital (15 mg·kg-1·h-1), and animals were instrumented as described before (16). For size 
finding (myocardial MSP retention), 1–5 X 106 placebo MSPs ranging from 12–17 µ.m 
were injected via intracoronary method in 11 animals for dispersion into the healthy 
myocardium with an infusion rate up to 1.5 X 106/min. After 2 h, animals were eutha-
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nized, and excised hearts were conventionally processed for infarct size determination 
by triphenyltetrazolium chloride (TTC) (16) and histological MSP quantification by 
Resorcin-Fuchsin staining, which stains MSPs black. To determine whether myocardial 
microinfarctions were produced by MSP infusion, we investigated the acute effects of 
placebo MSP infusion in four healthy swine. Under fluoroscopic guidance, distally to the 
first marginal branch of the left circumflex coronary artery (LCx, to mimic the delivery as 
planned for the efficacy study), 15-µ.m placebo MSPs were infused in anesthetized swine 
through a micro- catheter. Numbers of infused MSPs varied from 5 X 106 to 20 X 106 and 
were infused with a rate of 0.5 or 1.0 X 106 MSPs/min (Table 1). Serial blood sampling 
and quantification of markers for necrosis and follow-up infarct size measurements 
were executed as described before (16). For biocompatibility studies, the subacute and 
chronic inflammatory response to placebo MSPs were assessed in six swine infused with 
5 X 106 15-µ.m MSPs (0.5 X 106/min). After 5 days (n 3) or 28 days (n 3), animals were killed 
as described above, and tissues were retrieved and prepared for routine hematoxylin 
and eosin histology.
efficacy of VeGF-eluting MsP Therapy for AMI
Thirty-two swine (31.4 ± 0.4 kg) were sedated as above, and anesthesia was maintained 
with fentanyl (20 µ.g·kg-1·h-1 iv). Maximal transient coronary vasodilatation was induced 
for quantitative angiography (selective infusion of 1 mg isosorbidedinitrate) to deter- 
mine optimal balloon sizing. Coronary diameters were measured using a nonionic con-
trast agent (Iodixanol) and dedicated software (CAAS; Pie Medical Imaging, Eindhoven, 
The Netherlands). The occlusion and infusion sites were carefully selected by at least 
two investigators and were always selected distal to the first marginal branch. An ap-
propriately sized coronary angioplasty balloon with a standard guide wire was carefully 
Table 1. Dose tolerance
No. of Microspheres 5 x 106 10 x 106 10 x 106 20 x 106
Infusion Parameters
Infusion volume 10 ml 20 ml 40 ml 40 ml
Infusion density 5 x 105/ml 5 x 105/ml 2.5 x 105/ml 5 x 105/ml
Infusion speed 2 ml/min 2 ml/min 2 ml/min 2 ml/min
Infusion rate 1 x 106/min 1 x 106/min 0.5 x 106/min 1 x 106/min
Myocardial Damage
Infarct size, % MTA 0.00 2.54 0.00 9.67
[hsTnI], ng/ml 0.42 2.03 0.30 8.68
[hFABP], ng/ml 6.44 12.10 0.48 28.99
MTA, microsphere-treated areal hsTnI (baseline: below detectable levels); hFABP = heart-specific acid-bind-
ing protein (baseline: 6.1 ± 1.1 ng/ml)
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positioned under fluoroscopic guidance at the selected site of infusion. The LCx was 
occluded for 2 h followed by reperfusion. Upon occlusion, anesthesia was switched from 
fentanyl to isoflurane inhalation anesthesia (17, 18). Immedi- ately upon reperfusion by 
deflation of the angioplasty balloon, 10 X 106 15-µ.m MSPs containing placebo, low-dose, 
or high-dose VEGF165A were infused (in 40 ml saline, 2 ml/min, 0.5 X 106 particles/min). 
The route of administration and the area of distribution of the MSPs are illustrated in 
Fig. 1 and show that MSPs are given through the lumen of the angioplasty balloon upon 
deflation while remaining at the original location, leading to MSP treatment of the area 
at risk only (i.e., subjected to ischemia) and not outside the area at risk. Anesthetized 
animals were monitored for 2.5 h following reperfusion to serially assess biomarker re-
lease. Catheters were re- moved, the wound was closed, and animals received antibiotic 
prophylaxis (a mixture of procainebenzylpenicillin and dihydrostrepto- mycine sulfate, 
20 mg/kg and 25 mg/kg im, respectively) and were then allowed to recover.
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Figure 1 
 
Fig. 1. Graphic representation of the acute myocardial infarction (AMI) model showing the route of microsphere 
(MSP) administration. MSPs were admin- istered via the guidewire lumen following deflation of the “over-the-
wire” angioplasty balloon used to induce ischemia. Hence, MSPs were only deliv- ered to the area at risk. The 
cross-sections at the right indicate the areas of interest used for histological  analysis. 
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Global and Regional Cardiac Function by MRI
Global and regional cardiac function including microvascular obstruction was assessed, 
processed, and analyzed in a blinded manner at 1 and 5 wk after myocardial infarction 
and therapy using MRI as described before (25, 38). In short, animals were sedated and 
intubated as described above. Anesthesia was maintained with fentanyl (20 µ.g·kg-1·h-1) 
and, when necessary, supported with thiopental sodium (100-mg bolus). Mechanical 
ventilation and peri-imaging breath-holds were performed using a mobile ventilator 
(Carina; Draeger, Zoetermeer, The Netherlands). When necessary, and always in absence 
of pain reflexes, muscle relaxation was achieved using pan- curonium bromide (2– 4-mg 
bolus). Cardiac MRI examinations were performed on a 1.5-Tesla clinical scanner (Signa 
HD; GE Medical Systems, Milwaukee, WI) using a dedicated cardiac four-channel phased 
array cardiac receiver coil. Repeated breath-holds and gating to the electrocardiogram 
were applied to minimize the influence of cardiac and respiratory motion on data col-
lection. All cardiac MRI (CMR) protocols consisted of cine-MRI (myocardial function) and 
delayed enhancement MRI (DE-MRI, infarct size and no reflow). Cine-MRI was performed 
using a steady-state, free-precession technique (FIESTA, GE Medical System). With the 
use of standard techniques to identify the major cardiac axes, two-chamber and four-
chamber cine-CMR images were obtained. The two- and four- chamber end-diastolic im-
ages provided the reference images to obtain a series of short-axis views. This resulted 
in 8 –12-cine breath-hold short-axis images to cover the entire left ventricle. Delayed 
enhancement imaging was performed with a gated breath- hold two-dimensional 
T1-inversion recovery gradient-echo sequence minimally 10 min after infusion of gad-
olinium-diethyl-triamine- penta-acetic-acid (0.2 mmol/kg iv, Gadobutrol, 1.0 mmol/
ml; Bayer, Mijdrecht, the Netherlands) (19). After MRI imaging, animals were allowed to 
recover as described above (1 wk post-AMI) or transported back to the operating theatre 
for follow-up death.
MRI Image Processing and Analysis
All images were transferred to a Microsoft Windows-based personal computer for blind 
analysis using the CAAS-MRV program (version 3.3.1; Pie Medical Imaging). Cine and 
delayed-enhancement images were acquired during the same imaging session and 
were matched using identical slice positions. Registration of follow-up and baseline cine 
and delayed-enhancement images was achieved by consensus of two observers using 
anatomic landmarks such as papil- lary muscles and right ventricular insertion sites. The 
images were analyzed in a blind matter using the additional information of the long axis 
to limit the extent of volume at the base and the apex of the heart. Left ventricular end-
diastolic volume (LVEDV), LV end-systolic volume (LVESV), LV ejection fraction (LVEF), LV 
mass, and LV end-diastolic wall thickness of the infarct were measured by semiautomati-
cally drawing the endocardial and epicardial contour in end- systolic and end-diastolic 
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phase of the two- and four-chamber images with automatic segmentation to the short 
axis and if necessary corrected manually. Papillary muscles and trabeculations were 
considered part of the blood pool volume and excluded from myocardial mass. LVEF was 
calculated as (LVEDV - LVESV)/LVEDV. Infarct size (IS m/m) was determined on short-axis 
delayed-enhancement images using semiquantitative analyses for the detection of the 
de layed-enhancement regions (8).
Histology
At death of the anesthetized animal, a sternotomy was performed, and the pericardium 
was carefully opened; after an overdose of pentobarbital, the aorta was cross-clamped, 
and the vena cava was opened. Immediately upon euthanasia, proximally to the aorta 
clamp, an infusion setup was placed to flush the arrested heart with approximately 
1 l of ice-cold saline to remove blood and plasma from the heart. The flushed heart 
was excised and cut into five transversal slices on a cooled cutting board. Slices were 
sectioned into remote, border zone, and infarct tissue and subsequently fixed in 3.5– 
4.0% buffered formaldehyde, in preparation for paraffin embedding. Area at risk (see 
Fig. 1) is defined as the area subjected to ischemia and is the only area containing MSP. 
Infarct area is defined as the area showing extensive fibrosis and lack of cardiomyocytes. 
Border zone is defined as the area bordering the infarct and does not contain MSPs. For 
microvascular density of the remote area, tissue was taken from the LV wall opposite of 
the infarcted area (i.e., septum).
Microvascular Density Measurement
As arteriolar density does not change as a result of myocardial infarction (20), we mea-
sured total microvascular density in the MSP- treated infarct area reflecting changes 
in capillary density. To quantify microvascular density in myocardial tissue, 4-µ.m 
sections of paraffin- embedded infarct, border zone, and remote tissue were stained 
with the biotin-labeled lectin Dolichos Biflorus (DBA, L6533; 1:100, Sigma) followed by 
streptavidin-horseradish peroxidase (1:4,000, Sigma) and diaminobenzidine-H2O2 as a 
chromogen. With the use of a X40 magnification, four MSP-containing, nonoverlapping 
images were taken of every section (Clemex Vision 4.0; Clemex Technologies, Longueuil, 
Quebec, Canada). Microvascular density was quantified using an adapted Chalkley grid 
to rapidly and reliably quantify angiogenesis despite tortuosity (21) with a custom-built 
ImageJ macro (version 1.46r; National Institutes of Health, Bethesda, MD). The adapted 
Chalkley grid was manually placed over every image, with an MSP in the center of the 
image in case of infarcted tissue. With increments of 4°, the automated Chalkley grid 
was then rotated 90 times for each image to determine its maximum Chalkley score. 
Chalkley scores were converted to absolute microvascular densities with a calibration 
curve.
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extracellular Matrix and Regional Cardiomyocyte Presence
Collagen area and cardiomyocyte presence within the infarct region were quantified 
using a Resorcin-Fuchsin staining. MSP-containing areas (designated as having been 
subjected to ischemia) were divided into six nonoverlapping sections. Every section was 
analyzed to determine the percentage of collagen (red-stained areas) and cardio- myo-
cytes (yellow-stained cardiomyocytes).
biomarkers for Necrosis and Inflammation
Serial blood samples were analyzed for markers of necrosis as described before (16). 
Also, to assess the acute anti-inflammatory response of VEGF165A drug-laden MSP 
therapy, TNF-a and IL-6 levels were quantified in blood samples obtained at baseline, at 
2.5 h of reperfusion, and at 5 wk of follow-up using similar procedures and performed 
according to manufacturer’s instructions (R&D Systems).
Cumulative Regional VeGF Concentration per Gram of Infarct Tissue
The cumulative VEGF concentration eluted by 10 X 106 low- and high-dose MSPs was 
calculated by dividing the mean in vitro VEGF release in 35 days (i.e., 0.9 µ.g and 2.8 µ.g) 
by the weight of each
statistical Analysis
Data are presented as means ± SE. Data were analyzed with Sigmaplot (Version 11.0; Sigma-
plot, Drunen, The Netherlands) and SPSS (IBM SPSS statistics 21). Two-way (time X treatment) 
repeated-measures ANOVA or paired-sample t-test was used followed by post hoc Bonfer-
roni’s correction when appropriate. Statistical significance was accepted when P < 0.05.
ResULTs
In Vitro studies of size Distribution, surface Characteristics, and Release 
Kinetics of VeGF165A MsPs
Determination of MSP size showed a similar diameter in all formulations in the therapy 
study (placebo: 15.2 ± 0.01 µ.m; low dose: 15.3 ± 0.01 µ.m; high dose: 15.3 ± 0.00 µ.m). 
Scanning-electron microscopy was used to visually ascertain MSP integrity for the three 
formulations and showed an intact and smooth surface. The release patterns of the 15-µ.m 
VEGF- containing formulations is illustrated in Fig. 2. Cumulative dose for low- and high-
dose MSP was 0.92 ± 0.05 and 2.80 ± 0.17 µ.g VEGF165A per 10 X 106 MSPs. Importantly, 
the release pattern was not statistically different between the two active formulations. All 
MSPs showed a decrease in diameter at the end of a period of 35 days, but this was similar 
in all formulations (placebo: -9.8 ± 0.1%; low dose: -10.3 ± 0.7%; high dose: -10.5 ± 0.1%).
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In Vitro Angiogenic effects of VeGF165A
The HCMVEC tube-formation assay under hypoxic conditions (Fig. 3), as a marker for an-
giogenesis, showed a clear dose response to VEGF165A in terms of significantly increased 
tube length (P 0.007) and number of junctions (P 0.021). Post hoc analysis showed that this 
was dictated by the difference between 100 and 0 ng/g with a trend for 30 ng/g toward 
improved network formation. The low-dose VEGF165A group reflects this value, and 
therapy was steered toward a cumulative VEGF dose approximating 100 ng/g.
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Figure 2 
 
Fig. 2. Cumulative in vitro release curves   (n 3) of 10 X 106 MSPs in low- and high-dose drug-laden formulations, 
showing an early release burst of VEGF, followed by a steady increase in the cumulative release. Left: absolute 
values. Right: release ex- pressed as a percentage of the total cumula- tive dose. Data are shown as means ± SE. 
Œ, low-dose VEGF MSPs. e, high-dose VEGF MSPs. 
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Fig. 3. In vitro angiogenic response of human cardiac microvascular endothe- lial cells in a tube-formation assay 
(n  5) under ischemic conditions to   indicate the lower threshold of VEGF165A efficacy in the no-reflow zones. 
Data show a dose response with statistically significant effects at 100 ng/g, and this value was subsequently used 
to steer the low-dose VEGF165A group. Data are shown as means ± SE. Open bars represent tube length, and 
solid bars represent number of junctions. *P < 0.05 vs. corresponding 0-ng measure- ment. 
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size Finding, safety, and biocompatibility
The size-finding study data obtained by intracoronary infusion of MSPs of different size 
in swine myocardium confirmed that smaller MSPs of 12 µ.m were not well retained (6 ± 
1% compared with 17-µ.m spheres). The latter showed impaired distribution with con-
gestion of the microvasculature although TTC staining was negative. Therefore, 15-µ.m-
diameter MSPs were selected for subsequent studies of safety and biocompatibility. In 
the safety or dose-tolerance study with 15-µ.m spheres, the average MSP-treated area 
(MTA) was 21.4 ± 3.3% of the left ventricle (17.5 ± 3.2 g cardiac tissue) in all groups. Data 
show that infusion of 10 and 20 X 106 MSP at 1 X 106 MSP/min resulted in a macroscopi-
cally detectable TTC-stained infarct area of respectively 2.5 and 9.7% MTA. However, MSP 
infusion of 5 X 106 (1 X 106/min) and 10 X 106 (0.5 X 106/min) showed no macroscopic 
myocardial necrosis, which was confirmed by absence of hFABP and high- sensitivity 
troponin I release (Table 1). Histology confirmed adverse effects produced by the two 
high-dose and faster MSP infusion rates as hemorrhagic events. In contrast, the 5 X 106 
(1 X 106/min) and the 10 X 106 (0.5 X 106/min) groups did not show microbleedings. 
Analysis of the biocompatibility following intracoronary infusion of MSPs revealed no 
inflammation, either at 5 or at 28 days following infusion of the MSPs (Fig. 4) without 
signs of microvascular damage. These safety and biocompatibility results formed the 
basis for the longitudinal functional assessment of MSP therapy for myocardial infarc-
tion using 10 X 106 MSP at a rate of 0.5 X 105 MSP/min.
efficacy of VeGF-eluting MsP Therapy for AMI
Mortality following myocardial infarction was observed in eight swine (25%) who died 
prematurely. Mortality was not different between groups; nonconvertible ventricular 
fibrilla- tion during the infarct-reperfusion protocol occurred in four swine, two during 
coronary artery occlusion and two during reperfusion. No animals died during infusion 
of MSPs. Two animals died within 48 h postinfarction of subacute cardiac complications. 
One animal died at 1 wk because of severe heart failure, and one animal died because 
of technical failure. All remaining 24 swine (n 8 per group) completed the protocol and 
were included for final blinded analyses. Baseline Characteristics and Cumulative VEGF 
Exposure Infarct mass at baseline by markers of necrosis. To ascertain that infarct mass 
at baseline was similar in all groups, circulating hFABP levels were taken at 50 min of 
reperfusion to calculate infarct mass (41). Infarct masses did not differ be- tween groups 
(placebo: 13 ± 2 g; low dose: 14 ± 2 g; high dose: 16 ± 1 g; P 0.40). Cumulative VEGF ex-
posure. Cumulative local VEGF con- centration per infarct mass (infarct mass at baseline 
by hFABP divided by VEGF dose) showed that, per gram of infarcted myocardium, the 
low-dose group received 0.07 ± 0.01 µ.g VEGF165A, and the high-dose group received 
0.35 ± 0.06 µ.g VEGF165A. Placebo MSP-treated animals received no VEGF165A.
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Global and Regional Cardiac Function at 1 and 5 wk Post- AMI
To understand the early effects of VEGF therapy on cardiac function, 1 wk post-AMI, 
global and regional myocardial functions were assessed with cardiac MRI. Results (Table 
2) clearly show that global and regional myocardial functions are similar compared with 
placebo therapy. Global and regional myocardial functions were assessed again at 5 wk 
post-AMI. Importantly, no significant differences were found between VEGF groups and 
placebo, suggesting that VEGF did not have an effect on global and regional myocardial 
function either early (1 wk) or late (5 wk) post- AMI.
Inflammatory biomarker Release
To understand the effect of VEGF therapy on inflammation, TNF-a and IL-6 were quan-
tified at baseline, 2.5 h of reperfusion, and 5 wk of follow-up. Data are illustrated in 
Fig. 5 and show that, whereas placebo spheres showed a significant increase in TNF-a 
release during reperfusion (P < 0.01), levels decreased significantly to normal at 5 wk of 
follow-up (P < 0.01). TNF-a levels in both VEGF- containing MSP formulations remained 
at baseline levels. A similar pattern for placebo was observed for IL-6, and, although the 
high-dose group showed an increase at early reperfusion, this did not reach levels of 
statistical significance (P 0.15).
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Fig. 4. Histological analysis of in vivo bio- compatibility to assess safety of MSP ther- apy, illustrated for 6 different 
hearts, shows absence of MSP-induced inflammation at 5 days (top) and 28 days (bottom) following infusion in 
healthy, nonischemic myocar- dium. MSPs are light pink (arrow). Hema- toxylin and eosin stain, bar      80 µ.m. 
 
 
 
 
 
 
 
 
Figure 4. Histological analysis of in vivo bio- compatibility to assess safety of MSP ther- apy, illustrated for 6 
different hearts, shows absence of MSP-induced inflammation at 5 days (top) and 28 days (bottom) follow-
ing infusion in healthy, nonischemic myocar- dium. MSPs are light pink (arrow). Hema- toxylin and eosin 
stain, bar 80 µ.m.
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Histological Analysis
Microvascular density measurements. 
To study the effect of VEGF on microvascular density in the infarct zone, Chalk- ley 
counts of the infarct area were normalized to the non- infarcted remote areas. In 
contrast to placebo treatment (13 ± 7% decrease in Chalkley score vs. remote, Fig. 6), 
Table 2. global and regional myocardial characteristics by MRI
LV function and Remodeling Treatment Post-AMI
1 wk
Post-AMI
5 wk
Heart rate, beats/min Placebo 77 ± 8 80 ± 4
Low dose 71 ± 4 71 ± 4
High dose 64 ± 5 75 ± 7
End-diastolic volume, ml Placebo 104 ± 7 120 ± 7*
Low dose 106 ± 3 126 ± 6*
High dose 107 ± 8 125 ± 9*
Stroke volume, ml Placebo 46 ± 2 54 ± 2*
Low dose 42 ± 3 58 ± 3*
High dose 48 ± 2 49 ± 3‡
Ejection fraction, % Placebo 46 ± 3 46 ± 2
Low dose 40 ± 2 46 ± 2*
High dose 46 ± 2 40 ± 4*
LV mass, g Placebo 49 ± 2 54 ± 2*
Low dose 49 ± 2 54 ± 2*
High dose 48 ± 3 52 ± 3*
Infarct Characteristics
Infarct mass, g Placebo 8.0 ± 2.0 6.4 ± 1.6*
Low dose 9.3 ± 0.9 6.9 ± 0.6*
High dose 9.6 ± 1.6 7.6 ± 1.2*
Infarct size, % LV Placebo 15.5 ± 3.3 11.2 ± 2.3* 
Low dose 19.4 ± 2.2 13.3 ± 1.6*
High dose 19.4 ± 2.4 14.4 ± 1.8*
End-diastolic wall thickness, mm Placebo 4.2 ± 0.2 4.1 ± 0.2
Low dose 3.9 ± 0.1 3.6 ± 0.3
High dose 4.2 ± 0.1 3.6 ± 0.3*
No reflow, % IM Placebo 9.5 ± 4.9 -
Low dose 10.1 ± 4.6 -
High dose 7.7 ± 2.7 -
Data are mean ± SE; n = 8 per group. AMI, acute myocardial infarction; LV, left ventricular; IM infarct mass; -, 
not detectable. *P < 0.05 vs. corresponding week 1; ‡p <0.10 vs. corresponding low dose. At 5 wk post-AMI, 
no reflow can no longer be detected. 
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high-dose treatment resulted in a significantly higher Chalk- ley score (10 ± 6%, P < 0.04 
vs. placebo). This corresponds to a difference of -739 ± 278 vessels/mm2 (P < 0.05). The 
low-dose group remained similar to the remote area, indicating a dose-response effect. 
In Fig. 6, typical examples of microvascular density in the infarcted area are shown. Cap-
illary density in the border zones in the placebo, low-dose VEGF, and high-dose VEGF 
group (2,045 ± 125; 2,168 ± 115; 2,223 ± 134 vessels/mm, respectively) were similar to 
the remote area and showed no signs of VEGF effects. Chalkley scores of infarcted tissue 
with an MSP- containing viable rim, reliably measureable in a few animals (n 4 to 5/
group), similarly did not show differences with remote tissue in paired analyses.
Collagen and regional cardiomyocyte presence. 
To study whether differences in microvascular density affected infarct healing, we 
quantified the presence of collagen and cardiomyocytes in the area at risk, defined as 
the area containing MSP (Fig. 7). VEGF165A therapy at 5 wk post-AMI did not result in dif-
ferences in total collagen content (placebo: 24 ± 5%; low dose: 25 ± 3%; high dose: 33 ± 
3% surface area; P 0.25) or changes in cardiomyocyte presence compared with placebo 
(placebo: 41 ± 7%; low dose 37 ± 5%; high dose 27 ± 5%; P 0.21).
DIsCUssIoN
The present study was performed to test the safety, biocompatibility, and efficacy of 
controlled VEGF165A release from degradable MSPs as an off-the-shelf therapy for re-
gional angiogenic therapy following AMI in a setting of PCI. Intracoronary delivery was 
initiated directly upon reperfusion of the infarct tissue to allow delivery of drug-loaded 
MSPs before onset of reperfusion injury and no reflow. This approach allows optimal 
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Figure 5 
 
Fig. 5. Longitudinal assessment for release of inflammatory markers TNF-a and IL-6 in plasma as measured by 
ELISA shows that the VEGF release by the MSPs attenuates cytokine release at 2.5-h reperfusion, having returned 
to baseline at 5 wk of follow-up. Data are presented as means ± SE, n            8 per group. *P < 
0.01. Rep, reperfusion. IL-6 levels at 2.5-h reperfusion were not statistically different from baseline and 5 wk of 
follow-up (P            0.15). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Longitudinal assessment for release of inflammatory markers TNF-a and IL-6 in plasma as mea-
sured by ELISA shows that the VEGF release by the MSPs attenuates cytokine release at 2.5-h reperfusion, 
having returned to baseline at 5 wk of follow-up. Data are presented as means ± SE, n 8 per group. *P <0.01. 
Rep, reperfusion. IL-6 levels at 2.5-h reperfusion were not statistically different from baseline and 5 wk of 
follow-up (P 0.15).
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Figure 6 
 
Figure 6. Top: in vivo relative microvascular density measurements in the area at risk as a result of VEGF165A 
therapy at 5 wk of fol- low-up. Data, given as the difference be- tween infarct and remote area, are shown as 
means ± SE. Open bars represent differ- ences in the Chalkley counts, and solid bars represent the differences in 
the absolute number of capillaries *P < 0.05 vs. placebo. Bottom: microvascular staining of the area at risk in 
placebo (left), low-dose VEGF (mid- dle), and high-dose VEGF (right) MSPs by horseradish peroxidase (HRP)-
labeled lectin Dolichos Biflorus. MSPs were used to center the Chalkley grid before automated mea- surements of 
the microvasculature. HRP was visualized with  diaminobenzidine-H2O2.  Bar     50 µ.m. 
 
 
 
 
 
Figure 6. Top: in vivo relative microvascular density measurements in the area at risk as a result of VEG-
F165A therapy at 5 wk of fol- low-up. Data, given as the difference be- tween infarct and remote area, are 
shown as means ± SE. Open bars represent differ- ences in the Chalkley counts, and solid bars represent the 
differences in the absolute number of capillaries *P < 0.05 vs. placebo. Bottom: microvascular staining of the 
area at risk in placebo (left), low-dose VEGF (mid- dle), and high-dose VEGF (right) MSPs by horseradish per-
oxidase (HRP)-labeled lectin Dolichos Biflorus. MSPs were used to center the Chalkley grid before automat-
ed mea- surements of the microva culature. HRP was visualized with diaminobenzidi e-H2O2. Bar 50 µ.m.
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Figure 7 
 
Fig. 7. Endocardial border of the infarct area in the 3 groups showing extensive fibrosis with endocardial survival 
of cardiomyo- cytes, with collagen stained red and cellular elements such as muscle stained yellow. Resorcin-
Fuchsin stain. Bar      500 µ.m. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Endocardial border of the infarct area in the 3 groups showing extensive fibrosis with endocardial 
survival of cardiomyo- cytes, with collagen stained red and cellular elements such as muscle stained yellow. 
Resorcin-Fuchsin stain. Bar 500 µ.m.
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MSP distribution within the area at risk before development of perfusion defects as a 
result of no reflow.
Major Findings
We observed that 15-µ.m MSPs were effectively retained and distributed within the 
myocardium without inducing an acute or chronic local inflammatory response or 
(micro)infarc- tion. MSP presence did not negatively affect cardiac function compared 
with historic data with similar infarct size (heart rate 84 ± 19 vs. 80 ± 4 beats/min, stroke 
volume 60 ± 11 vs. 54 ± 2 ml) (28). VEGF-loaded MSP delivery in infarcted myocardium 
significantly reduced the acute release of the proinflammatory cytokines TNF-a and 
IL-6 during reperfusion. At follow-up, histology revealed dose-dependent changes in 
microvascular density within the MTA compared with the intrinsic nonischemic control 
area. Per gram of infarcted myocardium, a dose of 0.07 ± 0.01 µ.g VEGF165A maintained 
microvascular density, whereas 0.35 ± 0.06 µ.g VEGF165A increased microvascular den-
sity. However, these changes did not translate to changes in scar composition (collagen 
and cardiomyocyte presence) or global and regional myocardial function by cardiac MRI 
at 1 or 5 wk after AMI.
MsP Composition and size
We found that 15-µ.m diameter MSPs were effectively retained by the porcine myocar-
dium, whereas 12-µ.m MSPs were not, and 17-µ.m MSPs impaired optimal distribution. 
MSP retention may be dictated by, not only size, but also material properties because 
poly(lactide-co-glycolide) MSPs of 7-µ.m diameter were described to be retained well 
(22). Thus every (bio)material for local drug delivery needs to be tailored individually to 
the in- tended microvascular bed for optimal MSP sizing. Especially in case of angiogenic 
MSPs, it is prudent to regulate MSP retention to prevent angiogenesis in unwanted areas.
Timing of MsP Delivery
The timing of infusion, immediately upon reperfusion of the ischemic myocardium, al-
lows distribution before the major onset of reperfusion injury and no reflow (23). This 
opens up new therapeutic options for treatment of no reflow, as systemic drug delivery 
will be limited by the development of microvascular perfusion defects within half an 
hour after onset of reperfusion. The timing of MSP therapy upon reperfusion is of great 
clinical potential, as MSPs can be infused directly following PCI, thus limiting additional 
procedural risks to the patient.
Inhibition of Acute Inflammation
Reperfusion following myocardial infarction is typically associated with the release of 
proinflammatory cytokines such as TNF-a and IL-6 (24). The main source of TNF-a is 
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suggested to be the monocyte/macrophage, whereas others indicate that mast cells 
are the initial source of TNF-a that subsequently gives rise to influx of monocyte/mac-
rophages, with the latter as the main source for IL-6 (22, 24). However, cardiomyocytes 
and endothelium can also release TNF-a when stimulated (25). Given the chronic nature 
of our study, we were unable to assess the acute effect of VEGF MSP infusion on car-
diac macrophage accumulation and mast cell degranulation in tissue. Consequently, 
we were unable to identify the source of these cytokines. Whether reduction of TNF-a 
and IL-6 is detrimental or protective for the reperfused myocardium is difficult to say. 
TNF-a reduction can attenuate infarct size, but TNF-a can also increase the expression of 
cytoprotective proteins (25). In our study, it did not translate to differences in myocardial 
function.
VeGF Therapy and Global Function
VEGF165A therapy in our study resulted in a dose-dependent increase in microvascular 
density, but this did not translate into global or regional improvements of cardiac func-
tion as measured by cardiac MRI. However, we induced relatively small infarcts, and 5 
wk of follow-up may be considered short. Previous results from our laboratory indicate 
that, indeed, these conditions may not result in measurable global functional improve-
ments at the short term, despite regional improvements (18). Our study is the first to 
report MSP-based VEGF release for AMI in a setting of reperfused myocardial infarction 
in a large-animal model. Interestingly, -57% of small-animal VEGF studies that include 
functional measurements report improvements in global cardiac function, and 50% of 
large- animal studies show global functional improvements (Table 3); however, these are 
mostly studied in a setting of chronic ischemia. No clear therapeutic optima, including 
timing of administration and total cumulative dosage, can be distilled from this previous 
work. Thus differences in experimental conditions, including animal model, infarct size, 
and therapeu- tic protocol, may underlie differences in therapeutic outcome.
VeGF elicits a Dose-Dependent Increase in Cardiac Microvascular Density
It is remarkable that so few studies report the total cumulative dose of administered 
VEGF or the dose normalized to body weight or infarct mass. Consequently, an effective 
VEGF dosage remains to be established and may be species dependent. For example, 
two rat studies that applied a bolus-like administration of VEGF both report positive 
effects on global function while administering a striking 458-fold difference in cumula-
tive growth factor dosage (11 µ.g vs. 24 ng) (26, 27). These results suggest that at least a 
broad range of therapeutic efficacy of VEGF for chronic myocardial infarction exists. Our 
study, using a model of reperfused myocardial infarction, shows that, whereas placebo 
treatment resulted in loss of microvascular density in the infarct zone, a cumulative dose 
of 0.9 µ.g VEGF (0.07 ± 0.01 µ.g/g myocardium) preserved microvascular density and 2.8 
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µ.g (0.35 ± 0.06 µ.g/g myocardium) resulted in an increased microvascular density com-
pared with remote tissue. This demonstrates that VEGF indeed elicits dose-dependent 
angiogenesis in the infarcted tissue. When we place this outcome in perspective, it 
is striking that the effect of VEGF therapy in all previous studies consistently resulted 
in a significantly higher microvascular density of the infarct zone compared with the 
microvascular density of control infarcts. This effect appears independent of dosage, 
ther- apeutic protocol, or timing of administration. It must be noted, however, that we 
were the only group to compare microvascular density within the infarct region to the 
intrinsic control (remote area). It may well be that, although VEGF increased microvas-
cular density in infarcted tissue compared with control infarctions, it could still be lower 
than in the remote zone, which could affect long-term outcome.
Route of Administration and AMI Model
From a translational point of view, it is evident that an intravenous or intracoronary 
route of administration is less invasive as opposed to injecting growth factors di-
rectly into the myocardium. Considering the potential tumorigenic potency and blood 
pressure-lowering effects of VEGF (28), any bolus, either intravenous, intracoronary, or 
intramyocardially, is less appropriate, as it inevitably recirculates. VEGF, distributed via 
the microcirculation, binds avidly to endothelium and fibrin, where bound to the lat-
ter it still supports endothelial proliferation (29, 30). Slow and sustained VEGF delivery 
via degradable biomaterials following intracoronary delivery therefore seems a viable 
therapy as the growth factor can be more easily bound to the tissue, and subsequent 
circulating levels should remain low. So far, none of the studies in Table 3 used the clini-
cally relevant intracoronary route of biomaterial-mediated VEGF administration, and no 
conclusions can be drawn whether the outcome would have differed. We speculate, 
however, that optimal growth factor delivery and retention will be carrier dependent 
and needs to be tailored, as is true for cell therapy (31). Clearly a permanent occlusion, 
as used in the vast majority of the studies summarized in Table 3, is not representative 
for the clinical situation where interventions to re- store perfusion of the ischemic ter-
ritory are the golden standard in many countries. As a consequence, results obtained 
from these nonreperfused infarct studies will less likely predict the true effects of VEGF 
therapy following PCI for AMI.
Clinical Relevance
In our model of reperfused myocardial infarction, intracoronary delivery of VEGF by 
degradable MSPs clearly resulted in an increased microvascular density but not in im-
proved cardiac function. Whether the changes in microvascular density would translate 
to a better long-term outcome beyond our 5-wk period is unknown. Thus the long-term 
benefit of increased microvascular density remains to be determined. The present 
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study does serve as a proof of principle that chronic delivery of active protein using 
biocompatible polymers in the broader context is feasible. It is a versatile methodol-
ogy that is not limited to regional and global cardiac scar remodeling therapy or to one 
specific protein but rather might serve as a general platform for local drug delivery via 
the microvascular bed.
Limitations
The present formulation of MSPs showed an early (burst) release of VEGF in the in vitro 
study, which may have protected or stabilized the vascular bed from the acute ischemic 
insult, resulting in attenuated release of inflammatory cytokines, but also results in 
lower sustained VEGF levels. We cannot exclude that this may have affected efficacy of 
angiogenesis. In addition, multiple growth factors might also have improved efficacy of 
angiogenic therapy. It is also generally accepted that comorbidities, such as hyperten-
sion, diabetes, and atherosclerosis, often present in patients suffering AMI, can affect 
angiogenesis. Therefore, studies in large-animal models in which these risk factors are 
present would be useful before testing angiogenic strategies in clinical trials.
CoNCLUsIoNs
Regional, controlled VEGF delivery leads to a dose-dependent increase in microvascu-
lar density in infarcted tissue. This increase did not translate to changes in global or 
regional cardiac function or scar composition. Controlled regional VEGF delivery, how- 
ever, is safe and feasible and supports the development of novel adjunctive off-the-shelf 
therapeutic applications.
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AbsTRACT
Aim - More than 50% of patients with heart failure have preserved ejection fraction 
(HFpEF) characterized by diastolic dysfunction. HFpEF usually occurs in female patients 
with multiple comorbidities such as hypertension (HT), obesity, hypercholesterolemia 
(HC) and diabetes mellitus (DM), but its pathophysiological basis is still incompletely 
understood. These co-morbidities have been proposed to induce systemic inflamma-
tion, cardiac microvascular dysfunction and oxidative stress, leading to myocardial 
fibrosis and myocyte stiffening and ultimately diastolic dysfunction. Here we tested this 
hypothesis in a swine model chronically exposed to three common comorbidities. 
Methods and Results – DM (induced by streptozotocin), HC (high fat diet) and HT (result-
ing from renal artery embolization), (DM+HC+HT) were produced in ten female swine, 
which were followed for 6 months. Eight female healthy swine on normal pig-chow 
served as controls (CONTROL). The DM+HC+HT group showed hyperglycemia, hyper-
cholesterolemia, hypertriglyceridemia and hypertension, which were associated with 
systemic inflammation and impaired coronary small artery endothelium-dependent va-
sodilation. Myocardial superoxide production was markedly increased, due to increased 
NOX activity and eNOS uncoupling, and associated with reduced NO production. These 
abnormalities were accompanied by increased myocardial collagen content, reduced 
capillary/fiber ratio and elevated passive cardiomyocyte stiffness, resulting in a reduced 
E/A ratio (as measured with cardiac MRI), and an increased left ventricular end-diastolic 
stiffness (as measured with a pressure-volume catheter), while ejection fraction was 
maintained.
Conclusion - The combination of three common comorbidities leads to systemic inflam-
mation, myocardial oxidative stress and coronary microvascular dysfunction, which 
may be associated with myocardial stiffening and diastolic dysfunction with preserved 
ejection fraction.
Keywords: diastolic dysfunction, inflammation, coronary arteries, LV stiffness, oxidative 
stress
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INTRoDUCTIoN
More than 50% of patients with heart failure, present with heart failure with preserved 
ejection fraction (HFpEF) (1, 2). Hospitalized patients with HFpEF have high mortality 
and rehospitalization rates, and there is currently no effective treatment available for 
these patients (3, 4). Common metabolic and cardiovascular risk factors appear to be 
critical in the development of HFpEF, as the incidence of HFpEF rises with increasing 
prevalence of obesity, hypertension, chronic kidney disease, female sex and type 2 dia-
betes (5-7). Furthermore, studies in HFpEF patients have shown alterations in myocardial 
structure, function and cell signaling that are unique to this form of heart failure (8-11). 
However, the pathophysiological basis of HFpEF is still not fully understood, particularly 
at the myocardial tissue level. Consequently, findings from these earlier studies have 
led to the proposition of a novel paradigm, in which multiple comorbidities for HFpEF, 
including obesity, hypertension, hypercholesterolemia and diabetes induce a systemic 
pro-inflammatory state, that leads to coronary microvascular dysfunction and oxida-
tive stress, which in turn, result in myocardial stiffening and ultimately left ventricular 
dysfunction (12). However, direct experimental evidence for this unifying hypothesis is 
still lacking. Consequently, we set out to investigate the chain of events as proposed 
in this novel paradigm, using a large animal model chronically exposed to three com-
mon comorbidities that associate with HFpEF, i.e. hyperglycemia, hypercholesterolemia 
and hypertension. Since the prevalence of HFpEF is predicted to increase in our aging 
Western societies, (13) such a large animal model may offer a much needed platform for 
testing novel drug and lifestyle therapies for the treatment of HFpEF.
MATeRIALs AND MeTHoDs
Animals 
The study was performed in accordance with the “Guiding Principles in the Care and 
Use of Laboratory Animals” as approved by the Council of the American Physiological 
Society, and with approval of the Animal Care Committee at Erasmus University Medi-
cal Center, Rotterdam, The Netherlands, complying with the institutional and national 
guidelines for the care and use of laboratory animals. Ten female (21.7±0.3kg) Yorkshire 
x Landrace pigs were studied. Eight healthy female pigs, of similar age were studied 
as controls (Control). In addition, 6 fresh control hearts from slaughterhouse female 
pigs of similar body weight as the control animals (~100 kg at sacrifice) were studied to 
compare vascular function characteristics. 
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Induction of risk factors
The animals were made diabetic (DM) by injection of streptozotocin (Bio-connect B. V., 
Huissen, The Netherlands), given for 3 consecutive days (50 mg/kg/day i.v.) to destroy 
approximately 70-80% of the pancreatic b-cell islets(14). Pigs were housed in metabolic 
cages and their diabetic status was regularly monitored by measurements of urinary 
and venous blood glucose and ketones levels.
One-and-a–half week after DM-induction, hypertension (HT) was produced by micro-
embolization of afferent glomerular arteries in the kidneys. The animals were sedated 
with zoletil (Tiletamine/Zolazepam; 5 mg/kg), rompun (Xylazine; 2.25 mg/kg) and atro-
pine (2 ml, i.m.), and artificially ventilated with a mixture of O2 and N2 (1:2) to which 1–2% 
(vol/vol) isoflurane was added. Arterial access was obtained via a 9F sheath in the right 
carotid artery, allowing measurement of blood pressure and heart rate. A Swan-Ganz 
catheter (CorodynTM TD, B. Braun Melsungen, Germany) was advanced towards the renal 
arteries and 75 mg of polyethylene microspheres (38-42 μm, Cospheric, Santa Barbara, 
CA, USA) were infused separately in the right kidney as well as the bottom half of the left 
kidney. A port-a-cath catheter (Port-a-cath II POWER P.A.C., Smiths Medical International 
Ltd., UK) was then advanced via the carotid artery in the descending aorta and tunneled 
subcutaneously to the back. Thereafter the wound was closed and animals were allowed 
to recover. The catheter was flushed and blood pressure was measured in the awake 
state every 2 weeks for the rest of the study duration. 
One week after HT induction, a high fat diet, with 25% of fat and 1% of cholesterol 
(HC), was gradually introduced. The animals were fed two meals/day during which they 
had unlimited access to 600-800 grams of food for one hour. The diet was supplemented 
with 10g salt/day. All animals completed 6 months of study duration.
Hemodynamic assessment
At sacrifice, animals were sedated with zoletil (Tiletamine/Zolazepam; 5 mg/kg) rompun 
(Xylazine; 2.25 mg/kg) and atropine (2 ml i.m.), anesthetized with pentobarbital (20 mg/
kg i.v.) and artificially ventilated. In the morning, animals underwent cardiac magnetic 
resonance imaging (MRI) for assessment of left ventricular (LV) dimensions and func-
tion as detailed below. Thereafter, a 9F sheath was placed in the left carotid artery and 
catheters were implanted for measurement of mean aortic pressure (MAP), and LV pres-
sure (Millar catheter, LVP), pulmonary artery pressure (PAP), pulmonary capillary wedge 
pressure (PCWP), cardiac output (CO, by thermodilution) and for blood sampling. The 
pressure-volume loops and end diastolic (EDPVR) and end systolic pressure-volume 
relationships (ESPVR) were constructed using a pressure/volume catheter placed in the 
LV (CD Leycom, The Netherlands), both during baseline hemodynamic conditions and 
during preload reduction after complete obstruction of the inferior vena cava by infla-
tion of a Fogarty balloon (8/10F, Edwards Life sciences, Amsterdam, The Netherlands). 
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Following thoracotomy, LV anterior wall transmural biopsies were taken for single 
myocyte passive force measurements. 
Contrast-enhanced cardiovascular magnetic resonance acquisition and analysis
Contrast-enhanced cardiovascular magnetic resonance was performed using a 1.5-Tesla 
scanner (Discovery MR450, GE Medical System, Milwaukee, Wisconsin, USA). Swine 
were placed in lateral position and a dedicated 32-channel phased-array surface coil 
(GE Medical Systems, Milwaukee, Wisconsin, U.S.A.) was placed on the thorax. Four 
leads were placed subcutaneously and connected to the MRI’s ECG system to create a 
vectorcardiogram for consistent ECG gating. For assessment of the LV function, a breath 
hold, ECG gated, steady state free precession sequence (SSFP) was used. The field of 
view was adjusted to prevent fold-over artefacts. Reconstructed pixel size was 0.70 x 
0.70 mm, slice thickness; 6 mm, slice gap; 0 mm, with a temporal resolution of 42 ms . 
Two and four chamber views were acquired to cover the long axis of the LV. Using these 
orientations on the diastolic phase, the short axis functional scan was planned covering 
the entire length of the heart using approximately 17 slices. For the assessment of mitral 
valve flow, a 2D vascular phase contrast, breath hold, ECG gated sequence was used. 
Reconstructed pixel size; 1.41 x 1.41 mm, slice thickness; 7 mm, with a temporal resolu-
tion 42 ms , velocity encoding; 120 cm/s. Plane of acquisition was at the tip of the mitral 
valve leaflets, perpendicular to the flow and positioned during the (systolic or diastolic) 
phase. For myocardial fibrosis detection, late gadolinium enhancement imaging was 
performed. Slices covering the LV were acquired 10 minutes after intravenous injection 
of an bolus of 0.20 mmol/kg Gadovist (Gadovist 1.0 mmol/ml, Bayer, Mijdrecht, the Neth-
erlands), using an inversion recovery prepared radio-frequency spoiled gradient echo 
pulse sequence (IR-SPGR). The inversion time was selected to null out the myocardial 
muscle signal. Typical inversion times ranged between 200-300 ms. The reconstructed 
pixel size was 1.40 x 1.40 mm. LV function and mass, transmitral flow and late gado-
linium enhancement were analysed on a remote workstation using dedicated software. 
For evaluation of LV function CAAS MRV, 3.4, Pie Medical Imaging, 2011, Maastricht, the 
Netherlands was used. For the assessment of mitral valve flow CAAS MR Flow 1.2, (Pie 
Medical Imaging, 2011, Maastricht, the Netherlands) was used. LV end-diastolic volume 
(EDV) and LV end-systolic volume (ESV) were short axis-based and calculated using a 
combination of long and short axis images and are expressed in millilitres (15). Epicar-
dial and endocardial contours were automatically detected on short axis images and 
manually corrected. The papillary muscles and trabecula were considered to be part of 
the blood pool. LV mass was calculated as the differences in epicardial and endocardial 
EDV multiplied by 1.05 g/cm3 and was expressed in grams(15). To measure E/A ratio, 
peak velocities were measured within a region of interest placed at the orifice of the 
mitral valve for all cardiac phases (16). 
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Plasma measurements
Fasting arterial blood samples were obtained at sacrifice for determination of plasma 
glucose, triglycerides, total cholesterol, low-density lipoprotein (LDL), high-density 
lipoprotein (HDL), aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), 
and creatinine. Arterial plasma concentrations of interleukin-6 (Il-6, R&D Systems Europe 
Ltd., Abingdon, UK) and tumor necrosis factor alpha (TNF-α, R&D Systems Europe Ltd., 
Abingdon, UK), were determined using ELISA kits.
small artery function in vitro
After the LV biopsies were obtained, hearts were arrested, immediately excised and 
placed in cold, Krebs bicarbonate buffer solution. Epicardial small coronary arteries 
(~300 µm diameter) were isolated from the LV apex and studied in vitro using a Mulvany 
wire myograph (DMT, Aarhus, Denmark) as previously described (17). In short, vascular 
segments (~2mm length) were mounted on wires, and maintained at 37˚C, in Krebs 
buffer. After a 30 minutes stabilization period, the internal diameter was set to a ten-
sion equivalent to 90% of the estimated diameter at 100 mmHg effective transmural 
pressure(18), followed by depolarization by 10-1 mol/l potassium chloride (KCl, Sigma-
Aldrich, Zwijndrecht, The Netherlands) to achieve the maximal contractile response. The 
concentration-response curves (CRC) for the different substances were performed on 
separate segments, adjacent to each other in vivo. Endothelial-dependent vasodilator 
capacity was tested in response to bradykinin (BK, 10-10 to 10-6 mol/l, Sigma-Aldrich, 
Zwijndrecht, The Netherlands) upon preconstriction by 10-6 mol/l thromboxane-A2 
analogue U46619 (Sigma-Aldrich, Zwijndrecht, The Netherlands). Smooth muscle cell 
relaxation was tested using the exogenous NO-donor, S-nitroso-N-acetylpenicillamine 
(SNAP, 10-10 to 10-5 mol/l, Sigma-Aldrich, Zwijndrecht, The Netherlands). 
Reactive oxygen species (Ros) and cardiac nitric oxide (No) production 
measurements
To evaluate cardiac oxidative stress, basal superoxide generation from the endocardium 
of the anterior LV, was measured by lucigenin-enhanced chemiluminescence (Sigma 
Aldrich; 5 μmol/L) in a 96-well microplate using a luminometer (Luminoskan Ascent, 
ThermoLabsystem) in which dark-adapted lucigenin was added via an auto-dispenser 
as previously described.(19) Besides total superoxide production, nitric oxide synthase 
(NOS)-dependent superoxide production was determined by incubating the samples 
from the same homogenized LV for 20 minutes with the NOS inhibitor L-NAME (Sigma 
Aldrich; 1 mmol/l), while NADPH oxidase contribution to superoxide production was 
assessed using the NADPH oxidase inhibitor VAS2870, (10 mM). The experiment was 
repeated upon stimulation of superoxide production by 300 mM NADPH. The tempera-
ture was maintained at 37ºC and light emission was recorded and expressed as Tiron-
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inhibitable relative light units (RLU) per mg per second. All samples were measured in 
duplicate. Myocardial NO production in the same area was evaluated by measuring the 
production of NO metabolites NO2- and NO3- using the Griess reaction colorimetric assay 
(Cayman Chemical).
endothelial Nitric oxide synthase regulations
Total endothelial nitric oxide synthase (eNOS) protein expression, phosphorylated eNOS 
and eNOS monomer and dimer protein expression were determined in homogenized LV 
tissue samples. For detection of eNOS monomer and dimer fraction, low temperature 
SDS-PAGE was performed as previously described (20). Briefly, gels and buffers were 
equilibrated at 4°C before electrophoresis, and the buffer tank was placed in an ice bath 
during electrophoresis to maintain the low temperature. SDS-PAGE for phosphorylated 
eNOS, total eNOS protein content and housekeeping protein glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) was performed at room temperature. Subsequent to 
SDS-PAGE, the proteins were transferred to nitrocellulose membranes and the blots 
were probed with primary anti-phospho eNOS Ser1177 (1:1000, Cell Signaling), anti-
eNOS (1:500, Transduction Laboratory) and anti-GAPDH (1:10000, Imgenex). All blots 
were analysed using the Odyssey system (LI-COR).
Histology and immunohistochemistry
After excision of the heart, LV anterior myocardial tissue samples were cut, fixated in 4% 
buffered formaldehyde and embedded in paraffin. 4.5 μm thick slides were cut, deparaf-
finized and stained for histological analyses. 6-10 fields were examined in the endocardial 
and in the epicardial part of each slide, at ×20 magnification. Collagen deposition was 
quantified using picrosirius red staining. Using a linear polarization filter, the area oc-
cupied by collagen type I, collagen type III fibers, as well as total collagen was measured 
and expressed as percentage of the myocardial area. Myocyte size was quantified with a 
Gomori silver stain. Cross-sectional areas of 300-350 cells with clearly visible nuclei were 
measured in total per slide. Capillary density was quantified in the same area as used for 
measurements of myocyte size and collagen. Endothelial cells were stained with biotin-
labeled lectin (lectin 1/100 diluted in 1% bovine serum albumin in PBS, Sigma-Aldrich 
Chemie©, Zwijndrecht, The Netherlands). All vessels smaller in diameter than 10 μm 
were counted. Capillary-to-fiber ratio was calculated as the number of capillaries per tis-
sue area and corrected for the total number of cardiomyocytes present in the same field. 
All measurements were performed using a microscopy image analysis system (Impak C, 
Clemex Vision Image analysis system, Clemex Technologies, Quebec, Canada).
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Cardiomyocyte Measurements
Single cardiomyocytes were obtained via mechanical isolation in cold relaxing solu-
tion containing (in mM) free Mg2+ 1, KCl 100, EGTA 2, Mg-ATP 4, imidazole 10 (pH 7.0, 
adjusted with KOH). Subsequently, cells were incubated for 5 min in relaxing solution 
with Triton X-100 (0.5%) to remove all membranes as described previously(21). Isometric 
force was measured at maximal calcium concentration (31.6 μmol/L) at 15°C and sar-
comere length of 2.2 μm to determine the maximal force generating capacity of single 
cardiomyocytes. The diameters of the cardiomyocyte were measured microscopically, in 
two perpendicular directions. Cross-sectional area was calculated assuming an elliptical 
cross-section. Isometric force was measured after the preparation was transferred from 
relaxing to activating solution. When steady force was reached, the myocyte length was 
reduced by 20% within 2 ms using the piezoelectric motor and restretched after 30 ms 
(slack test). As a result, force first dropped to zero and then quickly redeveloped to the 
original steady-state level. Subsequently, the myocyte was returned to the relaxing solu-
tion, and a second slack test (10 s duration) was performed allowing the determination 
of passive force (Fpas). Active maximal isometric force, (Fact), was calculated from the 
total force level in activating solution – Fpas and corrected for cross-sectional area. Fpas 
measurement were performed at sarcomere lengths ranging from 1.8 to 2.2 μm.
Data analysis
Data are presented as mean±SEM. Comparison of variables between the two groups 
was performed by Student t-test (StatView 5.0 SAS Institute Inc.). Vasodilator responses 
to BK and SNAP were expressed as percentage of the preconstriction to U46619. Vaso-
constrictor responses to U46619 were normalized to 10-1 mol/l KCl. Statistical analysis of 
CRCs, MAP changes over time and Fpas was performed using two-way ANOVA. P<0.05 
was considered statistically significant.
ResULTs
Model characteristics
At 6-months follow-up, significant increases in glucose, cholesterol, LDL- and HDL-
cholesterol values, and the LDL/HDL ratio, and to a lesser extent in triglycerides (P=0.07), 
were observed in DM+HC+HT animals compared to controls (Table 1). TNF-α plasma 
levels were significantly higher than those of healthy controls, consistent with a chronic 
inflammatory status in these animals. No differences in plasma creatinine or urea values 
were observed between the groups. However, DM+HC+HT animals had lower body 
weights (79±3 kg) than the age-matched control animals (102±4 kg, P<0.05). Plasma lev-
els of ASAT were similar between groups (42±11 in DM+HC+HT vs 40±2 U/l in Control), 
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but ALAT was significantly lower in the DM+HC+HT animals as compared to the controls 
(24±4 vs 51±2 U/l, P<0.05). MAP, measured under general anesthesia, immediately prior 
to and following infusion of the polyethylene beads in the kidneys, rose from 62±3 
mmHg to 87±4 mmHg (P<0.05). The increase in MAP was well maintained over time, 
as indicated by the biweekly measurements in the awake state, with animals standing 
quietly in the cage (Fig. 1). 
Coronary small artery function in vitro
Small arteries from the DM+HC+HT animals showed similar preconstriction to 10-6M 
U46619 as compared to control vessels, i.e. 65±6% vs 70±16% of the response to 
10-1 mol/l KCl in the BK experiments, and 62±8% vs 64±8% in DM+HC+HT vs Control in 
the SNAP experiments, (both P=NS). The vasorelaxation to the endothelium-dependent 
Table 1. Arterial Blood characteristics in DM + HC + HT swine group versus healthy control swine (control) 
obtained at fasting state under anesthesia.
Parameter Control (n=8) DM + HC + HT (n = 10)
Glucose (mmol/l) 6.1 ± 0.7 22.7±0.9*
Cholesterol (mml/l) 2.2±0.12 16.8±3.4*
LDL-cholesterol (mmol/l) 1.1±0.1 14.0±3.2*
HDL-cholesterol (mmol/l) 1.1±0.1 5.1±0.7*
LDL/HDL-Cholesterol 1.1±0.1 2.7±0.4*
Triglycerides (mmol/l) 0.35±0.05 1.16±0.36#
Urea (mmol/l) 4.2±0.5 3.8±0.4
Creatinine (µmol/l) 130±6 129±11
TNF-a (pg/ml) 74±24 231±64*
IL-6 (pg/ml) 21±8 67±32
LDL=low density lipoprotein, HDL=high density lipoprotein, TNF-a=tumor necrosis factor alpha, IL-
6=interleukin-6, *P<0.05, #P=0.07, DM+HFD+HT vs Control
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Figure 1. Mean arterial pressure, measured in 
resting awake state, was increased in time in 
DM+HC+HT animals in comparison to historic 
healthy control animals. *P<0.05 in DM+HC+HT 
versus historic healthy control by two-way ANO-
VA. 
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vasodilator BK was significantly blunted in DM+HC+HT pigs (Fig. 2A), whereas the vaso-
relaxation to the endothelium-independent vasodilator SNAP was maintained (Fig. 2B), 
indicative of endothelial dysfunction. 
Ros measurements
Myocardial production of the NO metabolites NO2- and NO3- was significantly lower in 
the DM+HC+HT animals compared to controls, suggesting reduced NO production 
(Fig. 3A). Conversely, basal superoxide production was 3-fold increased in DM+HC+HT 
animals. This increase was suppressed by both L-NAME and VAS2870 (P<0.05 in the pres-
ence of L-NAME or VAS2870 versus baseline measurements), indicating that both NOS 
and NADPH oxidase contributed to superoxide production (Fig. 3B). NADPH resulted in 
aggravated – and VAS2870-inhibitable but not L-NAME-inhibitable – superoxide produc-
tion in DM+HC+HT animals as compared to controls (Fig. 3 C), confirming NADPH oxi-
dase as a major source of superoxide anion in DM+HC+HT animals. Moreover, although 
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Figure 2. Response to bradykinin (BK), the exogenous NO-donor, S-nitroso-N-acetylpenicillamine (SNAP) 
and endothelin-1 (ET-1) in small arteries isolated from the DM+HC+HT animals and healthy control hearts. 
BK-induced response was significantly impaired in the diseased animals, while no differences were record-
ed in the SNAP and ET-1 mediated responses. *P<0.05 DM+HC+HT versus Control by two-way ANOVA.
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Figure 3.             
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Figure 3. Basal NO production was significantly lower (Fig. 3A) while superoxide generation was signifi-
cantly higher in the endocardial layer of the left ventricle of DM+HC+HT animals as compared to healthy 
controls. This superoxide generation was significantly suppressed by L-NAME and VAS2870, (Fig. 3B). Upon 
NADPH oxidase stimulation, the superoxide anion production was dramatically increased (Fig. 3C), this re-
sponse being fairly independent of NOS, and significantly impaired by VAS2870 treatment, suggesting that 
NADPH oxidase is the major source of superoxide anion in the DM+HC+HT animals. *P<0.05 DM+HC+HT 
versus Control; #P<0.05 vs corresponding basal level.
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total eNOS expression was increased in DM+HC+HT as compared to control, (Fig. 4A), 
this increase was principally due to an increase in eNOS monomer, as the monomer/
dimer ratio was markedly higher than in controls (Fig. 4B). Also, eNOS phosphorylation 
on residue Ser1177 was higher (possibly phosphorylation of the eNOS monomer(22)), 
suggesting that not only expression, but also eNOS activity was increased, (Fig. 4C). The 
increase in monomer/dimer ratio in the DM+HC+HT animals points to uncoupling of 
eNOS as the mechanism behind increased NOS-dependent superoxide production
Myocardial structural changes: Collagen deposition, myocyte cross-sectional 
area and capillary density
Figure 5 summarizes the histological findings in the subendocardial layer of the LV 
anterior wall of animals from both groups. Total collagen deposition (collagen type I + 
III), were assessed in the subendocardial and subepicardial layers of the LV. Collagen de-
position was significantly increased in DM+HC+HT animals as compared to the healthy 
controls, (Fig. 5A). No difference was seen between the endocardium and the epicar-
dium, (data not shown). The measurement of the cardiomyocytes cross-sectional area 
revealed that cardiomyocytes from the DM+HC+HT animals were significantly smaller 
than those of control pigs (Fig. 5B). No significant difference in cardiomyocyte size was 
found between the endocardium and epicardium in DM+HC+HT animals (413±42 mm2 
in endo vs 379±29 mm2 in epi), whereas in Control animals the endocardial cells tended 
to be smaller than the epicardial cells (598±23 mm2 in endo and 676 ±31 mm2 in epi, 
P=0.06). When normalized to body weight, the difference in myocyte area between Con-
trol and DM+HC+HT disappeared. Capillary density was similar between the groups (Fig. 
5C) and also between the subendocardium and subepicardium in each group (data not 
 33 
Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total eNOS
0.0
0.5
1.0
1.5
2.0
*
Control
DM+HC+HT
eN
O
S
/G
A
P
D
H
(a
.u
.)
MoDi
0
1
2
3
4
*
M
on
om
er
/d
im
er
(a
.u
.)
peNOS
0.0
0.5
1.0
1.5
2.0
*
pe
N
O
S
/e
N
O
S
(a
.u
.)
eNOS%
GAPDH%
peNOS&
eNOS&
eNOS%d'
eNOS%m'
Control DM+HC+HT Control DM+HC+HT Control DM+HC+HT
A B C
Figure 4. eNOS expression was increased in the diseased animals (Fig. 4A), as was the monomer/dimer 
ratio (Fig. 4B), suggesting that eNOS uncoupling contributes to superoxide anion production. Phosphoryla-
tion of eNOS was also significantly increased in the diseased animals, (Fig. 4C). *P<0.05 DM+HC+HT versus 
Control.
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shown). However, the capillary-to-fiber ratio was significantly lower in the DM+HC+HT 
group as compared to Control animals, suggestive of capillary rarefaction (Fig. 5D). No 
differences were observed between the subendocardium and subepicardium of either 
group (not shown). Figure 6 presents typical examples of the LV subendocardium 
stained with picrosirius red for collagen (Fig. 6A, D), Gomori for myocyte size (Fig. 6B, C) 
and lectine for capillary density (Fig. 6C, E) in Control versus DM+HC+HT animals.
single myocyte passive and maximal force
Increased passive stiffness (Fpas, Fig. 7A) as well as increased maximal force (Fmax, Fig. 
7B) of the cardiomyocytes isolated from the subendocardium of the LV anterior wall of 
DM+HC+HT animals was observed as compared to the healthy controls. 
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Figure 5. Increased collagen deposition (Fig. 5A) but no myocyte hypertrophy (Fig. 5B) was recorded in 
endocardium of LV anterior wall of the DM+HC+HT animals when compared to healthy controls. Capillary 
density was similar between groups (Fig. 5C), however the capillary-to-fibre ratio was significantly reduced 
in DM+HC+HT (Fig. 5D), indicative of capillary rarefaction. *P<0.05 DM+HC+HT versus Control
in press
Figure 6. Typical examples of the endocardial layer of the LV stained with picrosirius red for collagen (Fig. 
6A, D), Gomori for myocyte size (Fig. 6B, C) and lectine for capillary density (Fig. 6C, E) in DM+HC+HT versus 
Control.
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Cardiac MRI and global LV function
MRI variables are shown in Table 2. LV EDV, was similar while SV was smaller in DM+HC+HT 
as compared to Control animals, while ejection fraction was not changed, (Fig. 8A). Late 
gadolinium enhancement did not show any difference despite an increased collagen 
content in the LV of DM+HC+HT animals as measured histologically, (data not shown). 
However, E/A ratio tended to be lower in the DM+HC+HT group, suggestive of early 
diastolic dysfunction (Fig. 8B), although LV dP/dtmin or the time constant of relaxation 
tau were not different. These findings were complemented by the pressure-volume 
data, showing that DM+HC+HT animals had increased LV end-diastolic elastance, in-
dicative of increased passive stiffness of the LV in vivo (Fig. 8D, P<0.05). LV end-systolic 
elastance also tended to be higher in these animals, although this failed to reach statisti-
cal significance (Fig. 8C, P=0.10). No significant group differences were observed in LV 
end-diastolic pressure, dP/dtmax or tau (Table 2). The LV EDV was significantly lower in the 
DM+HC+HT animals as measured by the pressure-volume catheter and showed a similar 
behavior when measured in the MRI, although it did not reach statistical significance. 
Similarly, the stroke volume was also significantly lower in the DM+HC+HT group versus 
Control animals, as measured by both pressure-volume catheter and MRI. 
Atrial, ventricular and renal weights
No group differences were detected in LV, right ventricle, left or right atrium mass, either 
in absolute terms or when normalized for body weight (Supplemental Table 1). Kidneys 
of the DM+HC+HT animals were smaller than kidneys of control healthy animals, 
however, when corrected for body weight, these differences were no longer apparent 
(Supplemental Table 1).
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Figure 7. Increased passive (Fig. 7A) and maximal force (Fig. 7B), was seen in DM+HC+HT group as com-
pared to healthy animals. *P<0.05 DM+HC+HT versus Control.
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Figure 8. No difference in ejection fraction (EF) was seen between groups as measured with MRI (Fig. 8A). 
However, the early-to-late filing velocity ratio of blood during diastole (E/A ratio) was significantly reduced 
in the DM+HC+HT animals (Fig. 8B). In accordance to these findings, increased end diastolic elastance was 
seen in these animals (Fig. 8D), while a trend towards significance in the end systolic elastance was record-
ed (Fig. 8C). *P<0.05 DM+HC+HT versus Control. **P<0.05 DM+HC+HT versus Control by one sided t-test.
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DIsCUssIoN
In the present study, we report that in the absence of major geometrical alterations in the 
heart, the coexistence of three common comorbidities leads to LV diastolic dysfunction 
as evidenced by reduced LV diastolic early-to-late filling velocities as well as increased 
passive LV stiffness in vivo, while EF was still preserved. The cascade of events leading 
to diastolic dysfunction included the presence of chronic systemic inflammation and 
decreased endothelium-dependent vasodilation in the coronary arteries as assessed in 
vitro. We also observed reduced capillary-to-fiber ratio, higher superoxide production 
due to NOX activation and eNOS uncoupling and reduced cardiac NO production, all 
likely to be important mechanisms for the observed increased collagen content in the LV 
contributing to LV stiffening and thereby reduced diastolic function (12). 
Paulus and Tschope (12) recently proposed that a systemic inflammatory state pro-
duced by cardiovascular comorbidities or risk factors is common in many HF patients 
including those with HFpEF (23, 24). The inflammatory state promotes coronary micro-
vascular endothelial dysfunction, which characterized by generation of reactive oxygen 
species and reduced NO bioavailability, leading to a cascade of signaling events that ulti-
Table 2. Left ventricular function in Control and DM + HC + HT groups under anesthesia 
Control DM + HC + HT
Body weight (kg) 102±4 79±3*
Pressure/Volume Catheter N=8 N=10
Heart rate (bpm) 85±3 91±5
LV EDV (ml) 174±22 113±11*
SV (ml) 75±3 55±4*
Ejection fraction (%) 47±5 50±3
Millar Catheter N=8 N=10
Heart rate (bpm) 88±4 85±3
dP/dt max (mmHg/s) 1470±138 1604±214
dP/dt min (mmHg/s) -2510±322 -2687±266
Tau (ms) 49±3 48±3
LV EDP (mmHg) 9±2 9±2
MRI N=6 N=7
Heart rate 89±7 71±3*
LV EDV (ml) 189±12 162±11
SV 98±9 73±7*
Ejection fraction (%) 51±3 45±4
LV= left ventricle, SV=stroke volume, EDV=End-diastolic volume, ESV= End-systolic volume, dP/dT min and 
dP/dT max = minimum and maximum rate of pressure change in the left ventricle, LV EDP=left ventricle 
end diastolic pressure, Tau=time constant of isovolumic relaxation; *P<0.05 compared to Controls
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mately promote cardiac fibrosis and myocyte stiffness. Indeed, it is now well established 
that multiple common comorbidities, including obesity, diabetes and hypertension, are 
strongly associated with HFpEF (5-7, 25-27). This cascade of events could be faithfully 
recapitulated in the present study. Thus, firstly, a pro-inflammatory state as documented 
by markedly elevated levels of circulating TNF-α in diseased animals. Secondly, coronary 
small artery endothelial dysfunction was also evident as relaxation responses to brady-
kinin were diminished, while smooth muscle cell function was preserved as responses to 
the exogenous NO donor SNAP were intact. Thirdly, and perhaps most importantly, ROS 
production paralleled by a decreased cardiac NO production was markedly increased. 
Specifically, the basal superoxide production was increased 3-fold in the DM+HC+HT 
animals as compared to controls. This increase was significantly suppressed by L-NAME 
as well as by VAS2870, indicating that both NOS and NADPH oxidase were the principal 
sources of superoxide production. Upon stimulation of NADPH oxidase, the superoxide 
production was markedly increased as compared to controls, confirming NADPH oxidase 
major source of superoxide anion. Furthermore, although increased eNOS expression 
and phosphorylation levels were observed in DM+HC+HT animals, the monomer/dimer 
ratio was increased almost 3-fold, indicating that eNOS-uncoupling accounted for the 
aggravated NOS-dependent superoxide production.
In addition to these functional alterations, structural vascular impairments were also 
present in the myocardium of DM+HC+HT animals. We observed capillary rarefaction 
as evidenced by lower capillary-to-fiber ratio in the diseased hearts. Capillary rarefac-
tion has only been sparsely investigated in previous studies, but our findings are well 
in accordance with a recent study by Mohammed et al. who reported a reduced capil-
lary density in the myocardium of HFpEF patients (28). This capillary rarefaction may 
have important clinical implications, particularly when occurring simultaneously with 
the observed coronary arterial endothelial dysfunction, as it will impair myocardial 
oxygenation especially during physical exercise (29). These microvascular alterations, 
at the level of both small arteries and capillaries may contribute to reduced exercise 
tolerance in HFpEF patients (30). The observed vascular changes were accompanied by 
an increase in the total collagen, which together with the increased passive stiffness of 
single cardiac myocytes translated into a higher LV stiffness (31, 32) as demonstrated 
by an increased LV end-diastolic elastance and increased E/A ratio, both clear indica-
tors of diastolic dysfunction. Interestingly, maximal force of single cardiomyocytes was 
increased accompanied by a trend towards increased LV end-systolic elastance. It could 
be speculated that the increase in contractility acted as a compensatory mechanisms 
to maintain LV function particularly in the face of the elevated blood pressure in the 
absence of LV hypertrophy (33). 
The animal model presented here is complementary to a recently reported porcine 
model of diastolic dysfunction (34). Thus, Schwarzl et al. produced hypertension and 
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hypercholesterolemia using DOCA-salt and western diet containing high amounts of 
salt, fat and cholesterol. An important difference between the two studies, besides 
the longer follow-up (6 months versus 12 weeks), was the induction of diabetes in our 
model. Although Schwarzl et al (34) reported several similar findings, including LV end-
diastolic stiffness, increased superoxide production and eNOS uncoupling, some find-
ings are distinctly different. Diabetes, which is a common comorbidity in HFpEF patients, 
likely contributed to the endothelial dysfunction and activation of NOX, which are also 
observed in HFpEF patients (22). Moreover, whereas concentric LV hypertrophy occurred 
in response to the pressure-overload in the study of Schwarzl et al. cardiomyocyte area 
was reduced in our model. The latter is in accordance with the concept that severe hy-
perglycemia induces muscle cell atrophy both in skeletal (35, 36) and cardiac muscle (37, 
38). Additionally, increased LV fibrosis was documented in the present study but not in 
the study by Schwarzl et al., most likely because hyperglycemia in addition to inflamma-
tion is an important trigger for extracellular matrix remodeling in HFpEF(39, 40). Further, 
diabetes is also known to lead to vascular deficiency, mediated by miR-320 according to 
a recent study (41) as also documented here as capillary rarefaction. Conversely, in the 
study by Schwarzl et al. (34) the contribution of titin, the giant molecular “spring” that is 
considered as one of the most important factors responsible for cardiomyocyte passive 
stiffness, was comprehensively addressed. Reduced total titin phosphorylation and a 
shift towards its stiffer isoform N2B were reported, supporting the concept that both 
collagen and titin contribute to myocardial stiffness in HFpEF patients (31). Clearly, both 
models identified potential targets for study and treatment of the observed structural 
and functional alterations in the LV. 
CoNCLUsIoNs
The present study demonstrates that in a large animal, chronic exposure to multiple 
common co-morbidities results in endothelium-dependent coronary artery dysfunc-
tion, capillary rarefaction, oxidative stress, and perturbed nitric oxide production, which 
are associated with increased myocardial fibrosis and passive cardiomyocyte stiffness, 
resulting in LV diastolic dysfunction. This large animal model provides an excellent 
translational tool for improving our understanding of the pathophysiology of heart 
failure with preserved ejection fraction and for testing novel therapeutic interventions, 
including drugs, exercise and diet interventions, for the treatment of the patients with 
this form of heart failure.
supplemental data
In online Supplemental data section kidney and heart weights are reported.
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supplemental Table 1. Kidneys and heart weights at sacrifice in Control and DM+HC+HT animals.
Controls (N=8) DM+HC+HT (N=10)
Body weight (kg) 102±4 79±3*
 Kidneys
Left kidney - absolute (g) 176±12 127±7*
 - relative (g/kg) 1.69±0.09 1.64±0.10 
Right kidney  - absolute (g) 173±14 132±10*
 - relative (g/kg) 1.66±0.12 1.71±0.14 
Heart
LV - absolute (g)
 - relative (g/kg)
231±17
2.2±0.1
184±9*
2.3±0.1
RV - absolute (g) 73±8 58±3
 - relative (g/kg) 0.68±0.08 0.74±0.02 
LA - absolute (g) 21±1 16±1*
 - relative (g/kg) 0.20±0.01 0.21±0.01 
RA - absolute (g) 14±1 13±1
 - relative (g/kg) 0.13±0.01 0.17±0.01* 
LV= left ventricle, RV= right ventricle, LA= left atrium, RA= right atrium. The data is presented as absolute 
value and also relative to the body weight. *P<0.05 compared to Controls. 
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AbsTRACT
The aim of this study was to evaluate the value of microvascular obstruction (MO) and 
infarct size as a percentage of left ventricular mass (IS%LV), as measured by contrast-
enhanced cardiac magnetic resonance, in predicting major cardiovascular adverse 
events (MACE) at 2 years in patients with ST-segment elevation myocardial infarction 
reperfused by primary percutaneous coronary intervention. Individual data from 1,025 
patients were entered into the pooled analysis. MO was associated with the occurrence 
of MACE, deﬁned as a composite of cardiac death, congestive heart failure, and myo-
cardial re-infarction (adjusted hazard ratio: 3.74; 95% conﬁdence interval: 2.21 to 6.34). 
IS% LV 25% was not associated with MACE (adjusted hazard ratio: 0.90; 95% conﬁdence 
interval: 0.59 to 1.37). The authors conclude that MO is an independent predictor of 
MACE and cardiac death, whereas IS%LV is not independently associated with MACE.
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INTRoDUCTIoN
In the setting of ST-segment elevation myocardial infarction (STEMI), primary percuta-
neous coronary intervention (pPCI) is the preferred reperfusion strategy and a corner-
stone in the treatment of patients with STEMI (1). A substantial proportion of STEMI 
patients display a “no-reﬂow” phenomenon despite successful epicardial reperfusion 
(2). This phenomenon is characterized by either absent or inadequate myocardial tissue 
reperfusion despite successful reopening of the infarct-related artery (3). No-reﬂow is 
thought to be a consequence of microvascular obstruction (MO), caused by numerous 
components, including distal atherothrombotic embolization, ischemic injury, reperfu-
sion injury, and susceptibility of the coronary microcirculation to injury (2). No-reﬂow 
can be assessed with cine coronary angiography, ST-segment resolution measured on 
electrocardiography, and noninvasive imaging techniques such as myocardial contrast 
echocardiography and contrast-enhanced cardiac magnetic resonance (CE-CMR). In 
patients with STEMI, the presence and magnitude of MO are visualized by CE-CMR, with 
accurate and reproducible measurements of left ventricular ejection fraction (LVEF) and 
infarct size (IS) (4). Compared with myocardial segments without MO, segments with 
MO are more likely to demonstrate wall thinning and are less likely to demonstrate 
improvement of segmental wall thickening during follow-up study (5). Moreover, MO 
is an important predictor of global functional recovery after STEMI(6). Several studies 
suggest that MO is associated with worse prognosis (7-13). However, previous studies in 
this regard have been hampered by a limited number of patients, evaluated a combined 
clinical endpoint, and were single-center studies. Furthermore, although intuitively 
IS measured within 2 weeks after STEMI is an important independent determinant of 
outcome, there is conﬂicting evidence to support its independent predictive value for 
major adverse cardiac events (MACE) (9, 12, 14).
We performed a meta-analysis of individual patient data to evaluate the hypotheses 
that MO and IS expressed as a percentage of left ventricular (LV) mass (IS%LV) are inde-
pendent predictors of MACE and cardiac death in patients with STEMI undergoing pPCI.
MeTHoDs
study selection
The MEDLINE database was searched for citations of in-human studies published in Eng-
lish from January 2004 to April 2012, using the following terms: microcirculation(MESH), 
magnetic resonance imaging, myocardial infarction, and microvascular obstruction. 
A total of 134 publications were identiﬁed. Related studies from the reference Lower 
Late Angioplasty Complications) risk score (15), the Zwolle primary PCI index(16), and the 
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Thrombolysis in Myocardial Infarction (TIMI) risk score(17); baseline CE-CMR variables; and 
clinical outcomes (MACE) were mentioned before- hand in a protocol, along with study ra-
tionale and study design. The protocol was sent to participating centers. Previous approval 
of the individual study design by a local ethics committee was necessary for participation. 
Datasets from participating centers were merged by the coordinating center (Erasmus 
Medical Center, Rotterdam, the Netherlands). Queries were sent to the primary investiga-
tors in cases in which further data and clariﬁcation were needed.
Definitions/ce-cmr. 
STEMI was deﬁned on the basis of the deﬁnitions used by the authors of the primary 
publications (8–13) (18, 19). All clinical and angiographic variables were study based. 
Angiographic left main coronary artery lesions were categorized as left anterior de-
scending artery lesions. Imaging was performed in different centers on 1.5-T scanners 
from different vendors (Online Table 1). The scanning protocols, CE-CMR parameters, 
and data analysis have been described in the included studies (8–13,18,19). All investi-
gators but one used a steady-state, free-precession sequence for cine CMR (Online Table 
1). LV end-diastolic volume, LV end- systolic volume, and LVEF were short-axis based, 
as provided by the investigators. If LV end-diastolic and end-systolic volume were not 
indexed, the Mosteller equation was used to adjust these for body surface area. Late 
gadolinium enhancement was performed by the different centers by use of a (phase-
sensitive) inversion recovery gradient echo sequence. MO, as visualized with late 
gadolinium enhancement, was deﬁned as any region of hypo- enhancement within the 
hyperenhanced area. IS was determined on short-axis images. IS was expressed both in 
grams and as a percentage of the LV mass (IS% LV). IS%LV was determined by manual or 
automated tracing of the infarct border. In patients with MO, regions of hypoenhance-
ment were included in the IS. In 2 studies, patients with prior infarction were included 
(8,12). In patients with prior myocardial infarction, only the region indicative of acute 
infarction (8), corresponding with edema in T2-weighted imaging (12), was measured in 
delayed-enhancement images.
endpoints. 
The primary endpoint was the prevalence of major adverse cardiovascular events 
(MACE), deﬁned as a composite of cardiac death, myocardial re-infarction, and new 
congestive heart failure, at 2 years. The secondary endpoint was cardiac mortality. Con-
gestive heart failure was deﬁned as any symptom of cardiac decompensation requiring 
hospitalization. The individual study investigators provided previously deﬁned and used 
events (Online Table 1). If a patient experienced more than one event, the ﬁrst event was 
chosen for the combined clinical endpoint. Patients were considered at risk from the 
time of admission for the treatment of STEMI. 
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statistical Analysis. 
Continuous data with normal distribution are presented as mean ± SD. Non-normally 
distributed variables are reported as median with corresponding interquartile range (IQR). 
Categorical variables are represented by frequencies and percentages. Patients were cat-
egorized according to the presence of MACE. Differences in continuous variables between 
categories of patients were studied by the unpaired Student t test or the Mann-Whitney U 
test (in cases of non-normal distribution). Proportions were compared using the chi-square 
test or the Fisher exact test, where applicable. The incidences of the primary and second-
ary endpoints are reported as Kaplan-Meier estimates at a follow-up of 2 years. As small 
infarcts and minor decreases in LVEF might not have an impact on outcome, the relationship 
between these variables on outcome was investigated by plotting IS%LV and LVEF against 
event-free survival. A log-rank test was used to evaluate differences in freedom from study 
endpoints between categories of patients. Univariate and multivariate Cox regression analy-
ses, stratiﬁed by study, were used to determine the prognostic value of MO, IS%LV, and LVEF 
with respect to the primary and secondary endpoints. Predictors of cardiac death and MACE 
in published reports—namely, age (>65 years); sex (female); the presence of diabetes, hyper-
tension, anterior myocardial infarction (culprit lesion in the left anterior descending artery), 
or multivessel disease; TIMI ﬂow grade after PCI (reference: TIMI ﬂow grade after PCI of 0 
or 1); and CMR-based LVEF (12,16,17)—were entered into the univariate regression model, 
along with MO, IS%LV, LV end-diastolic volume index, and LV end-systolic volume index (9). 
Variables that resulted in a p value of <0.10 in the univariate Cox model were entered into 
the multivariate Cox proportional hazards model, with respect to multicollinearity. LV end-
systolic volume index was not entered into the multivariate model due to a collinear relation 
with LVEF (Pearson correlation: –0.774). We applied the method of backward selection; all 
variables with a p value of <0.05 remained. The proportional hazards assumption was vali-
dated graphically. In cases of missing data (the requested variable data were unavailable in 
>5.0% of the cohort), these variables were not taken into account in the regression analysis 
(e.g., time to reperfusion and Killip class). We report unadjusted hazard ratios (HRs) and ad-
justed hazard ratios (aHRs), 95% conﬁdence in- tervals (CIs), and p values. We determined the 
c- index (20) to report on the performance of the models to discriminate between patients 
with and without the study endpoints. The incremental value of IS%LV, LVEF, and MO was 
compared with that from a model with established clinical variables. c- Index models were 
developed on the basis of multivariate Cox models. We applied, for these models, a back-
ward variable-selection method; all variables with a p value of <0.05 remained. Two- sided 
probability values with an a level of ≤0.05 were considered to be statistically signiﬁcant. 
Statistical analysis was performed using the statistical packages IBM SPSS Statistics version 
20.0.01 (IBM SPSS Statistics, IBM Corporation, Armonk, New York) and SAS version 9.2 (SAS 
Institute Inc., Cary, North Carolina). Kaplan-Meier curves were drawn with GraphPad Prism 
version 4.00 (GraphPad Soft- ware Inc., San Diego, California).
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Table 1. Patient Characteristics
Entire Cohort 
(n = 1025)
MACE 
(n = 130)
No MACE 
(n = 895)
P Value
Demographics
Age, yrs 59.7 ± 12,7 61.8 ± 13.3 59.4 ± 12.6 0.04
Male 796 (77.7) 94 (72.3) 702 (78.4) 0.12
BMI, kg/m2* 27.0 ± 3.8 27.2 ± 4.1 27.0 ± 3.7 0.60
CV risk factors
Hypertension 530/1,012 (52.4) 70/128 (54.7) 460/884 (52.0) 0.58
Hypercholesterolemia 380/1,010 (37.6) 57/128 (44.5) 323/882 (36.6) 0.08
Current or prior smoking 507/1,2023 (49.6) 54/130 (41.5) 455/893 (51.0) 0.02
Family history of MI† 278/937 (29.7) 37/121 (30.6) 241/816 (29.5) 0.81
Diabetes 176/1,012 (17.4) 35/128 (27.3) 141/884 (16.0) <0.001
Prior MI‡ 47/948 (5.0) 12/123 (9.8) 35/825 (4.2) 0.009
Prior CABG§ 10/947 (1.1) 2/123 (1.6) 8/824 (1.0) 0.51
Angiographic variables
Time to reperfusion 3.3 (2.1-4.9) 3.5 (2.1-4.9) 3.2 (2.1-4.9) 0.57
Infarct-related artery
LAD 514/1,023 (50.2) 73/128 (57.0) 441/895 (49.3) 0.10
RCA 413/1,023 (40.4) 43/128 (33.6) 370/895 (49.3) 0.10
LCA 96/1,023 (9.4) 12/128 (9.4) 84/895 (9.4) 0.99
N-vessel disease
1 563/1,004 (56,1) 53/126 (42.1) 510/878 (58.1) <0.001
2 280/1,004 (27.9) 39/126 (31.0) 241/878 (27.4) 0.41
3 161/1,004 (16.0) 34/126 (27.0) 127/878 (14.5) <0.001
Multivessel disease 441/1,013 (43.5) 73/127 (57.5) 368/886 (41.5) <0.001
TIMI flow grade after PCI
0 14/1,019 (1.4) 6/129 (4.7) 8/890 (0.9) <0.001
1 14/1,019 (1.4) 5/129 (3.9) 9/890 (1.0) 0.009
2 64/1,019 (6.3) 9/129 (7.0) 55/890 (6.2) 0.73
3 927/1,019 (91,0) 109/129 (84.5) 818/890 (91.9) 0.006
Enzymatic IS
Maximal CK|||| 2,161 (1,040-4,160) 2,729 (1,169-6,024) 2,109 (1,031-3,913) 0.04
CE-CMR variables
Time from MI to CE-CMR, days¶ 4 (2-6) 4 (2-6) 4 (2-6) 0.57
Presence of MO 577 (56.3) 109 (83.8) 468 (52.3) <0.001
IS, %LV 18.5 (9.2-28.3) 24.9 (14.4-37.4) 18.0 (8.9-26.7) <0.001
IS, g 22.3 (10.8-37.4) 33.7 (15.3-54.1) 21.0 (10.2-34.7) <0.001
LVEF, % 48.0 ± 12.3 41.4 ± 13.3 48.9 ± 11.9 <0.001
LVESV, ml 80.5 ± 35.7 94.7 ± 42.0 78.4 ± 34.2 <0.001
LVESV index, ml/m2 41.3 ± 17.2 48.4 ± 19.6 40.3 ± 16.6 <0.001
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ResULTs
Patient Characteristics. 
We identiﬁed 10 eligible observational and experimental studies. The principal inves-
tigators of these studies were invited to participate in this collaborative analysis. Eight 
of 10 investigators provided individual patient data (Figure 1). In this pooled analysis, 2 
studies with 193 potentially eligible patients were not included due to investigator un-
responsiveness (14) (21). The individual study characteristics are summarized in Online 
Table 1. The inclusion procedure is shown in Figure 2. Of 1,488 AMI patients, 150 patients 
(10.1%) were unable to have a CMR examination, and 313 patients were excluded due to 
other reasons (Figure 2). Consequently, data from 1,025 STEMI patients who underwent 
reperfusion by pPCI between April 9, 1999 and September 28, 2008 were included in 
the patient pooled analysis. The mean age at inclusion was 59.7 ± 12.7 years, and 77.7% 
of the cohort were men (n = 796). The median time to reperfusion was 3.3 h (IQR: 2.1 
to 4.9 h). CE-CMR was performed within a median of 4 days (IQR: 2 to 6 days) after the 
occurrence of STEMI. MO was present in 56.3% of patients in the overall cohort. Of 
patients with TIMI ﬂow grade after PCI of 3 (927 of 1,019 [91.0%]), MO was present in 
54.9%. The mean LVEF was 48.0 ± 12.3%. Of the entire cohort, 14.7% had a severely 
depressed (<35%) LVEF. The baseline characteristics of patients with MACE and patients 
without MACE are compared in Table 1. The median duration of available follow-up was 
12 months (IQR: 4 to 21 months).
Predictors of Mace. 
The composite endpoint occurred in 130 patients within 2 years of follow-up. In 9 pa-
tients, an event occurred between the index event and the CE-CMR study. Cardiac death 
occurred in 25 patients; myocardial re-infarction, in 47 patients; and congestive heart 
Table 1. Patient Characteristics (continued)
Entire Cohort 
(n = 1025)
MACE 
(n = 130)
No MACE 
(n = 895)
P Value
LVEDV, ml 150.5 ± 42.4 156.3 ± 45.3 149.6 ± 41.9 0.09
LVEDV index, ml/m2 77.4 ± 19.6 80.5 ± 20,9 77.0 ± 19.4 0.05
Values are mean ± SD, n/N (%), or median (IQR). Data missing in the following number of cases: *124 
(12.1%), †88 (8.6%), ‡77 (7.5%), §78 (7.6%), ||||278 (27.1%), and ¶446 (43.5%) (reperfusion within 12 h). Data 
missing in > 7.5% of the cohort.
BMI = body mass index; CABG = coronary artery bypass grafting; CE-CMR = contrast-enhanced cardiac 
magnetic resonance; CK = creatine kinase; CV = cardiovascular; IQR = interquartile range; IS = infarct size; 
LAD = left anterior descending; LCA = left circumflex artery; %LV = percentage of LV mass; LVEDV = left ven-
tricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic 
volume; MI = myocardial infarction; MO = microvascular obstruction; PCI = percutaneous intervention; RCA 
= right coronary artery; TIMI = Thrombolysis in Myocardial Infarction.
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both in grams and as a percentage of the LV mass (IS%
LV). IS%LV was determined by manual or automated
tracing of the infarct border. In patients with MO,
regions of hypoenhancement were included in the IS.
In 2 studies, patients with prior infarction were
included (8,12). In patients with prior myocardial
infarction, only the region indicative of acute infarc-
tion (8), corresponding with edema in T2-weighted
imaging (12), was measured in delayed-enhancement
images.
ENDPOINTS. The primary endpoint was the preva-
lence of major adverse cardiovascular events
(MACE), deﬁned as a composite of cardiac death,
myocardial re-infarction, and new congestive heart
failure, at 2 years. The secondary endpoint was cardiac
mortality. Congestive heart failure was deﬁned as
any symptom of cardiac decompensation requiring
hospitalization. The individual study investigators
provided previously deﬁned and used events (Online
Table 1). If a patient experienced more than
one event, the ﬁrst event was chosen for the com-
bined clinical endpoint. Patients were considered
at risk from the time of admission for the treatment
of STEMI.
STATISTICAL ANALYSIS. Continuous data with
normal distribution are presented as mean  SD.
Non-normally distributed variables are reported as
median with corresponding interquartile range
(IQR). Categorical variables are represented by fre-
quencies and percentages. Patients were categorized
according to the presence of MACE. Differences in
continuous variables between categories of patients
were studied by the unpaired Student t test or the
Mann-Whitney U test (in cases of non-normal dis-
tribution). Proportions were compared using the
chi-square test or the Fisher exact test, where
applicable. The incidences of the primary and sec-
ondary endpoints are reported as Kaplan-Meier es-
timates at a follow-up of 2 years. As small infarcts
and minor decreases in LVEF might not have an
impact on outcome, the relationship between these
variables on outcome was investigated by plotting
IS%LV and LVEF against event-free survival. A log-
rank test was used to evaluate differences in
freedom from study endpoints between categories
of patients. Univariate and multivariate Cox
regression analyses, stratiﬁed by study, were used
to determine the prognostic value of MO, IS%LV,
and LVEF with respect to the primary and second-
ary endpoints. Predictors of cardiac death and
MACE in published reports—namely, age (>65
years); sex (female); the presence of diabetes, hy-
pertension, anterior myocardial infarction (culprit
lesion in the left anterior descending artery), or
multivessel disease; TIMI ﬂow grade after PCI
(reference: TIMI ﬂow grade after PCI of 0 or 1); and
CMR-based LVEF (12,16,17)—were entered into the
univariate regression model, along with MO, IS%LV,
LV end-diastolic volume index, and LV end-systolic
volume index (9). Variables that resulted in a
p value of <0.10 in the univariate Cox model were
entered into the multivariate Cox proportional
hazards model, with respect to multicollinearity. LV
end-systolic volume index was not entered into the
multivariate model due to a collinear relation with
LVEF (Pearson correlation: –0.774). We applied the
method of backward selection; all variables with a
p value of <0.05 remained. The proportional haz-
ards assumption was validated graphically. In cases
of missing data (the requested variable data were
unavailable in >5.0% of the cohort), these variables
were not taken into account in the regression
analysis (e.g., time to reperfusion and Killip class).
We report unadjusted hazard ratios (HRs) and
adjusted hazard ratios (aHRs), 95% conﬁdence in-
tervals (CIs), and p values. We determined the c-
index (20) to report on the performance of the
models to discriminate between patients with and
without the study endpoints. The incremental value
of IS%LV, LVEF, and MO was compared with that
from a model with established clinical variables. c-
Index models were developed on the basis of
multivariate Cox models. We applied, for these
models, a backward variable-selection method; all
FIGURE 1 Computerized Search
A computerized literature search of citations was performed.
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variables with a p value of <0.05 remained. Two-
sided probability values with an a level of #0.05
were considered to be statistically signiﬁcant. Sta-
tistical analysis was performed using the statistical
packages IBM SPSS Statistics version 20.0.01 (IBM
SPSS Statistics, IBM Corporation, Armonk, New
York) and SAS version 9.2 (SAS Institute Inc., Cary,
North Carolina). Kaplan-Meier curves were drawn
with GraphPad Prism version 4.00 (GraphPad Soft-
ware Inc., San Diego, California).
RESULTS
PATIENT CHARACTERISTICS. We identiﬁed 10
eligible observational and experimental studies.
The principal investigators of these studies were
invited to participate in this collaborative analysis.
Eight of 10 investigators provided individual
patient data (Figure 1). In this pooled analysis,
2 studies with 193 potentially eligible patients were
not included due to investigator unresponsiveness
(14,21).
The individual study characteristics are summa-
rized in Online Table 1. The inclusion procedure
is shown in Figure 2. Of 1,488 AMI patients, 150 pa-
tients (10.1%) were unable to have a CMR examina-
tion, and 313 patients were excluded due to other
reasons (Figure 2). Consequently, data from 1,025
STEMI patients who underwent reperfusion by pPCI
between April 9, 1999 and September 28, 2008 were
included in the patient pooled analysis. The mean age
at inclusion was 59.7 � 12.7 years, and 77.7% of the
cohort were men (n ¼ 796). The median time to
reperfusion was 3.3 h (IQR: 2.1 to 4.9 h). CE-CMR was
performed within a median of 4 days (IQR: 2 to 6
days) after the occurrence of STEMI. MO was present
in 56.3% of patients in the overall cohort. Of patients
with TIMI ﬂow grade after PCI of 3 (927 of 1,019
[91.0%]), MO was present in 54.9%. The mean LVEF
was 48.0 � 12.3%. Of the entire cohort, 14.7% had a
severely depressed (<35%) LVEF. The baseline char-
acteristics of patients with MACE and patients
without MACE are compared in Table 1. The median
duration of available follow-up was 12 months (IQR:
4 to 21 months).
PREDICTORS OF MACE. The composite endpoint
occurred in 130 patients within 2 years of follow-up.
In 9 patients, an event occurred between the index
event and the CE-CMR study. Cardiac death
occurred in 25 patients; myocardial re-infarction, in
47 patients; and congestive heart failure, in 58 pa-
tients. The Kaplan-Meier estimate of freedom from
MACE at 2 years was 76.5% in patients with MO
versus 93.0% in patients without MO (p < 0.001).
For both LVEF and IS%LV, nonlinear relationships
were observed (Figures 3 and 4). Therefore, these 2
variables were categorized using tertiles, which
provides a large number of events per category
while respecting nonlinearity. For LVEF, the ﬁrst
tertile (cutoff: 42.7%, simpliﬁed to #40%, used in
the CADILLAC risk score [15]) was compared to the
reference group (LVEF >40%). For IS%LV, the last
tertile (cutoff: 24.7%, simpliﬁed to $25%) was
compared to the reference group (IS%LV <25%).
The Kaplan-Meier estimate of freedom from MACE
at 2 years was 74.3% in patients with IS%LV $25%
versus 87.4% in patients with IS%LV <25% (p <
0.001). Kaplan-Meier curves for MACE by MO and
IS%LV in the entire cohort, and grouped by MO and
FIGURE 2 Study Flow Chart
AMI ¼ acute myocardial infarction; CE-CMR ¼ contrast-enhanced cardiac
magnetic resonance; ICD ¼ implantable cardioverter-deﬁbrillator; NSTEMI ¼
non–ST-segment elevation myocardial infarction; pPCI ¼ primary percuta-
neous coronary intervention.
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failure, in 58 patients. The Kaplan-Meier estimate of freedom from MACE at 2 years was 
76.5% in patients with MO versus 93.0% in patients without MO (p < 0.001) For both LVEF 
and IS%LV, nonlinear relationships were observed (Figures 3 and 4). Therefore, these 2 
variables were categorized using tertiles, which provides a large number of events per 
category while respecting nonlinearity. For LVEF, the ﬁrst tertile (cutoff: 42.7%, simpliﬁed 
to ≤0%, used in the CADILLAC risk score [15]) was compared to the reference group 
(LVEF >40%). For IS%LV, the last tertile (cutoff: 24.7%, simpliﬁed to ≥25%) was compared 
to the reference group (IS%LV <25%). The Kaplan-Meier estimate of freedom from MACE 
at 2 years was 74.3% in patients with IS%LV >25% versus 87.4% in patients with IS%LV 
<25% (p < 0.001). Kaplan-Meier curves for MACE by MO and IS%LV in the entire cohort, 
and grouped by MO and IS%LV, are depicted in Figures 5 to 7. The Kaplan-Meier estimate 
of freedom from MACE was 71.3% in patients with IS%LV >25% with MO versus 94.9% 
in patients with IS%LV <25% without MO (p < 0.001). Univariate Cox regression is sum-
marized in Table 2. MO (HR: 4.68; 95% CI: 2.86 to 7.66), IS%LV ≥25% (HR: 2.04; 95% CI: 
1.42 to 2.92), and LVEF ≤40% (HR: 3.45; 95% CI: 2.40 to 4.97) were associated with MACE 
on univariate Cox regression analysis. Sex (HR: 1.34; 95% CI: 0.89 to 2.00) and anterior 
myocardial infarction (HR: 1.30; 95% CI: 0.90 to 1.87) were not associated with MACE on 
univariate Cox regression analysis. Multivariate Cox regression is summarized in Table 
3. MO (aHR: 3.74; 95% CI: 2.21 to 6.34) and LVEF ≤40% (aHR: 2.30; 95% CI: 1.48 to 3.58) 
Table 2. Association of patient characteristics with MACE at 2 years univariate Cox regression analysis
HR 95% CI p Value
Demographics
 Age 1.60 1.11-2.31 0.01
 Sex 1.34 0.89-2.00 0.16
CV risk factors
 Diabetes 1.66 1.09-2.53 0.02
 Hypertension 0.97 0.67-1.42 0.89
 Anterior MI 1.30 0.90-1.87 0.16
Angiographic variables
 Multivessel disease 1.65 1.13-2.40 0.009
 TIMI flow grade after PCI 3.31 1.70-6.43 <0.001
CE-CMR variables
 Presence of MO 4.68 2.86-7.66 <0.001
 IS%LV 2.04 1.42-2.92 <0.001
 LVEF 3.45 2.40-4.97 <0.001
 LVESV index 1.03 1.02-1.04 <0.001
 LVEDV index 1.02 1.01-1.02 <0.001
CI = confidence interval; HR = hazard ratio; MACE = major cardiovascular events; other abbreviations as in 
Table 1. 
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were associated with MACE, whereas IS%LV ≥25% and diabetes were not independently 
associated with MACE (model I). After the application of the backward variable-selection 
method, ﬁve variables (age, multi- vessel disease, TIMI ﬂow grade after PCI, MO, and LVEF 
≤40%) remained signiﬁcant (model II). In a separate analysis, IS%LV, unadjusted for MO 
and LVEF, but adjusted for age, multivessel disease, and TIMI ﬂow grade after PCI, was as-
sociated with the occurrence of MACE (aHR: 1.82; 95% CI: 1.26 to 2.63) (data not shown). 
The addition of IS%LV ≥25% to a model with age, multivessel disease, and TIMI ﬂow grade 
after PCI (model a) resulted in an increase of the c-index from 0.59 to 0.61 (model b) in the 
prediction of MACE. The addition of LVEF ≤40% resulted in an increase from 0.59 to 0.66 
(model c), with a further increase to 0.70 (model e) when MO was added (Table 4).
LVEF #40% (aHR: 2.30; 95% CI: 1.48 to 3.58) were
associated with MACE, whereas IS%LV $25% and
diabetes were not independently associated with
MACE (model I). After the application of the backward
variable-selection method, ﬁve variables (age, multi-
vessel disease, TIMI ﬂow grade after PCI, MO, and
LVEF #40%) remained signiﬁcant (model II). In a
separate analysis, IS%LV, unadjusted for MO and
LVEF, but adjusted for age, multivessel disease,
and TIMI ﬂow grade after PCI, was associated with the
occurrence of MACE (aHR: 1.82; 95% CI: 1.26 to 2.63)
(data not shown).
The addition of IS%LV $25% to a model with age,
multivessel disease, and TIMI ﬂow grade after PCI
(model a) resulted in an increase of the c-index
from 0.59 to 0.61 (model b) in the prediction of
MACE. The addition of LVEF #40% resulted in an
increase from 0.59 to 0.66 (model c), with a further
increase to 0.70 (model e) when MO was added
(Table 4).
PREDICTORS OF CARDIAC DEATH. The Kaplan-
Meier estimate of freedom from cardiac death at
2 years was 96.7% (MO vs. no MO: 99.8% vs. 94.6%;
FIGURE 3 Relationship Between LV Ejection Fraction and
Event-Free Survival
Values are Kaplan-Meier estimates (95% conﬁdence interval), by
LV ejection fraction category (>60%, 50% to #60%, 40
to #50%, 30% to #40%, or <30%). LV ¼ left ventricular.
FIGURE 4 Relationship Between IS%LV and
Event-Free Survival
Values are Kaplan-Meier estimates (95% conﬁdence interval), by
IS%LV category (0 to #10%, 10% to #20%, 20% to #30%, 30
to #40%, or >40%). I LV ¼ infarct size expressed as a per-
centage of left ventricular mass.
FIGURE 5 Relationship Between MO and Event-Free Survival
Values are Kaplan-Meier estimates in patients with microvascular
obstruction (MO) versus patients without MO, indicating the time
to major adverse cardiovascular events (MACE), follow-up 2
years.
FIGURE 6 Relationship Between IS%LV and
Event-Free Survival
Values are Kaplan-Meier estimates in patients with IS%LV $25%
versus <25%, indicating the time to MACE, follow-up 2 years.
Abbreviations as in Figures 4 and 5.
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LVEF #40% (aHR: 2.30; 95% CI: 1.48 to 3.58) were
associated with MACE, whereas IS%LV $25% and
diabetes were not independently associated with
MACE (model I). After the application of the backward
variable-selection method, ﬁve variables (age, multi-
vessel disease, TIMI ﬂow grade after PCI, MO, and
LVEF #40%) remained signiﬁcant (model II). In a
separate analysis, IS%LV, unadjusted for MO and
LVEF, but adjusted for age, multivessel disease,
and TIMI ﬂow grade after PCI, was associated with the
occurrence of MACE (aHR: 1.82; 95% CI: 1.26 to 2.63)
(data not shown).
The addition of IS%LV $25% to a model with age,
multivessel disease, and TIMI ﬂow grade after PCI
(model a) resulted in an increase of the c-index
from 0.59 to 0.61 (model b) in the prediction of
MACE. The addition of LVEF #40% resulted in an
increase from 0.59 to 0.66 (model c), with a further
increase to 0.70 (model e) when MO was added
(Table 4).
PREDICTORS OF CARDIAC DEATH. The Kaplan-
Meier estimate of freedom from cardiac death at
2 years was 96.7% (MO vs. no MO: 99.8% vs. 94.6%;
FIGURE 3 Relationship Between LV Ejection Fraction and
Event-Free Survival
Values are Kaplan-Meier estimates (95% conﬁdence interval), by
LV ejection fraction category (>60%, 50% to #60%, 40
to #50%, 30% to #40%, or <30%). LV ¼ left ventricular.
FIGURE 4 Relationship Between IS%LV and
Event-Free Survival
Values are Kaplan-Meier estimates (95% conﬁdence interval), by
IS%LV category (0 to #10%, 10% to #20%, 20% to #30%, 30
to #40%, or >40%). IS%LV ¼ infarct size expressed as a per-
centage of left ventricular mass.
FIGURE 5 Relationship Between MO and Event-Free Survival
Values are Kaplan-Meier estimates in patients with microvascular
obstruction (MO) versus patients without MO, indicating the time
to major adverse cardiovascular events (MACE), follow-up 2
years.
FIGURE 6 Relationship Between IS%LV and
Event-Free Survival
Values are Kaplan-Meier estimates in patients with IS%LV $25%
versus <25%, indicating the time to MACE, follow-up 2 years.
Abbreviations as in Figures 4 and 5.
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Predictors of Cardiac Death. 
The Kaplan- Meier estimate of freedom from cardiac death at 2 years was 96.7% (MO vs. 
no MO: 99.8% vs. 94.6%; p < 0.001). The Kaplan-Meier estimate of freedom from cardiac 
death at 2 years was 95.2% in patients with IS%LV ≥25% versus 97.3% in patients with 
IS%LV <25% (p < 0.21) (data not shown). Univariate Cox regression is summarized in 
Table 5. MO (HR: 15.02; 95% CI: 2.01 to 112.24) and LVEF ≤0% (HR: 2.26; 95% CI: 1.01 to 
5.05) were associated with cardiac death on univariate Cox regression analysis. IS%LV 
≥25% was not associated with cardiac death in a univariate Cox model (HR: 1.77; 95% CI: 
0.80 to 3.89). Independent predictors on multivariate Cox regression and their respec-
tive aHRs for cardiac death at 2 years are summarized in Table 6. MO was associated with 
the occurrence of cardiac death (aHR: 13.22; 95% CI: 1.75 to 99.82) when adjusted for age 
(aHR: 2.21; 95% CI: 0.96 to 5.06) and LVEF ≤40% (aHR: 1.66; 95% CI: 0.74 to 3.75).
Table 3. Association of patient characteristics with MACE at 2 years multivariate Cox regression analysis
aHR 95% CI p Value
Model I*
 Age 1.54 1.04-2.27 0.03
 Diabetes 1.25 0.80-1.94 0.33
 Multivessel disease 1.56 1.07-2.28 0.02
 TIMI flow grade after PCI 2.11 1.04-4.27 0.04
 Presence of MO 3.74 2.21-6.34 <0.001
 IS%LV ≥ 25% 0.90 0.59-1.37 0.63
 LVEF ≤ 40% 2.30 1.48-3.58 <0.001
 LVEDV index 1.00 0.99-1.01 0.58
Model II ¥
 Age 1.58 1.08-2.30 0.02
 Multivessel disease 1.56 1.08-2.27 0.02
 TIMI flow grade after PCI 2.25 1.14-4.45 0.02
 Presence of MO 3.72 2.22-6.25 <0.001
 LVEF ≤ 40% 2.40 1.63-3.53 <0.001
*Before backward variable selection in 970 patients, 118 events. ¥ Backward variable selection in 984 pa-
tients, 118 events.
aHR = adjusted hazard ratios; other abbreviations as in Tables 1 and 2. 
Table 4. Incremental value of MO, IS%LV, and LVEF ≤40%, in the prediction of MACE at 2 years
Model a: age + multivessel disease + TIMI flow grade after PCI 0.59
Model b: age + multivessel disease + TIMI flow grade after PCI + IS%LV ≥ 25% 0.61
Model c: age + multivessel disease + TIMI flow grade after PCI + LVEF ≤ 40% 0.66
Model d: age + multivessel disease + TIMI flow grade after PCI + LVEF ≤ 40% + IS%LV ≥ 25% 0.66
Model e: age + multivessel disease + TIMI flow grade after PCI + LVEF ≤ 40% + MO 0.70
Abbreviations as in Tables 1 and 2.
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DIsCUssIoN
The main ﬁndings of this study were that: 1) MO was present in >50% of patients with 
STEMI reperfused by pPCI (even in patients with TIMI ﬂow grade post pPCI of 3, MO was 
present in >50% of patients); 2) MO, IS%LV, and LVEF were predictors for MACE, with value 
added to clinical risk factors; 3) MO was associated with cardiac death when adjusted for 
age and LVEF; and 4) IS%LV, adjusted for MO and LVEF, was not an independent predictor 
of MACE or cardiac death. Previous studies that evaluated the prognostic value of MO, 
IS%LV, and LVEF in STEMI patients were limited by the inclusion of relatively small study 
sample sizes; evaluated composite clinical endpoints with “soft” components, including 
revascularization or angina; and were single-center studies (7–13). In the present inter-
Table 5. Association of Patient Characteristics With Cardiac Death at 2 Years: Univariate Cox Regression 
Analysis
HR 95% CI p Value
Demographics
 Age 2.18 0.95-5.01 0.07
 Sex 1.33 0.50-3.54 0.57
CV risk factors
 Diabetes 2.25 0.96-5.25 0.06
 Hypertension 1.05 0.44-2.49 0.91
 Anterior MI 1.41 0.64-3.10 0.40
Angiographic variables
 Multivessel disease 0.78 0.35-1.76 0.55
 TIMI flow grade after PCI 2.51 0.22
CE-CMR variables
 Presence of MO 15.02 2.01-112.24 0.01
 IS%LV ≥ 25% 1.77 0.80-3.89 0.16
 LVEF ≤ 40% 2.26 1.01-5.05 0.05
 LVESV index 1.01 0.99-1.04 0.22
 LVEDV index 1.00 0.98-1.02 0.91
Abbreviations as in Tables 1 and 2.
Table 6. Association of Age, MO, and LVEF ≤ 40% With Cardiac Death at 2 Years: Multivariate Cox Regression 
Analysis
aHR 95% CI p Value
Age 2.21 0.96 – 5.06 0.06
Presence of MO 13.22 1.75 – 99.82 0.01
LVEF ≤ 40% 1.66 0.74 – 3.75 0.22
N = 760 patients, 25 events. Abbreviations as in Tables 1, 2, and 3.
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nationally representative patient pooled analysis, we were able to assess the impact of 
CE-CMR variables on more clinically relevant events. With a sample size of 1,025 patients, 
the statistical power of the present pooled analysis was increased compared with that of 
previous single-center studies, which led to more robust predictions.
Our ﬁnding that the value of IS%LV, measured within 14 days after STEMI, is secondary 
to those of MO and LVEF is remarkable. It is important to realize that IS%LV is correlated 
with LVEF; however, LVEF is affected by additional factors, such as previous cardiovas-
cular conditions, which might explain the importance of LVEF as a predictor of MACE in 
the present study. However, the univariate association of IS with MACE, its correlation 
with LVEF, and its contribution to the model as shown by an improvement in the c-index 
suggest that IS%LV is an attractive option as an endpoint in studies investigating new 
treatments. The measurement of LVEF is inﬂuenced by the presence of stunned myocar-
dium, the relevance of which remains a topic of research, because most CMR studies are 
performed 4 to 7 days after STEMI, when stunning may be only partially resolved. The 
ﬁnding that MO was, in addition to IS%LV and LVEF, an independent predictor of MACE 
is in concordance with ﬁndings from previous single- center studies. In the largest study 
to date, by de Waha et al. (12), IS adjusted for TIMI risk score, MO, and LVEF was not an 
independent predictor of adverse outcomes. We draw the same conclusion in the pres-
ent study, in which IS%LV and LVEF were analyzed as continuous variables. The cause of 
the detrimental effect of MO remains speculative. Baks et al. (5) demonstrated that the 
presence of MO in dysfunctional myocardial segments was associated with signiﬁcantly 
p < 0.001). The Kaplan-Meier estimate of freedom
from cardiac death at 2 years was 95.2% in patients
with IS%LV $25% versus 97.3% in pa ients with IS%
LV <25% (p < 0.21) (data not shown).
Univariate Cox regression is summarized in
Table 5. MO (HR: 15.02; 95% CI: 2.01 to 112.24) and
LVEF #40% (HR: 2.26; 95% CI: 1.01 to 5.05) were
associated with cardiac death on univariate Cox
regression analysis. IS%LV $25% was not associated
with cardiac death in a univari te C x model (HR:
1.77; 95% CI: 0.80 to 3.89).
Independent predictors on multivariate Cox
regression a d their respective aHRs for cardiac death
at 2 years are summarized in Table 6. MO was asso-
ciated with the occurrence of cardiac death (aHR:
13.22; 95% CI: 1.75 to 99.82) when adjusted for age
(aHR: 2.21; 95% CI: 0.96 to 5.06) and LVEF #40%
(aHR: 1.66; 95% CI: 0.74 to 3.75).
DISCUSSION
The main ﬁndings of this study were that: 1) MO was
present in >50% of patients with STEMI reperfused
by pPCI (even in patients with TIMI ﬂow grade post
pPCI of 3, MO was present in >50% of patients); 2)
MO, IS%LV, and LVEF were predictors for MACE, with
value added to clinical risk factors; 3) MO was
FIGURE 7 Relationship Between MO and IS%LV and Event-Free Survival
Values are Kaplan-Meier estimates in patients with IS%LV$25% versus <25%, grouped by
the presence or absence of MO, indicating the time to MACE, follow-up 2 years. Abbre-
viations as in Figures 4 and 5.
TABLE 2 Association of Patient Characteristics With MACE at
2 Years: Univariate Cox Regression Analysis
HR 95% CI p Value
Demographics
Age 1.60 1.11–2.31 0.01
Sex 1.34 0.89–2.00 0.16
CV risk factors
Diabetes 1.66 1.09–2.53 0.02
Hypertension 0.97 0.67–1.42 0.89
Anterior MI 1.30 0.90–1.87 0.16
Angiographic variables
Multivessel disease 1.65 1.13–2.40 0.009
TIMI ﬂow grade after PCI 3.31 1.70–6.43 <0.001
CE-CMR variables
Presence of MO 4.68 2.86–7.66 <0.001
IS%LV $25% 2.04 1.42–2.92 <0.001
LVEF #40% 3.45 2.40–4.97 <0.001
LVESV index 1.03 1.02–1.04 <0.001
LVEDV index 1.02 1.01–1.02 <0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major cardiovascular events;
other abbreviations as in Table 1.
TABLE 3 Association of Patient Characteristics With MACE at
2 Years: Multivariate Cox Regression Analysis
aHR 95% CI p Value
Model I*
Age 1.54 1.04–2.27 0.03
Diabetes 1.25 0.80–1.94 0.33
Multivessel disease 1.56 1.07–2.28 0.02
TIMI ﬂow grade after PCI 2.11 1.04–4.27 0.04
Presence of MO 3.74 2.21–6.34 <0.001
IS%LV $25% 0.90 0.59–1.37 0.63
LVEF #40% 2.30 1.48–3.58 <0.001
LVEDV index 1.00 0.99–1.01 0.58
Model II†
Age 1.58 1.08–2.30 0.02
Multivessel disease 1.56 1.08–2.27 0.02
TIMI ﬂow grade after PCI 2.25 1.14–4.45 0.02
Presence of MO 3.72 2.22–6.25 <0.001
LVEF #40% 2.40 1.63–3.53 <0.001
*Before backward variable selection in 970 patients, 118 events. †Backward
variable selection in 984 patients, 118 events.
aHR ¼ adjusted hazard ratios; other abbreviations as in Tables 1 and 2.
TABLE 4 Incremental Value (c-Statistic) of MO, IS%LV,
and LVEF #40% in the Prediction of MACE at 2 Years
c-Statistic
Model a: age þ multivessel disease þ TIMI ﬂow grade
after PCI
0.59
Model b: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ IS%LV $25%
0.61
Model c: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ LVEF #40%
0.66
Model d: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ LVEF #40% þ IS%LV <25%
0.66
Model e: age þ multivessel disease þ TIMI ﬂow grade
after PCI þ LVEF #40% þ MO
0.70
Abbreviations as in Tables 1 and 2.
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greater thinning of the myocardium compared with that in segments without MO at 
follow-up. In contrast to segments without MO, segments with MO demon- strated no 
improvement in segmental wall thickening in a follow-up study at 5 months. Nijveldt et 
al. (6) found that a signiﬁcant proportion of patients with MO developed a signiﬁcant 
increase in LV end- diastolic volume, with no improvement in LVEF, whereas patients 
without MO showed a signiﬁcant improvement in LVEF, at 4 months of follow-up. 
Both of those studies suggest an important relation between MO and LV remodeling 
that potentially might result in heart failure used as a MACE, as in the present study. 
In addition to having predictive value for congestive heart failure, MO seems to be an 
important predictor of cardiac death. Reasons for cardiac death in patients with MO 
have been demonstrated by Ito et al. (22). Patients with no-reﬂow more often had ma-
lignant arrhythmias, cardiac tamponade, and early congestive heart failure compared 
with patients without no-reﬂow. An explanation of those ﬁndings might have been the 
reduced end-diastolic wall thickness in MO-positive segments, which might result in an 
increase in wall stress in the affected and adjacent segments (5). The ﬁndings from the 
present study demonstrate, in a large cohort, the prognostic value of MO in patients who 
sustained a STEMI. MO was present in >50% of the study population, even, importantly, 
in a large subgroup of patients with angiographic TIMI ﬂow grade after PCI of 3. These 
ﬁndings suggest that pPCI is not optimal yet and that there is a need for future novel 
treatment strategies. Of the current variables, MO is still the best predictor and probably 
indicates which patients should be investigated further. Screening for arrhythmias and 
progressive dilation, with follow-up echocardiography or CE- CMR, could potentially 
identify a high risk for cardiac death. The ﬁndings of this study are relevant in CMR trial 
design for the evaluation of the effects of, for example, thrombectomy devices, vasodila-
tors, coronary post-conditioning, cell therapy, and glycoprotein IIb/IIIa inhibitors (23) in 
patients with STEMI. It is advisable to use, in addition to the measurement of LVEF and 
IS%LV, MO as surrogate endpoint in CMR trials in STEMI patients as MO and IS%LV might 
be variables that represent separate pathophysiological processes.
sTUDY LIMITATIoNs. 
The results of our study should be viewed in light of limitations inherent to the design 
of meta-analyses of individual patient data. These limitations include publication bias, 
data- availability bias, unmeasured heterogeneity in the patients included, and the use of 
event adjudication by different clinical events committees (24). CE-CMR was performed 
at a wide range of days (up to 14) after STEMI, at different time points after contrast 
injection, and with different concentrations of gadolinium-based contrast agents (25). 
These variations may have inﬂuenced the detection of MO and may have inﬂuenced the 
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measurement of IS (26). CE-CMR analysis was conducted in different ways, which also 
might have inﬂuenced the measurements of IS and MO. In this analysis, we evaluated 
the prognostic value of MO only, without investigation of the extent of MO. A previous 
study (12) showed that the extent of MO provided incremental prognostic information. 
Unfortunately, this variable was available in only one study and therefore could not 
be included in the pooled analysis. In cases of missing data, variables that may have 
inﬂuenced the primary endpoint (e.g., extent of MO, myocardial salvage (27), and the 
presence of a hypo- intense infarct core (28)) were not taken into account. Due to a 
low cardiac death rate, we were not able to add more variables in the multivariate Cox 
regression analysis.
CoNCLUsIoNs
MO is an independent predictor of the occurrence of MACE and cardiac death at 2 years 
in patients with STEMI. IS%LV is not independently associated with the occurrence of 
MACE, but might be used, in addition to MO and LVEF, as a surrogate endpoint in clinical 
trials investigating new treatment options.
sUPPLeMeNTAL
Editorial
Meta-analysis of MACE in MI: What’s the MO?* Nathaniel Reichek 
JACC Cardiovasc Imaging. 2014 Sep; 7(9):953-5. 
http://www.sciencedirect.com/science/article/pii/S1936878X14005397
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Prognostic significance of microvascular 
obstruction and infarct size measured by 
cardiovascular magnetic resonance for 
the prediction of adverse left ventricular 
remodelling in patients with ST-segment 
elevation myocardial infarction: insight from 
a pooled analysis of individual patient data.
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AbsTRACT
Background - Left ventricular remodeling and dilatation is a precursor of the develop-
ment of heart failure and is an important predictor of morbidity and mortality after 
ST-elevation myocardial infarction (STEMI). Data on functional outcome assessed by 
contrast-enhanced cardiovascular magnetic resonance (CE-CMR) are scarce and limited 
to small single-centre data. We sought to gain insight in whether microvascular obstruc-
tion (MO) and infarct size (IS) determined by CE-CMR are predictors of adverse left 
ventricular (LV) remodeling patients with STEMI in a large pooled data set. 
Methods - A network meta-analysis of individual patient data was performed. LV adverse 
remodeling measured by CE-CMR was defined as more than 20% increase in LV end-
diastolic volume index (LVEDVi) between baseline and follow-up imaging. 
Results - Individual data of 392 STEMI patients enrolled in five studies were analysed. 
Baseline CE-CMR was performed in 5 days (interquartile range [IQR]: 3-7) after the oc-
currence of STEMI. Follow-up CE-CMR was performed in 4 months (IQR: 3-6 months). 
Adverse LV remodeling was present in 16.3% (N=64) and absent in 83.7% (N=328) of 
the patients. Baseline LVEDVi (hazard ratio [HR]: 0.97, 95% confidence interval [CI]: 0.96-
0.99, p<0.001), baseline LV ejection fraction (HR: 2.53, 95%CI: 1.44-4.45, p<0.001), IS (HR: 
1.04, 95% CI: 1.02-1.05, p<0.001)), and MO (HR: 1.73, 95%CI: 1.01-2.96, p=0.05) were 
significantly associated with adverse LV remodeling in univariate logistic regression 
analysis. In multivariate logistic regression, all of these parameters were associated with 
adverse LV remodeling and notably IS and MO were independent related with adverse 
LV remodeling.
Conclusion - In this so far largest reported multi-center cohort evaluating LV remodeling 
with CE-CMR, both IS and the presence of MO were independently associated with LV 
adverse remodeling besides early dilatation and reduced ejection fraction in patients 
with STEMI. 
Keywords: Cardiovascular magnetic resonance, Infarct size, Left ventricular remodeling, 
Microvascular obstruction, ST-segment elevation myocardial infarction
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INTRoDUCTIoN
Left ventricular (LV) remodeling after ST-segment elevation myocardial infarction (STE-
MI) is a precursor of the development of heart failure and is also a predictor for mortality 
(1,2). The term ventricular remodeling refers to alteration in ventricular architecture, 
with associated increased volume and altered chamber configuration. The armamen-
tarium to measure LV remodeling after cardiac injury includes repeated measurements 
of 2-dimensional echocardiography, single-photon emission computed tomography 
and contrast-enhanced cardiovascular magnetic resonance (CE-CMR), or a combination 
of these modalities. In patients with STEMI, CE-CMR provides information about infarct 
size (IS) and microvascular obstruction (MO) as visualized with delayed enhancement in 
the same session with accurate and reproducible measurements of functional measure-
ments, using a gadolinium based contrast agent (3) . 
The clinical value of MO, as measured by CE–CMR, was first introduced in 1998 (4) and 
has been associated with worse prognosis in one study (5) and subsequently in a robust 
pooled patient-level analysis performed by our network (6). In patients with STEMI, the 
myocardial segments exhibiting MO are associated with wall thinning and an absence 
of improvement of segmental wall thickening compared with segments without MO 
during follow-up (7). MO is also an important predictor of global functional recovery 
after STEMI (8) and an ominous indicator of adverse LV remodeling (8,9). Although there 
is a strong relation between IS and MO in small-sized studies, it is not clear whether IS 
and MO (8,10-14) play an independent role in LV remodeling. 
Comprehension of the temporal associations between IS, MO and LV remodeling is 
imperative, not only for our understanding of the pathophysiology following acute 
myocardial infarction, but also for optimizing treatment strategies in this population, 
especially when considering that IS and MO are used as surrogate endpoints in clinical 
trials (15,16). Therefore, we sought to identify CE-CMR variables for the prediction of LV 
remodeling and to evaluate whether LV remodeling measured by CE-CMR determines 
outcome after STEMI in a pooled patient-level dataset, thereby potentially providing 
valuable insights in the process of LV remodeling.
MeTHoDs
study selection
A computerized literature search of citations ranging from January 2004 to April 2012 
in the MEDLINE database was performed using the following terms: “Microcirculation” 
[Mesh] OR “Magnetic Resonance Imaging” AND “Myocardial Infarction” AND “Microvas-
cular Obstruction”, with the following limitations: humans, English language, resulting 
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in 134 publications. Related articles from reference lists of retrieved articles, and the 
bibliographies of the co-authors were included. Observational studies including STEMI 
patients reperfused by primary percutaneous coronary intervention (pPCI) within 12 h 
of symptom onset, followed by CE-CMR within 14 days were eligible. Studies with more 
than 60 participants were invited to participate. In case of experimental studies; only the 
placebo group was included in the analysis. 
Data collection
Requested variables comprised baseline characteristics, variables used in the CADILLAC 
risk score (17), Zwolle pPCI index (18) and Thrombolysis in Myocardial Infarction risk 
score (19), baseline CE-CMR variables and clinical outcomes (MACE). These variables 
were stated beforehand in a protocol, along with study rationale and study design, 
sent to participating centers. Previous approval of the individual study design by a local 
ethics committee was necessary for participation. Data sets from participating centers 
were merged by the coordinating center: Erasmus MC, Rotterdam, the Netherlands. 
The merged database was checked for completeness and consistency of definitions in 
variables by the coordinating center. Queries were sent to the primary investigators, in 
case of need of further data and clarification. 
Definitions / contrast enhanced cardiovascular magnetic resonance
The definition of STEMI was based on those used by the authors of the primary publica-
tions(20). All clinical and angiographic variables were study based. Angiographic left 
main coronary artery lesions were categorized as left anterior descending artery (LAD) 
lesions. Imaging was performed in different centers on 1.5 Tesla scanners from different 
vendors (table X1 supplemental table). The scan protocols, CE-CMR parameters and data 
analysis have been described in the included studies. For functional imaging Steady-
state free precession gradient echo sequences were used. LV end-diastolic volume, 
LV end-systolic volume and LV ejection fraction were short-axis based, as provided by 
the investigators. If not indexed, the Mosteller equation was used to adjust LV end-
diastolic volume and LV end-systolic volume for body surface area. Late gadolinium 
enhancement (LGE) was performed by the different centers by use of an inversion 
recovery gradient echo sequence. MO visualized with LGE was defined as any region of 
hypo-enhancement within the hyper-enhanced area. IS was determined in short axis 
images. IS was expressed as a percentage of the LV mass (IS%LV). IS%LV was determined 
by manual or automatic tracing of the infarct border. In patients with MO, regions of 
hypoenhancement were included in the IS.
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objectives and endpoints
The primary objective was to determine independent predictors for adverse LV remod-
eling. Adverse LV remodeling was defined as the occurrence of >20% increase in left 
ventricular end diastolic volume index (LVEDVi). The relationship between adverse LV 
remodeling and the occurrence of MACE was explored. MACE was defined as any of the 
following events: cardiac death and congestive heart failure. Congestive heart failure 
was defined as any symptom of cardiac decompensation requiring hospitalization. The 
individual study investigators provided previously defined and used events (table X1: 
supplemental table). When a patient experienced more than one event, the first event 
was chosen for the combined clinical endpoint. Patients were considered at risk from the 
time of admission for treatment of STEMI. 
statistical analysis
Continuous data with normal distribution are presented as mean ± standard deviation 
(SD). Non-normally distributed variables are reported as medians with the correspond-
ing interquartile range (IQR). Categorical variables are represented by frequencies and 
percentages. Patients were categorized according to the presence of MACE. Differences 
in continuous variables between categories of patients were studied by unpaired Stu-
dent’s t test or Mann-Whitney U test (in case of a non-normal distribution). Proportions 
were compared using the chi-square test or the Fisher’s exact test, where applicable. 
The incidences of the primary and secondary endpoints are reported as Kaplan-Meier 
estimates at a follow-up of 2 years. A univariate and multivariate logistic regression 
analysis was used to determine CE-CMR predictors of adverse LV remodeling. Variables 
associated with adverse LV remodeling in previous studies (in univariate and multivari-
ate analysis) namely; age (11), anterior myocardial infarction (21), multi-vessel disease 
(22), infarct size (10), baseline LV ejection fraction (10), MO (9,11), in addition to LV 
end-diastolic volume index and LV end-systolic volume index entered the univariate 
logistic regression analysis. Variables that resulted in a P < 0.10 in the univariate logistic 
regression model entered the multivariate logistic regression model using the backward 
variable selection method. In case of missing data (variable data in > 7.5% of cohort not 
present), these variables were not taken into account in the regression analysis. Hazard 
ratios, 95% confidence intervals (CI) and P-values were reported. Two-sided P-values 
values with α ≤ 0.05 were considered to be statistically significant. Statistical analysis 
was performed using the statistical package IBM SPSS Statistics (version 20.0.01 (SPSS, 
Chicago, IL). A Kaplan-Meier curve was drawn with GraphPad Software Inc, GraphPad 
Prism 6, version 6.02 (La Jolla, Ca)
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ResULTs
Patient characteristics
We identifi ed ten eligible observational (7) and experimental studies (3). The principal 
investigators of these studies were invited to participate in this collaborative analysis. 
Eight out of ten investigators provided individual patient data (fi gure 1). In fi ve out of 
eight a follow- up CE-CMR scan was performed (23-27). The study fl owchart is shown 
in fi gure 1. Of 672 enrolled acute myocardial infarction (AMI) patients, paired CE-CMR 
examinations were available in 392 STEMI patients. Between April 1999 and April 2008 
(IQR: March 2003 - May 2007), these patients were admitted to a coronary care unit. 
Patients with adverse LV remodeling were compared to patients without adverse LV 
remodeling in table 1. Adverse LV remodeling was present in 64/392 (16.3%) of patients 
and absent in 328 (83.7%) of the patients. pPCI was performed in 295/392 (75.3%) of the 
patients. Age at inclusion was 57.4 ± 11.5 and 83.4% of the cohort was men. Patients in 
the two groups had no signifi cant diff erences between baseline characteristics. 
Contrast-enhanced cardiovascular magnetic resonance 
Baseline and follow-up CE-CMR variables were compared in table 2. Baseline CE- CMR 
was performed in 5 days (IQR: 3-7) after the occurrence of STEMI. IS%LV was 26.2% (IQR: 
15.7%-45%) in patients with adverse LV remodeling versus 19.4 (IQR: 10.1%-28.0%) in 
patients without adverse adverse LV remodeling (P < 0.001). MO was more prevalent in 
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Figure 1: flow chart: systematic search process in the MEDLINE database 
Figure 1. fl ow chart: systematic search process in the MEDLINE database
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Table 1. patient characteristics.
Variable Entire cohort LV remodeling LV remodeling absent P-value
392 64 (16.3%) 328 (83.7%)
Treatment 
pPCI 295/392 (75.3%) 48/64 (75.0%) 247/328 (75.3%) 0.96
Fibrinolysis 90/392 (23.0%) 16/64 (25.0%) 74/328 (22.6%) 0.67
Rescue or Facilitated PCI 10/392 (2.6%) 1/64 (1.6%) 9/328 (2.7%) 0.58
Cardiovascular Risk Factors 
Age 57.4 ± 11.5 57.5 ± 11.1 57.3 ± 11.5 0.94
Male 327/392 (83.4) 55/64 (85.9%) 272/328 (14.1%) 0.55
BMI 27.2 ± 3.5 27.7 ± 3.5 27.1 ± 3.5 0.26
Diabetes 43/381 (11.3%) 7/59 (11.9%) 36/322 (11.2%) 0.88
Hypertension 158/381 (41.5%) 23/59 (39.0%) 135/322 (41.9%) 0.67
Hypercholesterolemia 128/379 (33.8%) 22/59 (37.3%) 106/320 (33.1%) 0.53
Smoking/prior smoking 238/391 (60.9%) 41/63 (65.1%) 197/328 (60.1%) 0.46
Family history of myocardial 
infarction 
81/257 (31.5%) 10/33 (30.3%) 71/224 (31.7%) 0.87
History of myocardial infarction 8/267 (3.0%) 8/230 (3.5%) 0/37 (0%) 0.60
Angiographic variables
Time to reperfusion 3.3 (IQR: 2.2-4.7) 3.3 (IQR: 2.2-4.9) 3.0 (2.1-4.3) 0.68
Infarct-related artery
Right coronary 134/391 (34.3%) 21/64 (32.8%) 113/327 (34.6%) 0.79
Left anterior descending 222/391 (56.8%) 40/64 (62.5%) 182/327 (55.7%) 0.31
Left circumflex 35/391 (9.0%) 3/64 (4.7%) 32/327 (9.8%) 0.19
N-vessel disease
 1 238/381 (62.5%) 33/60 (55.0%) 205/321 (63.9%) 0.30
 2 89/381 (23.4%) 17/60 (28.3%) 72/321 (20.4%) 0.26
 3 45/381 (11.8%) 7/60 (11.7%) 38/321 (11.8%) 0.96
Multi-vessel disease 134/381 (35.2%) 24/60 (40.0%) 110/321 (34.3%) 0.39
TIMI flow grade post PCI
 0 5/385 (1.3%) 1/62 (1.6%) 4/323 (1.2%) 0.59
 1 1/385 (0.3%) 0/62 (0%) 1/323 (0.3%) 1.00
 2 32/385 (8.3%) 8/62 (12.9%) 24/323 (7.4%) 0.15
 3 347/385 (90.1%) 53/62 (85.5%) 294/323 (91.0%) 0.18
Enzymatic infarct size
Maximal Creatine Kinase 1603 (IQR: 859-3311) 2818 (IQR: 1321-5658 1500 (IQR: 782-3138) 0.30
Values are means ± SD, if applicable medians and IQR are reported, pPCI; primary percutaneous coronary 
intervention, BMI; body mass index * missing in 124 cases (12.1%), Family history of myocardial infarction 
* missing in 88 cases (8.6%), prior myocardial infarction * missing in 77 cases (7.5%), Time to reperfusion is 
ischemic time * missing in 446 cases, 446 cases reperfusion within 12 hours (43.5%), LV; left ventricular, TIMI; 
thrombolysis in myocardial infarction, Maximal Creatine Kinase * missing in 278 cases (27.1%), 
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patients with LV adverse remodeling 51.6% versus 38.1% in patients without adverse LV 
remodeling (p = 0.05). Follow-up CE-CMR was performed in 4 months (IQR: 3-6 months) 
after performance of the baseline CE-CMR. Follow-up LV ejection fraction was 47.3% 
± 14.4 in patients with adverse LV remodeling versus 52.4 ± 11.9 in patients without 
adverse LV remodeling (0.012). Baseline IS%LV and MO were associated with the occur-
rence of LV remodeling (figure 2 and figure 3). Follow-up LV ejection fraction increased 
both in patients without MO (baseline LV ejection fraction 51.9% ± 10.9, follow-up LV 
ejection fraction 55.9% ± 11.0, p ≤ 0.001) and in patients with MO (baseline LV ejection 
fraction 42.2% ± 10.6, follow-up LV ejection fraction 45.2% ± 11.8, p ≤ 0.001, figure 4). 
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Figure 2: Occurrence of adverse LV remodeling related to IS%LV 
LV; left ventricular, IS; infarct size. 
Figure 2. Occurrence of adverse LV remodeling related to IS%LV
LV; left ventricular, IS; infarct size.
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Predictors of LV remodeling
Univariate logistic regression is summarized in table 3. Variables associated with the 
occurrence of LV remodeling were LVEDVI [HR = 0.97 (95% CI: 0.96-0.99)], baseline LV 
ejection fraction (ref: >40%) [HR = 2.53 (95% CI: 1.44-4.45)], baseline IS%LV [HR = 1.04 
(95% CI: 1.02-1.05)], MO [HR = 1.73 (95% CI: 1.01-2.96)] while Age, anterior myocardial in-
farction, multi-vessel disease, TIMI flow grade post PCI and LV end-systolic volume index 
were not associated with the occurrence of LV remodeling. In the multivariable logistic 
regression analysis baseline LV end-diastolic volume index, baseline IS%LV, baseline LV 
ejection fraction and MO were independently associated with the occurrence of LV re-
modeling, where the independency between the last two is most remarkable (Table 4).
Clinical outcome
The combined endpoint occurred in 24 patients, including 3 cardiac deaths and 21 
patients with admission for congestive heart failure (LV remodeling vs. no LV remodel-
202
Figure 3: Occurrence of adverse LV remodeling related to presence of MO 
 LV; left ventricular, MO; microvascular obstruction,  
Figure 3. Occurrence of adverse LV remodeling related to presence of MO
LV; left ventricular, MO; microvascular obstruction, 
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ing, n = 17 vs. n = 7) within 2 years of follow-up. The Kaplan-Meier estimate of MACE 
grouped by LV remodeling was 73.5% in patients with adverse LV remodeling and 87.3% 
in patients without adverse LV remodeling (P = 0.121). 
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Figure 4: changes in LV ejection fraction from baseline to follow-up in patients without microvascular 
obstruction versus with microvascular obstruction  
Figure 5: LV; left ventricular, MO; microvascular obstruction.  
 
 
 
Figure 4. changes in LV ejection fraction from baseline to follow-up in patients without microvascular ob-
struction versus with microvascular obstruction 
Table 3. univariate Logistic – regression for LV remodelling
Variable HR 95% CI P-value
Age 0.91 0.50-1.64 0.74
Anterior myocardial infarction 1.33 0.77-2.30 0.31
Multi-vessel disease 1.28 0.73-2.25 0.39
TIMI flow grade post PCI 1.04 0.12-9.08 0.97
Baseline LV end-systolic volume index 0.99 0.98-1.01 0.34
Baseline LV end-diastolic volume index 0.97 0.96-0.99 <0.001
Baseline LV ejection fraction, >40% 2.53 1.44-4.45 <0.001
Baseline IS%LV 1.04 1.02-1.05 <0.001
MO 1.73 1.01-2.96 0.05
CI; confidence interval HR; hazard ratio, IS%LV: infarct size expressed as percentage of LV mass LV; left ven-
tricular, MO: microvascular obstruction, TIMI: trombolysis in myocardial infarction.
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DIsCUssIoN
The main findings of the study were that: (i) mean LV ejection fraction (EF) improved 
after reperfusion therapy for acute MI, whereas the majority of the patients still showed 
increased end-diastolic volumes during follow-up with significant LV remodeling in 
16.3%; (ii) baseline LV ejection fraction, baseline IS%LV, MO and baseline LV end-diastolic 
volume index are important predictors for the occurrence of adverse LV remodeling;(iii) 
and IS%LV and MO independently correlate with LV dilatation. 
Table 4. multivariate logistic – regression analysis for LV remodeling.
Variable HR 95% CI P-value
LV end-diastolic volume index, ml/m2 0.95 0.94-0.97 <0.001
Baseline LV ejection fraction, >40% 2.47 1.22-4.99 0.012
Baseline IS%LV, continuous 1.03 1.00-1.05 0.018
MO 2.13 1.09-4.18 0.027
CI; confidence interval, HR; hazard ratio, IS%LV: infarct size expressed as percentage of LV mass, LV; left 
ventricular, MO microvascular obstruction. 
Figure 5. changes in LV ejection fraction from baseline to follow-up in patients without microvascular ob-
struction versus with microvascular obstruction.
LV; left ventricular, MO; microvascular obstruction.
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To our knowledge, the present study represents the largest patient pooled analysis 
investigating LV remodeling which evaluates clinical and CE-CMR variables in patients 
with STEMI. These observations extend findings obtained from previous studies evaluat-
ing paired CE-CMR examinations for LV remodeling, which were single-center studies 
(5,7-11),(28) and provide important insight into the determinants of LV remodeling, 
therefore potentially guiding the direction of development of novel therapies. 
LV ejection fraction measured shortly after primary PCI is of limited value for primary 
prevention of acute death due to ventricular fibrillation. In this regard, the current study 
shows an independent prediction for adverse remodeling post STEMI both for IS%LV 
and MO in the era of primary PCI. An average of 4-5% of improvement in LV EF post 
reperfusion therapy is seen in most studies with CMR but variability is large. Although 
the mean LV EF is improving during follow-up, remodeling is standard for all patients 
and about 1/3 of the patients show progressive dilatation in the long-term, increasing 
the risk of arrhythmias and heart failure in these patients (29). Identification of these 
patients in an early phase is valuable in efficient healthcare strategies post STEMI and 
pPCI where CMR with both measurement of MO and IS could be applied. 
Furthermore, Previous studies on IS and MO as predictors for MACE were mainly driven 
by re-MI and heart failure with a minority on cardiac death. We previously showed that MO 
eliminated IS as predictor of cardiac death and the combined endpoint (6). In the current 
analysis IS remained an independent predictor for remodeling as a precursor of heart failure. 
Previous studies linked multivessel disease (6) and SyntaxScore (30) (both representing the 
extent of atherosclerotic disease) to the presence of MO and might explain the stronger 
relation between MO and repeat-myocardial infarction. Our results are in-line with a recent 
large single center study where both %IS and MO predicted remodeling(28). In this study 
remodeling was defined as >10% increase in left ventricular end systolic volume index, 
selecting also patients with less extensive remodeling and potentially less clinical impact.
Myocardial remodeling by itself is in the era of reperfusion therapy is mainly a 
phenomenon of the remote area. In an animal experiment with detailed CMR analysis 
the circumferential area of the MI was not increasing with only a reduction of the wall 
thickness during the remodeling process (31). The general increase in EDVi could be at-
tributed to increase in the circumferential length of the remote area with an associated 
decrease in wall thickness in these areas. Importantly, however, remodeling after AMI is 
also a process with alterations in structure and function in response to hemodynamic 
load and/or cardiac injury involving both infarcted and non-infarcted myocardium. The 
infarct area is characterized by acute ischemic injury, MO and with persistent ischemia 
after restoration of coronary artery flow and reperfusion injury. Finally the remote area is 
also effected by the systemic inflammatory and immunological responses. All these steps 
can potentially be improved with additional pharmacological therapies and assessed by 
different CMR techniques. Despite optimal treatment of STEMI with pPCI, remodeling still 
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occurs in numerous patients, which is a major determinant of heart failure (32). In addition 
there is evidence that leucocyte recruitment (33), leucocyte infiltration with upregulation 
of inflammation markers and increased edema also occur in the remote myocardium and 
not just in the infarct region (34)and (35). The combination of these factors can lead to 
decreased cell-cell interaction and result in diminished wall contraction. In the following 
days/weeks, edema will resolve and fibroblasts will be removed and the remote myocar-
dial cells will adjust to the increased wall stress by compensatory increase of contractile 
intracellular structures causing increased remote circumferential length which will im-
prove remote pump function. In this sense, a recent elegant study using T1 measurement 
in humans of the remote myocardium demonstrated an increased T1 time in the remote 
zone in patients with incomplete ST segment resolution and inflammation markers on 
admission. Prolonged T1-time in remote areas represents edema and hypercellularity and 
was associated with remodeling and signs of heart failure. (36)
study Limitations
There are several limitations inherent to the design of a meta-analysis that deserve com-
ment. Study authors may not be contactable or willing to collaborate, definitions might 
vary along studies, individual participant data might have been not retrievable or there 
might be qualitative or quantitative differences between included studies. Furthermore, 
the study-design might be prone to publication, selection and data availability bias (37). 
Several limitations we need to specifically address for this meta-analysis: CMR was per-
formed in a wide range up to 14 days post STEMI, on different time points after contrast 
injection with different concentrations of gadolinium based contrast agents. This may 
influence the detection of MO and might influence the “extension” of IS (38-40). CMR 
analysis did not take place in one center and different ways of analysis were performed 
which also influences the measured infarct size (3). Transmurality and the presence of 
hemorrhage were not available from all studies and could not be included as potential 
parameter for the prediction of adverse LV remodeling. 
CoNCLUsIoNs
In this so far largest reported multi-center cohort evaluating LV remodeling with CE-
CMR, both IS and the presence of MO were independently associated with LV dilatation 
in patients with STEMI
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AbsTRACT
Background: Whether ischemic postconditioning (IPOC) immediately after routine 
thrombus aspiration (TA) reduces infarct size (IS) in patients with ST-segment elevation 
myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention 
(PPCI) has not been established. Study design: The POstconditioning Rotterdam Trial 
(PORT) is a dual-center, prospective, open-label, randomized trial with blinded end- 
point evaluation enrolling 72 subjects with first-time STEMI, and an occluded infarct- re-
lated artery (IRA) without collaterals undergoing PPCI. Subjects are randomized 1:1 to a 
strategy of IPOC immediately after TA followed by stenting of the IRA or to conventional 
percutaneous coronary intervention (PCI), including TA followed by stenting of the IRA 
(controls). Cardiac magnetic resonance imaging (MRI) is performed at 3–5 days after 
STEMI and at 3 months. The primary endpoint is IS at 3 months measured by delayed 
enhancement MRI. Other secondary endpoints include MRI-derived micro- vascular 
obstruction (MVO), left ventricular ejection fraction, myocardial salvage index, enzy-
matic IS, ST-segment resolution, myocardial blush grade, microcirculatory resistance, 
inflammation markers, and clinical events through 3-month follow-up. Conclusions: 
PORT is testing the hypothesis that adding IPOC (against lethal reperfusion injury) to 
TA (against distal embolization and MVO) is cardioprotective and reduces ultimate IS in 
STEMI patients undergoing PPCI (Dutch Trial Register identifier: NTR4040).
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INTRoDUCTIoN
Prompt restoration of coronary blood flow by primary percutaneous coronary interven-
tion (PPCI) is essential to salvage viable myocardium and limit myocardial infarct size (IS) 
in patients presenting with ST-segment elevation myocardial infarction (STEMI), thereby 
preserving left ventricular (LV) systolic function and improving clinical outcomes. 
However, reperfusion itself initiates a cascade of harmful events, resulting not only in 
mitochondrial dysfunction and cardiomyocyte death, termed lethal reperfusion injury 
(1, 2), but also major ultrastructural damage to capillary endothelium, leading to mi-
crovascular obstruction (MVO), termed no-reflow (3). Consequently, the full benefits of 
myocardial reperfusion are not realized with reperfusion- mediated injury constituting 
a key therapeutic target
Lethal Reperfusion Injury and Ischemic Postconditioning
Ischemic postconditioning (IPOC) is an interventional strategy in which controlled, brief, 
intermittent episodes of reocclusions in the first few minutes of reperfusion can protect 
myocardium from lethal reperfusion injury. In 2003, Zhao et al. (4) reported that inter-
rupting reperfusion of previously ischemic myocardium by three short-lived episodes 
(of 30 sec each) of coronary artery reocclusion reduced myocardial IS in canine hearts 
by 44% following 60 min of left anterior descending artery occlusion. Importantly, the 
reduction in IS was associated with decreased myocardial edema, reduced neutro- phil 
accumulation, attenuation of apoptotic cell death, and improved endothelial function, 
factors associated with myocardial reperfusion injury (4). Further mechanisms by which 
IPOC alters the pathophysiology of reperfusion injury involves physiological effects (e.g., 
reducing oxidative stress, delaying rapid restoration of normal pH, reducing calcium 
overload) and molecular effects (e.g., triggering release of autacoids and activation of 
their cell-surface receptors, thereby, recruiting signal transduction pathways) (2, 5-7). 
Ultimately, both the physiological and molecular mechanisms seem to converge on the 
mitochondria and result in prevention of cardiomyocyte hypercontracture and inhibi-
tion of opening of the mitochondrial permeability transition pore (2). Within 2 years 
after the initial discovery in 2003 (4), the first clinical studies of IPOC in small groups 
of patients with STEMI were published. In these studies, it was reported that interrupt-
ing reperfusion with four cycles of 1-min low pressure inflations and defla- tions of the 
angioplasty balloon immediately after direct stenting of the infarct-related artery (IRA) 
improved myocardial reperfusion, reduced myocardial IS both acutely and at 6 months, 
and improved LV ejection fraction up to 7% (percent points) at 1 year (8-10). However, 
recent (larger) trials were not able to confirm the initially observed benefits with IPOC 
and provide inconsistent results (11-14). The reasons for the contradictory findings have 
been comprehensively reviewed elsewhere (15) and briefly, may be related to a number 
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of factors, such as the inability to take into account the major determinants of IS; choice 
of inappropriate endpoints; brief window of protection against reperfusion injury; 
and impact of comorbidities and concurrent treatments on IPOC. Importantly and of 
additional concern, the potential interaction between the application of thrombus as-
piration (TA) and the IPOC protocol might represent another crucial factor in achieving 
cardioprotection which is further discussed below.
Microvascular obstruction and TA
Impaired myocardial perfusion after ischemia was first observed by Krug et al. (16) and 
described as “the inability to reperfuse a previously ischemic region.” Many factors may 
contribute to this phenomenon, including capillary damage with impaired vasodilation, 
compression of capillaries by swollen cardiomyocytes, blebbing of endothelial cells into 
the lumen, capillary plugging by neutrophils, and distal embolization of friable mate-
rial released from the ruptured atherosclerotic plaque (17). Measures that prevent at 
least one of these components of MVO are, therefore, likely to improve microcirculatory 
flow. Moreover, MVO has been shown to be an independent predictor of MACE and 
cardiac death at 2 years after STEMI (18). In this regard, TA has emerged as a useful tool 
to further enhance the benefit of reperfusion during PPCI. The landmark TAPAS trial (19) 
demonstrated that TA prior to stenting resulted in improved myocardial reperfusion, as 
indicated by myocardial blush grade and ST- segment resolution, and clinical outcome 
(20) com- pared with conventional PCI after STEMI, which facilitated the use of this 
modality as an important myocardial adjunct in this setting. However, although manual 
TA was associated with significantly lower mortality and reduced major adverse cardiac 
events in the TAPAS trial (20) and subsequent meta-analyses (21, 22), a recent large trial 
(23) was not able to con- firm the benefit of TA with respect to mortality or other clinical 
outcome measures at 1 year.
TA and IPoC
Until now, none of the conducted IPOC trials randomly assigned the use of TA which 
was applied in a small proportion of patients with its use being at operator discretion. 
Yet, these interventions have the potential to undermine the magnitude of benefit of 
one another. TA usually re-establishes a significant blood flow in the IRA and the delay 
between applying the procedure and initiating the IPOC protocol might exceed the very 
short time frame in which IPOC has been shown to be efficient, potentially modifying 
the efficiency of IPOC (24). Conversely, the application of the IPOC protocol (before TA) at 
an inappropriate site might dislodge atherosclerotic plaque or thromboemboli, induc-
ing distal embolization of this material. In this regard, particular attention was paid to 
execution of the IPOC algorithm upstream of the culprit lesion to preclude inadvertent 
microembolization during the IPOC protocol in trials led by Ovize and his group [9,10, 
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(25, 26)], although the application of TA, if per- formed, and its sequence in relation to 
the IPOC proto- col was not randomized or routinely implemented. In contrast, when the 
IPOC protocol was performed at the site of the index lesion, where thrombus is maximal, 
a detrimental effect of IPOC on IS and MVO was reported (11). Thus, distal embolization 
might have counterbalanced the potential beneficial effects of IPOC and might even 
have exaggerated final myocardial damage (27). For these reasons, it is of paramount 
importance to apply TA and IPOC in an appropriate manner and sequence not interfer-
ing with each other’s merits. The two modalities might even lead to an increased effec-
tiveness resulting from their cumulative action when properly combined in a (routine) 
standardized fashion, in contrast to previous IPOC trials.
study Rationale
With multiple etiologies of reperfusion-mediated injury, a strategy aimed at minimizing 
one part of the process may not have much impact, especially, considering that man-
agement of STEMI has evolved substantially over the past decades (e.g., STEMI network 
activation decreasing treatment delays, more potent antiplatelet and antithrombotic 
agents maintaining patency of the IRA, and advances in PCI improving its efficacy). 
Thus, with TA offering the potential to reduce thrombus burden, distal embolization and 
MVO, and IPOC lethal reperfusion injury, it is hypothesized that combining these two 
interventions adequately in a standardized fashion would act in concert to modulate 
multiple components of reperfusion-mediated injury, and in turn, would increase myo-
cardial salvage and reduce ultimate IS in STEMI patients undergoing PPCI. To test this 
hypothesis, we designed the POstconditioning Rotterdam Trial (PORT).
MeTHoDs
study Design and Patient Population
The PORT (Dutch Trial Register unique identifier: NTR4040) is a dual-center, prospective, 
open-label, randomized trial with blinded evaluation of outcomes. The study has been 
approved by the ethics committee of the participating centers and will take place at 
the cardiology departments of the Erasmus University Medical Centre in Rotterdam and 
the Radboud University Medical Centre in Nijmegen, the Netherlands (Appendix 1). 
All patients with STEMI and candidates for PPCI are considered for participation in the 
study. The eligibility criteria are outlined in Table I.
study objectives and endpoints
The primary objective of this study is to evaluate whether IPOC immediately after 
routine TA but before stent implantation results in reduced IS, as measured by delayed 
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enhancement (DE) cardiac magnetic resonance imaging (MRI) at 3 months, compared 
with conventional treatment (including routine TA before stent implantation) in STEMI 
patients. Secondary objectives include investigating whether IPOC after routine TA im-
proves myocardial salvage index; reduces MVO by MRI at 3–5 days, enzymatic IS, micro-
circulatory resistance; enhances reperfusion and inflammation markers; and improves 
clinical outcomes at 1 and 3 months. The primary and secondary endpoints of the study 
are detailed in Table II.
Randomization and Treatment Protocol
All patients will receive aspirin 250–500 mg intravenously, 5,000 IU heparin and either 
600 mg clopidogrel, 60 mg prasugrel, or 180 mg ticagrelor. Notably, the treatment 
guidelines of the participating hospitals include prasugrel and ticagrelor as first-line 
treatment options for antiplatelet therapy. After written informed consent and emer-
gent coronary angiography, eligible patients are randomized 1:1 to a strategy of IPOC 
immediately after manual TA using the Export aspiration catheter (Medtronic, Inc., 
Minneapolis, MN) followed by stenting of the IRA or to conventional PCI, includ- ing 
TA followed by stenting of the IRA (controls). Randomization will be performed at the 
catheterization laboratory by a computer-generated random sequence, integrated in a 
dedicated web-based case report form, and stratified by infarct location and gender. All 
patients will receive procedural anticoagulation according to practice guideline recom-
mendations (28) and local standards of care. The use of glycoprotein IIb/IIIa inhibitors as 
a bailout therapy or bivalirudin will be left to operator discretion. In the control group, 
no additional intervention will be performed after TA during the first 8 min of reperfu-
sion. In the IPOC group, immediately after successful TA but within 1 min of reflow, 4 
cycles of 1-min balloon occlusions (4-6 atm) proximal or distal to the culprit lesion will 
be performed, each separated by 1-min reperfusion intervals (Fig. 1). During inflation 
of the balloon, one film will be made with a small bolus of contrast to ensure coronary 
artery occlusion. After completion of the IPOC protocol in the IPOC group and at 8 min 
of reperfusion in the control group, pre- and poststenting intracoronary hemodynamic 
measurements (Table II) will be performed using a guidewire tipped with pressure and 
temperature sensors (PressureWireTM CertusTM; St. Jude Medical, Inc., St. Paul, MN) po-
sitioned distal to the culprit lesion. Hereafter, coronary angiography will be performed 
in both groups to assess coronary patency and to estimate the myocardial perfusion in-
dex using the blush grade evaluation (29). Standard pharmacological therapies after the 
procedure will include aspirin, P2Y12 inhibitors, beta-blockers, lipid- lowering agents, 
and angiotensin-converting enzyme inhibitors or angiotensin-II receptor blockers, ac-
cording to current guide lines (28).
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Table 1. Eligibility Criteria.
Eligibility criteria
Inclusion criteria
 Written informed consent
 Delay between onset of chest pain and percutaneous coronary intervention ≤ 6 hr in case of inferolateral wall 
infarction and ≤ 12 hr in case of anterior wall infarction
 An occluded infarct-related artery must be demonstrated (TIMI 0-1)
 Successful treatment of a culprit artery lesion in the LAD, RCA, or LCX (segment 1,2,3,6,7,11,12, or 13) according 
to the CASS quantification)
Exclusion criteria
 Younger than 18 or older than 75 years of age
 Cardiogenic shock defined as a sustained systolic blood pressure ≤ 80 mm Hg despite fluid hydration and/or 
the inability to discontinue vasopressors in less than 1 hr before
 Postcardiac resuscitation
 Thrombolytic therapy in the previous week
 Myocardial infarction biomarkers at admission > 5 times the upper limit of normal since this implies longer 
lasting myocardial infarction
 TIMI > 1 before intervention or TIMI < 2 after initial thrombus aspiration 
 Significant collateral blood flow to the distal vasculature of the occluded vessel (Rentrop grade ≥ 2)
 An extended myocardial infarction, as evidenced by a new episode of chest pain with new ST-segment 
elevations and a new CK/CK-MB peak
 Documented hospital admission for heart failure
 Known pre-existent left ventricular dysfunction measured by any technique (ejection fraction < 45% prior to 
current admission for myocardial infarction)
 History of known previous myocardial infarction
 Prior coronary artery bypass grafting
 Moderate to severe cardiac valve disease
 Known cardiomyopathy
 Congenital cardiac disease
 Blood transfusion in the previous 24 hr.
 Stroke or transient ischemic attack within the previous 24 hr
 Any contra-indication for magnetic resonance imaging, that is 
 Pacemaker 
 Cerebrovascular clips
 Claustrophobia
 Chronic use of anti-inflammatory medication, except for the use of nonsteroidal anti-inflammatory drugs
 Serious known concomitant disease with a life expectancy of less than 1 year
 Follow-up impossible (no fixed abode)
 Previous participation in this study of any other trial within the previous 30 days
CK indicates creatine kinase; CK-MB, creatine kinase myocardial bound; LAD, left anterior descending coro-
nary artery; RCA, right coronary artery; LCX, left circumflex coronary artery; and TIMI, thrombolysis in myo-
cardial infarction. aaResidual stenosis of culprit lesion < 50% and TIMI 2-3 after intervention.
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MRI Protocol
Contrast-enhanced MRI will be performed early (3– 5 days) after STEMI and after 3 months 
using a 1.5-T, or 3-T scanner using dedicated cardiac surface coils. For LV function cine 
steady-state free-precession sequences will be used in standard orientations (2- cham-
ber, 4-chamber, and a stack of short-axis slices). Field of view and imaging matrix will be 
optimized to achieve a resolution of <1.5 x 1.5 mm and a maxi-mum temporal resolution 
of 50 ms. Slice thickness will be set to 8 mm with for the set of short axis images a gap of 2 
mm. We will also evaluate the area at risk (identified with myocardial oedema), applying 
a breath-hold, black-blood, T2-weighted triple inversion recovery sequence. Orientation 
of acquisition will be equal to short axis cine imaging with the same slice thickness and 
gap. For early no-reflow rest first-pass myocardial perfusion will be performed during 
administration of a gadolinium-based contrast agent (0.10 mmol/kg, Gadovist, Bayer, 
Mijdrecht, the Netherlands) at a rate of 4.0 ml/s, using a single-shot saturation recovery 
gradient-echo pulse sequence. Three slices will cover the infarct area as seen during cine 
imaging over a period of 20–30 sec. Immediately after first-pass perfusion, an additional 
0.1 mmol/kg gadolinium-based contrast agent will be administered (cumulative dose 
0.2 mmol/kg) for IS and late no-reflow quantification. Late gadolinium enhancement 
images will be acquired 10–15 min after the second contrast administration using a 2D 
segmented inversion recovery gradient-echo pulse sequence, with slice position identi-
cal to the cine images, including long-axis views. The inversion time will be set to null 
the signal of viable myocardium (typical range 200–300 ms).
MRI Analysis
All the studies will be analyzed on a remote work- station. For evaluation of LV, T2-
weighted, and late gadolinium enhancement images dedicated software: CAAS MRV, 
3.4, Pie Medical Imaging, 2011, Maastricht, the Netherlands will be used. LV functional 
analysis: LV end-diastolic volume and LV end-systolic volume are expressed in milliliters 
will be calculated using a combination of long axis and short axis images (30). Epicar-
dial and endocardial contours will be automatically detected on short axis images and 
manually corrected (31). The papillary muscles and trabeculations will be considered 
to be part of the blood pool. Regional systolic function will be determined using a 
modified 17-segment model. First-pass perfusion will be evaluated qualitatively for 
early MVO which will be identified by the presence of a hypoenhancement region. Area 
at risk will determined in the T2-weighted short axis images by manual contouring and 
expressed in mass (g) and as percentage of the LV volume (%). IS will be determined in 
short axis late enhancement images using semiautomatic contouring (32). In patients 
with MVO, regions of hypoenhancement will be included in the IS. IS will be expressed in 
mass (g) and as a percentage of the LV mass (IS%LV). Quantitative analysis of no-reflow 
will be done in the same slices with manual contouring of the hypoenhanced regions. 
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Myocardial salvage will be calculated as the difference between the area at risk (in g) 
minus the IS (in g). Myocardial salvage index will be calculated as the difference between 
area at risk (g) minus IS (g) divided by the area at risk (g).
blood sampling
Blood sampling will be performed before the angiographic procedure and during PCI 
(from the arterial cannula) and every 6 hr during the first 24 hr after reperfusion, every 
12 hr during day 2, once daily on day 3, and at the visits to the outpatient clinic at 1 and 
3 months. For cardiac biomarkers, including creatine kinase and its myocardial bound, 
high-sensitivity troponin T and heart-specific fatty acid binding protein, both peak 
values and the area under the curve will be determined. Analysis of other biomarkers, 
including markers of inflammation and NT-proBNP will also be performed (Table II).
Clinical Follow-Up
All patients will be followed up with clinical examination and blood analyses during 
hospitalization and at 1 and 3 months. All major adverse clinical events during follow-up 
period will be recorded (Table II).
statistical Considerations
Primary analyses will be performed according to the intention-to-treat principle for the 
whole population. An analysis per protocol will also be performed. Continuous variables 
will be summarized as mean and standard deviation or median and interquartile range, 
depending on normal distribution and will be compared using the Student’s t-test or 
Mann–Whitney U-test, as appropriate. Categorical variables will be summarized as pro-
portions and compared using the chi-square test or Fisher exact test. Linear regression 
will be used for comparing IS in relation to the area at risk between treatment groups. 
The Cox regression will be used to evaluate differences in clinical outcomes between 
groups. A two-tailed P < 0.05 will be considered statistically significant. The primary 
study endpoint is the IS at 3 months by DE MRI. In a previous series of unselected PPCI- 
treated STEMI patients in our institution who under- went DE MRI (33), anatomical IS 
was 35 ± 21 gr at baseline and 24 ± 17 gr at follow-up. Based on an expected relative 
reduction in IS of 20% by IPOC to 19 ± 9 gr (assuming IS is not normally distributed), 56 
patients in each group will be needed to achieve P < 0.05 with a power of 80% and a 
two-tailed test. Assuming a drop-out rate of 10%, the total sample size will consist of (2 
x 62) 124 patients randomized equally to the two groups. However, based on a previous 
trial (34) showing a 12% dropout rate due to the inability to obtain paired cine MRI im-
ages, among others, this study will continue enrollment until 124 patients are included 
with paired MRI studies.
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sUMMARY AND CoNCLUsIoN
Currently, there is no effective clinical therapy to limit myocardial reperfusion-mediated 
injury. PORT will enroll patients undergoing PPCI for STEMI in the early hours of infarct 
evolution, a time during which myocardial salvage should be possible. It will provide 
data primarily regarding the efficacy of IPOC immediately after routine TA compared to 
conventional treatment including TA on MRI-derived MVO at 3–5 days and IS determi-
Table 2. Study Endpoints.
Study endpoints
MRI-derived endpoints
 Infarct size at 3 months (primary endpoint)
 Microvascular obstruction at 3-5 days post-intervention
 Myocardial salvage measured as AAR on T2-weighed MRI minus final infarct size on delayed enhancement MRI
 Regional myocardial function at 3 months
 Left ventricular ejection fraction at 3 months
Cardiac biomarkers
 Creatine kinase
 Creatine kinase myocardial bounda
 High sensitivity troponine ta
 Heart-specific fatty acid binding proteinb
Reperfusion markers
 ST-resolution 60 and 90 min postintervention
 Myocardial blush grade
 TIMI flow grade
 Corrected TIMI frame count
Coronary physiologyc
 Index microcirculatory resistance
 Coronary flow reserve
 Fractional flow reserve
Inflammation and other markersd
 Cytokines (interleukins 1β, 6, 8, 10, 12; tumor necrosis factor-α; p 70)
 N-terminal pro-brain natriuretic peptide
 Tissue macrophages
Clinical outcomes
 MACE defined as cardiac death, myocardial infarction, coronary bypass grafting or a repeat percutaneous 
intervention during 3-month follow-up
AAR indicates area at risk; MACE, major adverse cardiac events; MRI, cardiac magnetic resonance imaging; 
and TIMI, thrombolysis in myocardial infarction.aboth peak value and 72-hr area under the curve determi-
nation.bmeasurement at 30, 45, and 60 min post-reflow. cMeasurement pre- and poststenting.dChange in 
concentrations at 3 months relative to 24 hr.
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nation at 3 months. In essence, the trial will provide important information regarding 
the question whether two interventions offering the potential to modulate different 
components of reperfusion-mediated injury are able to act jointly and augment their 
magnitude of benefit by potentially increasing myocardial salvage and reducing ulti-
mate IS in STEMI patients undergoing PPCI.
APPeNDIX 1: sTUDY oRGANIZATIoN
Principal investigators: O.C. Manintveld, MD, PhD and F. Zijlstra, MD, PhD, Erasmus MC, 
Rotterdam. Coordinating investigators: O.C. Manintveld, MD, PhD, Erasmus MC, Rotter-
dam; T. ten Cate, MD, PhD, UMC St Radboud, Nijmegen.
Combined clinical event committee and data safety monitoring board: M.L. Simoons, 
MD, PhD; A.H.M.M. Balk, MD, PhD and C.A.G.M van Montfort
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AbsTRACT
Aims - To determine whether atrial-based pacing prevents atrial arrhythmias in adults 
with congenital heart disease (CHD) com- pared with ventricular pacing 
Methods and Results - All adult CHD patients from four participating centres with a 
permanent pacemaker were identified. Patients with permanent atrial arrhythmias at 
pacemaker implantation and patients who received a pacemaker for treatment of drug- 
refractory atrial arrhythmias were excluded. The final study population consisted of 211 
patients (52% male, 36% complex CHD) who received a first pacemaker for sick sinus 
dysfunction (n = 82) or atrioventricular block (n = 129) at a median age of 24 years [inter-
quartile range (IQR), 12 - 34]. A history of atrial arrhythmias at implantation was present 
in 49 patients (23%). Atrial-based pacing was the initial pacing mode in 139 patients 
(66%) while the others (34%) received ventricular pacing. During a median follow-up 
of 13 years (IQR, 7 - 21), 90 patients (43%) developed an atrial arrhythmia. Multivariate 
analysis demonstrated no significant effect of atrial-based pacing on subsequent atrial 
arrhythmias [hazard ratio (HR), 1.53; 95% confidence interval (CI), 0.91 - 2.56; P = 0.1]. 
Independent predictors of atrial arrhythmia were history of atrial arrhythmias (HR, 5.55; 
95% CI, 3.47 - 8.89; P < 0.0001), older age (18 years) at pacemaker implantation (HR, 2.29; 
95% CI, 1.29 - 4.04; P = 0.005), and complex CHD (HR, 1.57; 95% CI, 1.01 - 2.45; P = 0.04) 
Conclusion - In contrast to the general population, atrial-based pacing was not associ-
ated with a lower incidence of atrial arrhythmia in adults with CHD.
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INTRoDUCTIoN
Atrial arrhythmias play an important role in the management of adults with congenital 
heart disease (CHD) (1). The prevalence of atrial arrhythmias is 15% in the adult CHD 
population, and the risk of developing atrial arrhythmias increases steadily with age (2). 
Atrial arrhythmias contribute significantly to morbidity and mortality in this population 
(2-4). Therefore, strategies to reduce the burden of atrial arrhythmias in this population 
are highly welcome. An interesting subgroup is the adult CHD population with bradycar-
dia indications for permanent pacemaker implantation. In the general population, sev-
eral prospective randomized trials have clearly demonstrated that atrial-based pacing 
(‘physiological pacing’) reduces the incidence of atrial fibrillation compared with ven-
tricular pacing (5-10). This is not surprising, as loss of atrioventricular (AV) synchrony due 
to ventricular pacing is associated with increased natriuretic peptide levels, sympathetic 
nervous activation, and atrial pressures; all factors associated with the development of 
atrial fibrillation (11, 12). Whether atrial-based pacing is also beneficial in the adult CHD 
population is not clear (13). The aim of the present multicentre study is to investigate 
whether atrial-based pacing prevents atrial arrhythmias in adults with CHD.
MeTHoDs
For the present retrospective observational study, all adults with CHD and pacemaker 
implantation were identified using the nationwide CONgenital CORvita (CONCOR) 
registry in the Netherlands, and a Belgian tertiary care adult CHD database (14). The 
central medical ethics committee in the Netherlands and the local Belgian Ethics Board 
approved the protocol. This study complies with the declaration of Helsinki. Data 
were collected from medical records and pacemaker databases. Baseline data prior to 
pacemaker implantation were registered from the patient records including gender, 
congenital anatomic diagnosis, surgical procedures, and history of atrial arrhythmias. 
The complexity of the CHD diagnosis was defined as simple, moderate, or complex 
according to the classification adopted at the American Heart Association Task Force 
on Adults with CHD (15). Detailed information concerning pacemaker implantation was 
recorded and included age at implantation, indication for pacemaker implantation, 
method of implant (endocardial/ epicardial), pacing mode (AAI/VVI/DDD/VDD), and the 
occurrence of sustained atrial arrhythmias during follow-up. Atrial-based pacing, which 
includes AAI, DDD, and VDD, was compared with ventricular pacing (VVI). The endpoint 
was the occurrence of sustained atrial arrhythmias (i.e. intra-atrial reentrant tachycardia, 
atrial tachycardia, and atrial fibrillation) documented by electrocardiogram, Holter, or 
stored logs.
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statistical analysis
Continuous data are presented as mean ± SD or median with interquartile ranges (IQRs) 
as appropriate. Categorical variables are represented by frequencies and percentages. 
Comparison of continuous variables between groups was made by unpaired Student’s 
t-tests. In the case of a skewed distribution, the Mann - Whitney U test was used. When 
com- paring frequencies, the x2 test or Fisher’s exact test was used, where appropriate. 
Cumulative freedom from atrial arrhythmias was constructed with the use of the Kaplan 
– Meier method and groups were compared by log-rank statistics. To determine predic-
tors of sustained atrial arrhythmias during follow-up, univariate and multivariate Cox 
proportional hazard models were constructed after proportional hazard assumptions 
were verified. The patient was set as unit of analysis and time to first atrial arrhythmia 
was determined. Candidate variables included: atrial-based pacing, older age (≥18 years) 
at pacemaker implantation, complex CHD, female gender, history of atrial arrhythmia, 
endocardial pacing system, and sick sinus syndrome. Two-tailed probability values of 
<0.05 were considered statistically significant. Statistic- al analysis was performed using 
the statistical package R (64 bit) for Mac, version 2.14.2.
ResULTs
Patient characteristics
Crosscheck with local pacemaker registries of the four participating tertiary centres 
revealed a total of 274 patients. After exclusion of 63 patients with permanent or drug-
refractory atrial arrhythmias at implantation, 211 patients comprised the final study 
population. The baseline characteristics of the included patients are summarized in 
Table 1. Patients with complex CHD comprised 37% of the population, and were mainly 
patients with transposition of the great arteries and single ventricle physiology. The 
majority of patients (66%) received atrial-based pacing at initial implantation (Figure 1). 
There were important baseline differences between patients with atrial-based pacing 
and those with ventricular pacing. Patients with ventricular pacing more often had the 
first pacemaker implantation at paediatric/adolescent age (64 vs. 22%, P < 0.001) and 
in an older era (before 1994) (75 vs. 21%, P < 0.001). Furthermore, an epicardial pacing 
system was more often used in patients with ventricular pacing (49 vs. 25%, P < 0.001). 
There was no difference in the complexity of the underlying CHD or the prevalence of a 
history of atrial arrhythmias between the two groups.
Atrial arrhythmias during follow-up
During a median follow-up of 13 years, 90 patients (43%) developed atrial arrhythmias. 
Of these 90 patients, 58 patients (64%) had intra-atrial reentrant tachycardia/atrial 
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Figure 1: 
Figure 1: Congenital heart disease (CHD) diagnosis stratified by pacing mode at initial implantation.  Ao valve, 
aortic valve disease; ASD, atrial septal defect; AVSD, atrioventricular septal defect; cc-TGA, congenital 
corrected  transposition of the great arteries; Coarctation, coarctation of the aorta; Ebstein, Ebstein's 
anomaly; PAPVR/TAPVR,  partial or  total  anomalous pulmonary venous return; Pul valv, pulmonary valve disease; 
SV, single ventricle physi- ology; TGA, Transposition of the Great Arteries; ToF, Tetralogy of Fallot; VSD, ventricular 
septal defect. 
Figure 1. Congenital heart disease (CHD) di-
agnosis stratified by pacing mode at initial 
implantation. Ao valve, aortic valve disease; 
ASD, atrial septal defect; AVSD, atrioventricu-
lar septal defect; cc-TGA, congenital corrected 
transposition of the great arteries; Coarcta-
tion, coarctation of the aorta; Ebstein, Eb-
stein’s anomaly; PAPVR/TAPVR, partial or total 
anomalous pulmonary venous return; Pul valv, 
pulmonary valve disease; SV, single ventricle 
physi- ology; TGA, Transposition of the Great 
Arteries; ToF, Tetralogy of Fallot; VSD, ventricu-
lar septal defect.
Table 1. Baseline Characteristics at first pacemaker implantation
Variable Total (n = 211) Atrial based 
pacing (n = 139)
Ventricular 
pacing (n = 72)
P value
Age at first implantation (years) a 24 (12-34) 26 (19-39) 12 (7-26) <0.001
First implant < 18 years 77 (36%) 31 (22%) 46 (64%) <0.001
Male gender 110 (52%) 72 (52%) 38 (53%) 0.9
Complex CHD 79 (37%) 52 (37%) 27 (38%) 1.0
History of atrial arrhythmias 49 (23%) 36 (26%) 13 (18%) 0.2
Pacemaker implantation before 1994 83 (39%) 29 (21%) 54 (75%) <0.001
Indication of pacemaker
Acquired sick sinus syndrome 78 (37%) 45 (32%) 33 (46%) 0.05
Acquired atrioventricular block 69 (33%) 51 (37%) 18 (25%) 0.09
Surgical atrioventricular block 60 (28%) 41 (29%) 19 (26%) 0.6
Surgical sick sinus syndrome 4 (2%) 2 (1%) 2 (3%) 0.6
Pacing mode
AAI (R) 14 (7%) 14 (10%) - < 0.001
DDD (R) 120 (57%) 120 (86%) -
VDD (R) 5 (2%) 5 (4%) -
VVI (R) 72 (34%) - 72 (100%)
Implantation technique
Endocardial leads 141 (67%) 104 (75%) 37 (51%) < 0.001
Epicardial leads 70 (33%) 35 (25%) 35 (49%)
CHD: congenital heart disease
a: expressed as median with IQR
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tachycardia and 32 patients (36%) had atrial fibrillation as the first presenting atrial ar-
rhythmia. The cumulative rate of atrial arrhythmias was 21, 29, and 39% at 5, 10, and 15 
years, respectively. Univariate predictors of atrial arrhythmias are depicted in Table 2. 
Atrial-based pacing, history of atrial arrhythmias, older age (≥18 years) at pacemaker 
implantation, sick sinus syndrome, complex CHD, and endocardial pacing system were 
identified as significant univariate predictors of atrial arrhythmias. Multivariate analysis, 
including all significant univariate predictors, demonstrated that only a history of atrial 
arrhythmias, older age (≥18 years) at pacemaker implantation, and complex CHD were 
independent predictors of atrial arrhythmias. Atrial-based pacing was not an indepen-
dent predictor of sustained atrial arrhyth- mias during follow-up [hazard ratio (HR), 1.53; 
95% confidence interval (CI), 0.91 - 2.56; P = 0.1] (Figure 2).
subgroup analysis
Subgroup analysis demonstrates that patients with single ventricle physiology had 
a high prevalence of previous atrial arrhythmias (50%) at pacemaker implantation 
Table 2. Predictors of atrial arrhythmia in CHD patients receiving pacemaker therapy
Variable
Univariate analysis
P value
Multivariate analysis
P valueHazard ratio (95% CI) Hazard ratio (95% CI)
History of atrial arrhythmia 6.90 (4.40-10.8) < 0.0001 5.55 (3.47-8.89) < 0.0001
Older age (≥ 18 years) at implant 2.74 (1.71-4.40) < 0.0001 2.29 (1.29-4.04) 0.005
Sick sinus syndrome 1.99 (1.32-3.01) 0.001 1.50 (0.96-2.36) 0.08
Atrial-based pacing 1.89 (1.19-3.01) 0.007 1.53 (0.91-2.56) 0.1
Complex CHD 1.67 (1.10-2.54) 0.02 1.57 (1.01-2.45) 0.04
Endocardial pacemaker 1.66 (1.06-2.62) 0.02 1.10 (0.65-1.86) 0.7
Female gender 0.71 (0.47-1.08) 0.1
CHD, congenital heart disease.
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Figure 2 
Freedom from atrial arrhythmias for ventricular pacing and atrial-based pacing in patients with CHD. Atrial, 
atrial-based pacing; HRadj,  adjusted hazard ratio, HRunadj,  unadjusted hazard ratio; ventricular, ventricular 
pacing. 
Figure 2. Freedom from atrial arrhyth-
mias for ventricular pacing and atrial-
based pacing in patients with CHD. Atrial, 
atrial-based pacing; HRadj, adjusted haz-
ard ratio, HRunadj, unadjusted hazard ra-
tio; ventricular, ventricular pacing.
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(Table 3). Interestingly, no patient with aortic valve disease was known with a history of 
atrial arrhythmia prior to implantation. During follow-up, patients with a single ventricle 
physiology were more prone to develop atrial arrhythmias compared with the other 
groups (Figure 3, Table 3).
Table 3. Overview of pacemaker details and atrial arrhythmias in selected CHD groups
Variable Complete 
TGAa
(n = 35)
Tetralogy 
of Fallot
(n = 26)
Aortic valve 
disease
(n = 26)
ASD 
secundum 
(n = 25)
Single 
ventricle 
physiology 
(n = 18)
P value
Clinical and pacemaker data
Age at fi rst implantation (years)b 18 (8-25) 28 (15-40) 34 (18-51) 27 (15-45) 24 (13-29)
Male gender 69% 62% 73% 36% 44% 0.03
First implant < 18 years 49% 39% 23% 32% 33% 0.33
History of atrial arrhythmias 29% 23% 0% 28% 50% 0.004
Atrial-based pacing 54% 54% 77% 60% 88% 0.05
Epicardial leads 46% 12% 15% 28% 72% 0.07
Follow-up data
5 year rate of atrial arrhythmias 20% 25% 0% 21% 51% -
10 year rate of atrial arrhythmias 32% 30% 11% 27% 60% -
TGA, transposition of the great arteries; ASD, atrial septal defect. a Atrial repair, b Expressed as median with IQR.
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Figure 3: Freedom from atrial arrhythmias for ventricular pacing and atrial-based pacing in patients with CHD. 
Atrial, atrial-based pacing; HRadj,  adjusted hazard ratio, HRunadj,  unadjusted hazard ratio; ventricular, 
ventricular pacing. 
 
 
 
 
 
 
Figure 3. Freedom from atrial arrhythmias 
for ventricular pacing and atrial-based pac-
ing in patients with CHD. Atrial, atrial-based 
pacing; HRadj, adjusted hazard ratio, HRun-
adj, unadjusted hazard ratio; ventricular, 
ventricular pacing.
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Peri-procedural complications
Overall, the peri-procedural complication rate is comparable between patients with atrial-
based pacing and those with ventricular pacing (Table 4). When looking at the different 
complications, there was a higher incidence of pocket infection in those with ventricular 
pacing when compared with those with atrial-based pacing (5.6 vs. 0%, P = 0.01).
DIsCUssIoN
In the general population without CHD, atrial-based pacing is beneficial in reducing 
the incidence of atrial fibrillation compared with ventricular pacing (5-10). The present 
multicentre study, however, demonstrates that the beneficial effects of atrial-based pac-
ing cannot be extrapolated to the adult CHD population. After correction for important 
confounders, the incidence of atrial arrhythmias was not different between atrial-based 
pacing and ventricular pacing. These findings suggest that the mode of pacing does not 
play an important role in adults with CHD for the reduction of atrial arrhythmias. Patients 
with CHD are prone to rhythm and conduction disease, which is not surprising consider-
ing the underlying congenital cardiac defect, abnormal anatomy, longstanding haemo-
dynamic alterations, and the consequences of surgical interventions. Atrial arrhythmias 
are a burden to the adult CHD population and are associated with increased morbidity 
and mortality (2-4). These arrhythmias may be difficult to treat pharmacologically and 
may require (a combination of ) catheter ablation or atrial antitachycardia pacing (16, 
17). The purpose of the present study was to explore whether the pacing mode may 
play a role in the prevention of atrial arrhythmias in CHD patients who had a bradycardia 
indication for permanent pacing. Loss of AV synchrony due to ventricular pacing may 
contribute to increased atrial arrhythmogenesis. A meta-analysis by Healey et al. (5), 
summarizing the data of five randomized trials in patients without CHD, demonstrated 
that atrial-based pacing reduced the incidence of atrial fibrillation (HR, 0.80; 95% CI, 
0.72 - 0.89; P < 0.001) and stroke (HR, 0.81; 95% CI, 0.67 - 0.99, P = 0.035) compared with 
ventricular pacing.
Table 4. Peri-procedural complication rates for atrial-based and ventricular pacing
Complication Total (n = 211) Atrial-based (n = 139) Ventricular (n = 72) P value
Total number of patients 22 (10.4%) 11 (7.9%) 11 (15.3%) 0.1
Lead failure 9 (4.3%) 5 (3.6%) 4 (5.6%) 0.5
Bleeding 3 (1.4%) 3 (2.2%) - 0.5
Pneumothorax 2 (0.9%) 2 (1.4%) - 0.5
Pocket infection 4 (1.9%) - 4 (5.6%) 0.01
Ventricular arrhythmias 2 (0.9%) - 2 (2.8%) 0.1
Other 2 (0.9%) 1 (0.7%) 1 (1.4%) 1.0
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Interestingly, our study cohort showed no beneficial effect of atrial-based pacing in 
preventing atrial arrhythmias. Unexpectedly, we found that atrial-based pacing was 
associated with an increased risk of atrial arrhythmias in the univariate analysis (HR, 
1.89; 95% CI, 1.19 - 3.00, P = 0.006). This can be explained by the older age at pace-
maker implantation of the cohort who received atrial-based pacing. In the multivariate 
analysis, the pacing mode was not a predictor of atrial arrhythmias. One previous single-
centre study demonstrated that atrial-based pacing did not appear to be protective 
against subsequent atrial arrhythmias (13). The reason for this lack of beneficial effect 
of atrial-based pacing may be inherent to the increased vulnerability of the adult CHD 
population for atrial arrhythmias due to increased natriuretic peptides, altered load-
ing conditions, and presence of surgical atrial scar (18, 19). The loss of AV synchrony 
induced by ventricular pacing may add little incremental arrhythmogenic risk in such 
patients, and therefore atrial-based pacing may not be as beneficial as in the general 
population. This is in agreement with results from the Mode Selection Trial (MOST) in 
Sinus-Node Dysfunction, where a significant reduction in atrial fibrillation with DDDR 
pacing when compare with ventricular pacing was observed solely in the subgroup 
of patients without a history of atrial fibrillation (9). These results support that pacing 
mode selection is less important with respect to later development of atrial fibrillation 
in patients who already are at high risk of developing atrial fibrillation. Another explana-
tion for the lack of beneficial effect of atrial-based pacing may be related to the type of 
atrial arrhythmias in the CHD population. In the present study, the majority of patients 
with atrial arrhythmias during follow-up experienced intra-atrial reentry tachycardia. 
Approximately one-third of patients had atrial fibrillation. This ratio is in accordance 
with a previous study in adult CHD patients who underwent electrical cardioversion(20). 
Atrial-based pacing may be less beneficial for the prevention of intra-atrial reentrant 
tachycardia than atrial fibrillation. With regard to predictors for future arrhythmias after 
pacemaker implantation, Harris and coworkers identified a history of atrial arrhythmias 
as an independent predictor. In addition, we identified older age (≥18 years) at pace-
maker implantation and complex CHD as independent predictors of atrial arrhythmias. 
In particular, patients with single ventricle physiology, mostly Fontan patients with an 
atriopulmonary connection, are at increased risk of developing atrial arrhythmias later 
in life (Figure 3). Previous electrophysiological mapping studies have shown that Fontan 
patients undergo progressive adverse atrial mechano-electrical remodelling with in- 
creasing age, rendering them more prone to atrial arrhythmias (19). It is important to 
stress that the primary aim of the current study was to investigate the role of pacing 
mode on the incidence of
atrial arrhythmias. This study does not evaluate the potential beneficial effects of 
atrial-based pacing, by maintaining AY synchrony, on haemodynamic parameters, risk 
of heart failure, and avoidance of symptoms related to pacemaker syndrome.
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The current study demonstrated in a relative high proportion of patients who received 
ventricular pacing as the initial pacing mode (34%). Implantation of the pacemaker in an 
older era (before 1994) or at paediatric/adolescent age may explain this phenomenon. 
The beneficial effects of dual-chamber pacing became more appreciated from the early 
1990’s (7-9). However in the paediatric population, there is still some debate whether 
dual-chamber pacing is superior to ventricular pacing (21).
Finally, the rate of peri-procedural complication in the general population without 
CHD is nearly twice as high with atrial-based pacing compared with ventricular pac-
ing (6.2 vs. 3.2%), primarily due to a significant increase in the rate of lead failure and 
infarction (5). Our study cohort did not confirm this difference in overall peri-procedural 
complication rate between patients with atrial-based pacing or ventricular pacing. 
However, CHD patients with ventricular pacing did demonstrate more pocket infections 
(5.6 vs. 0%, P = 0.01).
study limitations
This study has limitations inherent to any retrospective study. The major limitation of 
the present study is the observational study design, which renders the data subject 
to selection bias. We tried to overcome this limitation by using a multivariate analysis 
including all potential confounders. Clearly, this approach cannot replace a randomized 
controlled trial design. Furthermore, despite its relative large size due to its multicentre 
nature, this study may be underpowered to demonstrate a potential benefit of atrial-
based pacing. In addition, the heterogeneity of pacemaker settings limited our ability to 
draw conclusions with regard to desired pacemaker settings. Owing to the retrospective 
study design, we had incomplete echocardiographic data limiting our ability to cor-
rect for potential con- founders such as atrial dilatation or significant atrioventricular 
regurgitation. Finally, the patient sample is drawn from an adult-based practice and 
hence skewed towards this age group. Therefore, the patients who died or were lost to 
follow-up before reaching adulthood are not addressed in this study. Considering the 
abovementioned limitations, the conclusions of the present study must be drawn with 
caution.
CoNCLUsIoN
Compared with ventricular pacing, the use of atrial-based pacing was not associated 
with a lower incidence of atrial arrhythmias in adults with CHD. There is a high vulner-
ability for developing atrial arrhythmias, especially intra-atrial reentrant tachycardia, 
which is largely determined by older age, underlying atrial substrate, and prior atrial 
arrhythmias. Atrial-based pacing may be less beneficial for prevention of intra-atrial re-
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entrant tachycardia than atrial fibrillation. To develop effective therapies for preventing 
atrial arrhythmias, future research should focus on understanding the pathophysiology 
of atrial arrhythmia in adults with CHD.
Conflict of interest: none declared.
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AbsTRACT
Background - This study aims to investigate indications and complications of permanent 
cardiac pacing in adults with congenital heart disease (CHD).
Methods and results - Two-hundred and seventy-four CHD patients were identified who 
underwent permanent pacemaker implantation between 1972 and 2009. The indication 
for pacing was acquired sinus node or AV node conduction disease (63%), sinus node or 
AV node conduction disease after cardiac surgery (28%), and drug/arrhythmia-related 
indications (9%). Patients with complex CHD received a pacemaker at younger age (23 
versus 31 years, p < 0.0001) and more often received an epicardial pacing system (51% 
versus 23%, p < 0.0001) compared to those with simple or moderate CHD. Twenty-nine 
patients (10.6%) had a periprocedural complication during the primary pacemaker im-
plantation (general population: 5.2%). The most common acute complications were lead 
dysfunction (4.0%), bleeding (2.6%), pocket infection (1.5%) and pneumothorax (1.5%). 
During a median follow-up of 12 years, pacemaker-related complications requiring 
intervention occurred in 95 patients (34.6%). The most common late pacemaker-related 
complications included lead failure (24.8%), pacemaker dysfunction/early battery deple-
tion (5.1%), pacemaker migration (4.7%) and erosion (4.7%). Pacemaker implantation at 
younger age (< 18 years) was an independent predictor of late pacemaker-related com-
plication (adjusted hazard ratio 1.68, 95% confidence interval 1.07 to 2.63, p = 0.023).
Conclusions - The risk of periprocedural complications seems higher in the CHD popu-
lation compared to the general population and more than one-third of CHD patients 
encountered a pacemaker-related complication during long-term follow-up. This risk 
increases for those who receive a pacemaker at younger age.
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INTRoDUCTIoN
The population of adult patients with congenital heart disease (CHD) is rapidly expand-
ing due to advances in pediatric cardiology and cardiothoracic surgery over the past 
several decades (1, 2). How- ever, this improved survival following congenital heart 
surgery is hampered by both structural and electrical late sequelae including atrio-
ventricular (AV) block, sinus node dysfunction and atrial arrhythmias (3, 4). Many will 
require pacemaker therapy and are subject to lifelong need for reinterventions and 
follow-up (3). Pacemaker implantation in this population may be a challenge due to the 
complexity of the systemic venous anatomy, venous obstructions and/or residual intra-
cardiac shunting (5, 6). Furthermore, pacemaker implantation at young age and the use 
of epicardial leads have been associated with a high incidence of lead failures during 
follow-up (6-10). Because of these issues, pacemaker therapy should be considered 
carefully in the patient with CHD. To improve patient management, knowledge regard-
ing the indications and impact of pacemaker therapy is essential. Unfortunately, these 
data are scarce for the adult CHD population and large multi-center studies are lacking 
(5, 6). Furthermore, most CHD studies only focus on lead failure rate. The objective of 
the present multi-center study is to investigate the indications, periprocedural and late 
complications of permanent pacemaker therapy in adults with CHD.
MeTHoDs
For the present retrospective study, all adults with CHD and a history of pacemaker 
implantation were identified from the participating centers using the nationwide CON-
genital CORvitia (CONCOR) registry in The Netherlands and a Belgian tertiary care center 
adult CHD database (11). Patients with a primary electrical disease or cardiomyopathy 
were excluded from analysis. We also excluded patients with an implantable cardioverter 
defibrillator as we previously published our experience with this specific patient group 
(12). Crosscheck with the local pacemaker registries of the four participating tertiary 
centers revealed a total of 274 patients. The central medical Ethics Committee in The 
Netherlands and the local Belgian Ethics Board approved the protocol. The authors of 
this manuscript have certified that they comply with the Principles of Ethical Publishing 
in the International Journal of Cardiology. Data were collected from medical records and 
pacemaker databases. Baseline data prior to pacemaker implantation were registered 
from the patient records including, gender, congenital anatomic diagnosis, surgical 
procedures, and history of atrial arrhythmias. The complexity of the CHD diagnosis was 
defined as simple, moderate or complex according to the classification adopted at the 
American Heart Association Task Force on Adults with CHD (13). Detailed information 
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concerning the pacemaker implantation was recorded, including age at implantation, 
indication for pacemaker implantation, method of implant (endocardial/epicardial), 
pacing mode (AAI, VVI, DDD, or VDD), and periprocedural complications. Periproce-
dural pacemaker complications were defined as complications occurring in the first 
30 days after initial pacemaker implantation. Follow-up data included late pacemaker 
complications (> 30 days of implantation), major clinical complications and pacemaker 
reinterventions. Major clinical complications included endocarditis (not pacing system-
related), hospitalization for heart failure, stroke, heart transplantation, aborted sudden 
cardiac death, and death. Documented pacemaker complications were: bleeding (any 
swelling of the pocket with clinical suspicion of hematoma requiring intervention), pac-
ing system-related endocarditis, erosion (skin penetration of the pacemaker requiring 
intervention), lead failure (leads repaired, repositioned, replaced, or abandoned due to 
fracture, insulation break, dislodgment, or abnormalities in pacing or sensing), pace-
maker dysfunction/ early battery depletion (pacemaker malfunction requiring pace-
maker replacement or early battery depletion necessitating replacement < 3 years post 
implant), pacemaker migration (requiring pacemaker repositioning), pneumothorax 
(absence of lung markings over the lung ipsilateral to the pacemaker pocket assessed 
from x-ray), pocket infection (superficial wound infection), and ventricular arrhythmias 
(related to lead manipulation). Normal elective replacement of a pacemaker (> 3 years 
post-implant) or pacemaker upgrade was not considered a pacemaker complication.
statistical Methods
Continuous data are presented as mean ± SD. In the case of skewed data, medians and 
interquartile ranges (IQR) were used. Categorical variables are represented by frequen-
cies and percentages. Comparison of continuous variables between groups was made 
by unpaired Student’s t-tests. In the case of a skewed distribution, the Mann- Whitney 
U test was used. When comparing frequencies, the chi-square test or Fisher’s exact test 
was used, where applicable. Potential predictors of late pacemaker-related complica-
tions were identified by means of Cox regression models, and hazard ratios (HR) and 
95% confidence intervals (95%CI) are reported. Variables with a p < 0.10 on univariable 
analysis were included in a multivariable model. Two-tailed probability values < 0.05 
were considered statistically significant. Statistical analysis was performed using the 
statistical package R (64 bit) for Mac, version 2.14.2.
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ResULTs
Patient characteristics, pacemaker indications, procedural details
The baseline characteristics of the 274 included patients with CHD are summarized in 
Table 1. Patients with complex CHD comprised 36% of the population, and were mainly 
patients with transposition of the great arteries (after atrial correction or congenitally 
corrected transposition) or single ventricle physiology (Fig. 1). The first implant for most 
patients occurred in adulthood (70%). Patients with complex CHD underwent primary 
pacemaker implantation at younger age compared to those with simple/moderate 
CHD (median age 23 versus 31 years, p < 0.0001). Furthermore, patients who received 
an epicardial pacing system were younger at implantation compared to those with an 
endocardial pacing system (median age 14 versus 31 years, p < 0.0001). The primary 
pacemaker devices were implanted be- tween March 1972 and Jan 2009.
The major indication for pacemaker therapy was acquired sinus node or AV node con-
duction disease (63%), the majority of patients had undergone surgery years previously. 
Seventy-seven patients (28%) required pacing within 30 days after cardiac surgical repair 
or palliation. The remainder (9%) required pacing for drug-refractory atrial arrhythmias 
or drug-induced bradycardia. Patients with complex CHD more often received an epi-
Table 1. Baseline characteristics at first pacemaker implantation
Variable
Total 
(n =274)
Simple / 
moderate 
CHD
(n = 175)
Complex 
CHD 
(n = 99)
P value
Age at first implantation (years), median (IQR) 26 [15-39] 31 [18-44] 23 [12-32] < 0.0001
First implant < 18 years 83 (30) 46 (26) 37 (37) 0.06
Male gender 152 (55) 92 (53) 60 (61) 0.20
History of atrial arrhythmias 103 (38) 63 (36) 40 (40) 0.52
Indication for pacemaker
Acquired SSS 91 (33) 56 (32) 35 (35) 0.57
Acquired AV block 81 (30) 47 (27) 34 (34) 0.19
Surgical AV block 70 (26) 57 (33) 13 (13) < 0.001
Drug refractory atrial arrhythmias or drug-related bradycardia 25 (9) 14 (8) 11 (11) 0.39
Surgical SSS 7 (3) 1 (1) 6 (6) 0.01
Initial pacing mode: physiologic pacing (DDD, AAI, VDD) 239 (65) 113 (65) 66 (67) 0.86
Implantation technique: 
Endocardial leads 184 (67) 135 (77) 49 (49) < 0.0001
Epicardial leads 90 (33) 40 (23) 50 (51)
Data are presented as n (%), unless stated otherwise, AV = atrioventricular; SSS = sick sinus syndrome.
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cardial pacing system compared to those with simple/moderate CHD (51% versus 23%, 
p < 0.0001). Reasons for implanting an epicardial system were small body size or young 
age (n = 22, 24%), complex systemic venous anatomy or venous access problems (n = 
20, 22%), concomitant cardiac surgery (n = 17, 19%), right-sided mechanical AV valve (n 
= 10, 11%), intra-cardiac shunt (n = 5, 6%), endocarditis (n = 2, 2%), and unknown reason 
(n = 14, 16%). There were no diff erences in pacing mode between patients with complex 
and simple/ moderate CHD. Table 2 provides an overview of pacemaker details in the fi ve 
most common CHD groups. Patients with complete transposition of the great arteries 
usually required a pacemaker for acquired sick sinus dysfunction. In contrast, patients 
with aortic valve disease are more prone to surgical AV block. In addition, patients with 
single ventricle physiology are at high risk of atrial arrhythmias and a signifi cant propor-
tion requires a pacemaker related to treatment of atrial arrhythmias. Table 3 summarizes 
the initial mode of pacing and change in mode over time. The majority of patients (59%) 
received atrial-based/ physiologic pacing (i.e., AAI, DDD, VDD) at baseline and during to 
atrial-based/physiologic pacing (i.e. VVI to DDD or VVI to AAI). The pacemaker was up-
graded to an implantable cardioverter defi brillator in 20 patients (7%) during follow-up.
Periprocedural complications
Twenty-nine patients (10.6%) experienced one or more peri-procedural complications 
(< 30 days after implantation) during their fi rst pacemaker implantation (Table 4). The 
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Table 2. overview of pacemaker details in the fi ve most common CHD groups.
Variable
Complete 
TGA
(n = 45)
Single 
ventricle 
physiology 
(n =25)
Tetralogy 
of Fallot 
(n =33)
Aortic 
valve 
disease
(n = 30)
ASD 
secundum 
(n = 37)
Clinical 
Age at fi rst implantation (years), median [IQR] 23 [10-27] 24 [15-30] 33 [17-41] 34 [22-50[ 35 [18-52]
Follow-up duration (years), median [IQR] 15 [9-20] 8 [2-15] 13 [6-26] 10 [6-16] 12 [8-26]
Male gender 69% 52% 61% 73% 41%
History of atrial arrhythmias 44% 64% 39% 13% 51%
Indication for pacemaker
Acquired SSS 60% 28% 48% 7% 43%
Acquired AV block 13% 36% 27% 30% 27%
Surgical AV block 7% 12% 18% 60% 16%
Drug-refractory atrial arrhythmias or drug 
induced bradycardia
11% 20% 6% 3% 14%
Surgical SSS 9% - - -
Pacemaker details
Physiologic pacing 53% 88% 58% 77% 62%
Epicardial leads 42% 76% 12% 17% 22%
Pacemaker complications
Periprocedural complications 13% 12% 15% - 8%
Late pacemaker-related complications 38% 20% 24% 23% 32%
Data are presented as percentages, unless stated otherwise, ASD = atrial septal defect; AV = atrioventricu-
lar; SSS= sick sinus syndrome; TGA = transposition of the great arteries, ASD = atrial septal defect.
Table 3. Mode of pacing at baseline and at most recent follow-up
Baseline Follow-up Number of patients (%)
AAI AAI 16 (6%)
AAI DDD 5 (2%)
VVI VVI 55 (20%)
VVI DDD 36 (13%)
VVI AAI 4 (2%)
DDD DDD 136 (50%)
DDD VVI 15 (6%)
DDD AAI 1 (0.4%)
VDD VDD 3 (1%)
VDD DDD 2 (0.7%)
VDD VVi 1 (0.4%)
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most common complication was lead failure requiring intervention (4.0%). Patients with 
complex CHD showed a trend towards more periprocedural complications compared 
to those with simple/moderate CHD (15% versus 8%, p = 0.07). There was a numerical 
decrease in the incidence of periprocedural complications when primary pacemaker 
implantations in a more contemporary cohort (1997-2009) were compared to an earlier 
cohort (1972-1996), however, this was not statistically significant (7.6% versus 13.4%, 
p = 0.12). Younger age (< 18 years) at implantation was not associated with a higher 
periprocedural com- plication rate (7.4% versus 11.9%, p = 0.27).
Late pacemaker-related complications
During a median follow-up period of 12 years (IQR 6-19 years) 95 patients (35%) expe-
rienced a late pacemaker-related complication (Table 5). The most common observed 
complication was lead failure in 68 patients (25%). A large proportion of patients expe-
rienced an infection-related complication (pocket infection 4.4%, pacing system-related 
endocarditis 2.5%). The cumulative rate of late pacemaker- related complication was 8, 
19, 28 and 41% at 1, 5, 10 and 15 years, respectively
Predictors of late pacemaker-related complications
Five variables were evaluated as possible predictors for late pacemaker-related complica-
tions: young age at implantation (< 18 years), complex CHD, epicardial leads, pacemaker 
implantation before 1997 and female gender. Only young age at implantation (< 18 
years) was an independent predictor of late pacemaker- related complications (adjusted 
hazard ratio 1.68, 95% confidence interval 1.07 to 2.63, p = 0.023) (Table 6, Fig. 2).
Table 4. Periprocedural complications during first pacemaker implantation.
Complication Total
(n = 274) 
Simple / Moderate 
CHD
(n = 175) 
Complex 
CHD 
(n = 99)
p-value General 
populationa
Total number of patients 29 (10.6) 14 (8.0) 15 (15.2) 0.07 5.2%
Early lead failure 11 (4.0) 5 (2.9) 6 (6.1) 0.21 2.3%
Bleeding 7 (2.6) 3 (1.7) 4 (4.0) 0.26 0.8%
Pneumothorax 4 (1.5) 2 (1.1) 2 (2.0) 0.62 0.5%
Pocket infection 4 (1.5) 2 (1.1) 2 (2.0 0.62 0.1%
Ventricular arrhythmias 2 (0.7) - 2 (2.0) 0.13 0.1%
Other 2 (0.7) 2 (1.1) - 0.54 0.8%
Data are presented as n (%). CHD = congenital heart disease. a Modified from Nowak et al. [14].
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Long-term outcome
During follow-up, a large proportion of patients was hospitalized for heart failure (n = 
41, 15%) and ultimately four patients under- went heart transplantation (1.5%). Other 
clinical events were stroke (n = 13, 4.7%), aborted sudden cardiac death (n = 13, 4.7%) 
and endocarditis not related to the pacing system (n = 8, 2.9%). Twenty-three patients 
(8.4%) died during follow-up at a mean age of 46 ± 17 years. The cumulative rate of 
survival was 99, 96 and 92% at 5, 10 and 15 years, respectively.
Table 5. Late pacemaker –related complications 
Variable Total population (n = 274)
Duration of follow-up (years), median (IQR) 12 [6-19]
Total number of patients 95 (34.6)
Late lead failure 68 (24.8)
Pacemaker dysfunction/early battery depletion 14 (5.1)
Pacemaker migration 13 (4.7)
Erosion 13 (4.7)
Pocket infection 12 (4.4)
Pacing system-related endocarditis 7 (2.5)
Other 9 (3.3)
Data are presented as n (%), unless stated otherwise.
Table 6.
Variable
Univariate analysis Multivariate analysis
Hazard ratio [95% CI] and p-value Hazard ratio [95% CI] and p-value
Young age (<18 years) at implantation 1.78 [1.18-2.68], 0.006 1.68 [1.07-2.63], 0.023
Complex CHD 0.94 [0.62-1.43], 0.78 -
Epicardial leads 1.43 [0.95-2.14], 0.09 0.84 [0.53-1.34], 0.52
Pacemaker implantation before 1997a 1.30 [0.80-2.12], 0.29 -
Female gender 1.25 [0.83-1.86], 0.29 -
CHD = congenital heart disease. a compared to the period 1997-2009.
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DIsCUssIoN
Several anatomical and pathological issues render pacemaker implantation in patients 
with CHD more difficult compared to the general population [5,6]. Our study shows that 
the incidence of periprocedural complications in patients with CHD seems higher than 
in the general population (10.6% versus 5.2%)(14). Furthermore, more than one-third of 
our cohort (34.6%) experienced a late pacemaker-related complication during a median 
follow-up of 12 years. The most common late complication was lead failure necessitat-
ing intervention.
CHD patients are prone to rhythm and conduction disease, which is not surprising 
considering the underlying congenital cardiac defect, longstanding hemodynamic 
alterations, and the consequences of surgical interventions. Our study demonstrates 
that the indication for pacemaker therapy is associated with the underlying congenital 
anatomical diagnosis and the associated cardiac surgical procedures (Table 2). Sinus 
node dysfunction is a common late sequela in patients who underwent atrial surgery, 
while acquired AV conduction disorders are more common in those with displacement 
of the AV node outside the triangle of Koch. Furthermore, certain operations are associ-
ated with a high risk of AV block due to proximity of the AV conduction tissue. Besides 
conduction disorders, drug-refractory atrial arrhythmias are important late complica-
tions especially in Fontan patients palliated with an atriopulmonary connection (15).
Implantation of a pacemaker in a patient with CHD can be challenging. Our study 
population experienced more periprocedural complications (10.6%) compared to the 
general population. Using data from a large-scale German prospective pacemaker regis-
try (n = 17.826, mean age 75 ± 10 years), the incidence of periprocedural complications 
after first pacemaker implantation was 5.2% in a non-CHD population (14). It is possible 
that the observed higher periprocedural complication rate in our cohort is related to the 
younger age of the study population and not to presence of congenital heart disease 
in itself. However, in our study population age was not associated with periprocedural 
complication rates.
Although the transvenous approach is the first choice, this approach may not be suit-
able for those with small body size, an intra-cardiac shunt, anatomic constraints (i.e. Fon-
tan), a right-sided mechanical valve or absence of venous access. One-third of our study 
population received epicardial leads. This is in agreement with other large single-center 
studies in adults with CHD (Table 7)(5, 6). Interestingly, in our study the use of epicardial 
leads was not associated with a higher incidence of late pacemaker-related complica-
tions. This is in contrast to previous studies demonstrating a higher lead-failure rate in 
those with epicardial pacing systems (6-10). Previous studies have shown that the use of 
steroid-eluting epicardial leads renders the lead failure rate comparable to endocardial 
leads (10, 16). Data with regard to late pacemaker-related complications in adults with 
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CHD is scarce; most studies only report lead failures (5, 6). Our study demonstrates a 
high incidence of late pacemaker- related complications after primary device implanta-
tion. The overall cumulative 10-year rate of late pacemaker-related complications requir-
ing intervention is 24%. Younger age at implantation (< 18 years) was independently 
associated with a higher risk of late pacemaker-related complications. This might be 
explained by the rapid body growth, more active lifestyle and more frequent traumatic 
events rendering these patients more prone to lead failure, pacemaker migration and 
erosion. Finally, protracted pacemaker procedures in patients with complex anatomy 
may render these patients more prone to both acute and late pacing-system-related 
infections. Our data shows that patients with complex CHD are younger when receiving 
their first pacemaker compared to those with simple/moderate CHD. The combination 
Table 7. Comparison of studies of pacemaker therapy in adults with CHD
Variable Walker 2004 [5] Mcleod 2010 [6] Opic 2012
Study design
Time period
Single-center, 
retrospective
NA
Single-center, 
retrospective 1967-
2005 (38 years)
Multi-center, 
retrospective 1972-
2009 (37 years)
Number of patients 168 106 274
Male 47% 50% 55%
Complex CHD 40% 50% 36%
Indication for pacemaker:
Acquired SSS 19% 40% 33%
Acquired AV block 27% 33% 30%
Surgical AV block 37% 15% 26%
Drug-refractory atrial arrhythmias or drug-
induced bradycardia
9% 12% 9%
Surgical SSS 8% 0% 3%
Age at first implantation (years)a 28 37 ± 19 26 [15-39]
First implant < 18 years 33% 16% 30%
Epicardial leads 37% 33% 33%
Periprocedural complications during first 
implantation
NA 12%b 11%
Duration of follow-up (years) 11 ± 9 12 ± 14 26 [15-39]
Late pacemaker-related complications NA NA 35%
Lead failure during follow-up 27% 24%c 25%
Pocket infection 3.6% 4% 4.4%
Erosion 1.1% NA 4.7%
Pacing system-related endocarditis 0.6% NA 2.5%
Mortality 2.4% 20% 8.4%
NA = not available. a Data are presented as mean ± SD or median [IQR]. b Excluding failed or difficult place-
ment. c Unit of analysis: number of leads.
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of abovementioned factors may explain why younger patients experience more late 
pacemaker-related complications.
study limitations
This study has limitations inherent to any retrospective study. The most important limi-
tation is the potential for missing complications, which were not described in medical 
records. However, if we have underestimated the complication rate, this only strengthens 
our conclusion that the CHD population is at higher risk of periprocedural pacemaker 
complications compared to the general population. Furthermore, the comparison to 
other CHD studies may be hampered by differences in definitions of pacemaker-related 
complications (Table 7). The multi-center design limited our ability to collect information 
on certain risk facvtors, including pacing and sensing thresholds and lead impedances, 
the precise method of transvenous vascular access, or the precise types of fixation 
methods and materials used. The Patient sample is drawn from an adult-based practice 
and hence skewed towards this age group. Therefore, the patients who died or were lost 
to follow-up before reaching adulthood are not addressed in this study and this could 
introduce bias. Finally, although our study is the largest multicenter study in adults with 
CHD, some of our analyses may be underpowered. Therefore, the conclusions of the 
present study must be drawn with caution.
CoNCLUsIoN
In this large multi-center study of adult patients with CHD receiving pacemaker therapy, 
we found a high incidence of periprocedural and late pacemaker-related complications. 
More than one third of patients will experience a late pacemaker-related complication 
during long-term follow-up. The most common late complication was lead failure. Age 
proved to be an independent predictor of late pacemaker-related complications, with a 
68% increased relative risk in CHD patients younger than 18 years. Our data stress that 
meticulous follow-up is mandatory in this population to identify potential pacemaker 
complications, especially in the younger and active CHD population.
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sUMMARY, GeNeRAL DIsCUssIoN AND FUTURe PeRsPeCTIVes
This thesis investigated the application of cardiac MRI in patients with IHD and CHD and 
evaluated novel non-invasive MRI techniques in both humans and in a porcine model. 
As you may notice, unfortunately we did not succeed in finishing our main objective to 
limit infarct size with bivalirudine. However, the results of this thesis could contribute 
to the application of MRI in IHD trials and establishing a diagnosis in patients with CHD. 
Magnetic resonance imaging is an excellent non-invasive imaging modality that depicts 
the infarct size, global left ventricular function and MO, as well as offers detailed and 
reproducible information of renal artery characteristics. In this thesis we used novel MRI 
techniques to measure the effect of novel treatment strategies and to predict prognosis 
in the clinical setting. In this general discussion we will address the results of our stud-
ies against the background of the published literature and its implications for clinical 
practice and further research.
VALIDATIoN oF MAGNeTIC ResoNANCe ANGIoGRAPHY AND CMR 4D FLoW 
IN PATIeNTs WITH ResIsTeNT HYPeRTeNsIoN AND CoNGeNITAL HeART 
DIseAse
Magnetic resonance angiography (MRA) is a well-established modality for assessment 
of renal artery stenosis (1). In chapter 2 we studied the application of MRA in patients 
with resistant hypertension in which renal sympathetic denervation, a potential treat-
ment, was performed (2). The purpose of this study was to test the reproducibility of a 
novel MRA quantitative imaging tool to measure renal artery dimensions and to validate 
these measurements against invasive intravascular ultrasound (IVUS). Hypertension is a 
well-known risk factor for ischaemic and diastolic heart failure, and is therefore an at-
tractive parameter to treat. The results might shed further light on the long-term safety 
of this experimental procedure in patients with resistant hypertension. Some early re-
ports showed that there might be vascular damage induced by the catheters (3, 4). By 
postdenervation optical coherence tomography, an invasive method to image vessels 
inside the human body, dissection was seen in 14/50 arteries (32.6%). The percentage of 
frames with dissection was higher in balloon-based denervation catheters. Using MRA, 
we tested a non-invasive method to depict the renal arteries, to observe the short-term 
safety of renal denervation. We used a high resolution spoiled gradient-echo sequence 
with a high spatial resolution of 0.89 x 0.89 x 1.66 mm. Our study (5) demonstrated 
that with MRA, renal artery dimensions can be measured with good intraobserver and 
interobserver variability of less than 5%. The correlation of total lumen volume as mea-
sured with MRA against IVUS was excellent with an R-value (a measurement of correla-
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tion) of 0.951. The technique required minimal user interaction. To our best knowledge, 
this is the first study validating MRA measurements with IVUS measurements. In chapter 
3 we describe the results of patients with resistant hypertension treated with renal 
sympathetic denervation. Besides the fact that initial promising, but non-controlled, 
studies on clinical efficacy in patients with therapy resistant hypertension were recently 
challenged by a negative randomised controlled trial, data on long-term safety have 
been mainly limited to the use of the first generation radiofrequency devices (6-8). In 
this study, quantitative MRA of patients treated with RDN revealed no significant change 
in renal artery dimensions up to 12 months follow-up. Over the past 10 years there has 
been intense research in the development of volumetric visualisation of intra and extra 
cardiac flow, so called CMR 4D (9). The acquisition offers, in a free breathing acquisition, 
information about blood flow and anatomical information. In chapter 4, we authors 
evaluated a cloud-based application package that combines volumetric data. Detection 
and grading of aortic valve regurgitation using CMR 4D flow imaging were evaluated 
against transthoracic echocardiography. The agreement between the two techniques 
was good with a kappa value of 0.73. The aortic regurgitation can be well visualised with 
excellent sensitivity and specificity. To our best knowledge this is the first report on the 
performance of a cloud-based software that applies eddy currents correction and direct, 
interactive flow visualisation of CMR 4D flow data in a single tool package by internet 
connection, with remote processing of transferred raw datasets on high performance 
workstations. This was a small, single centre study, and as a proof of concept we limited 
the analysis to the qualitative evaluation of aortic valve regurgitation. 
CARDIAC MAGNeTIC ResoNANCe IMAGING IN IsCHeMIC HeART DIseAse 
TRIALs
In chapters 5, (11), we investigated whether proteins known to stimulate angiogenesis 
(VEGF), which should help to restore the delivery of oxygen to the heart and may help to 
reduce the amount of damage. VEGF was delivered by biodegradable microspheres. In 
32 swine, the left circumflex artery was occluded for two hours followed by reperfusion. 
The microspheres appeared to be non-toxic. However no significant reduction in infarct 
size was noticed between the groups. VEGF165A therapy resulted in a dose dependent 
increase in microvascular density, but this did not translate into global or regional 
improvements of cardiac function. More than 50% of patients with heart failure pres-
ent with heart failure with a preserved ejection fraction (HFpEF) (12, 13). Hospitalised 
patients with HFpEF have high mortality and rehospitalisation rates, and there is cur-
rently no effective treatment available for these patients (14). Common metabolic and 
cardiovascular risk factors appear to be critical in the development of HFpEF. In chapter 
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6 we tested whether swine exposed to common comorbidities, diabetes mellitus (DM) 
(induced by streptozotocin), hypercholesterolaemia (HC) (high fat diet) and hyperten-
sion (HT) (resulting from renal artery embolisation) are prone to developing HFpEF. In 
summary, the conclusion of this study was that the combination of three comorbidities 
leads to systemic inflammation, myocardial oxidative stress and coronary microvascular 
dysfunction, which may be associated with myocardial stiffening and diastolic dysfunc-
tion with a preserved ejection fraction. Paulus and Tschope (15) recently suggested that 
a systemic inflammatory state produced by cardiovascular comorbidities or risk factors 
is common in many heart failure patients including those with HFpEF (16, 17). The 
inflammatory state promotes coronary microvascular endothelial dysfunction, which 
is characterised by generation of reactive oxygen species and reduced nitric oxide 
bioavailability, leading to a cascade of signaling events that ultimately promote cardiac 
fibrosis and myocyte stiffness. It seems to be that multiple common comorbidities, 
including obesity, diabetes and hypertension, are strongly associated with HFpEF (18). 
Results in line with this hypothesis were faithfully produced in the present study.
Predicting the future after STEMI has been a subject of great interest since the in-
troduction of MRI (19). Engineers, radiologists and cardiologists play a pivotal role in 
this challenging field (20). The enormous possibilities in pulse sequences might be 
disturbing for the end-user, and therefore specific, tailor-made study protocols are used 
(21, 22). A pPCI is the best available reperfusion strategy to open an occluded artery in 
patients with STEMI. Despite re-establishing epicardial flow, a failure of reperfusion of 
the myocardium may occur known as no-reflow due to MO (23). No-reflow occurs in 
up to 60% of STEMI patients (24). One potential problem is the heterogeneity of MO. 
Broadly speaking, there are three essential components for MO: (i) ischaemic injury; (ii) 
reperfusion injury; and (iii) atherothrombotic embolisation (25). Several studies suggest 
that MO is an important predictor of outcome, but these studies were hampered by a 
limited number of patients, evaluated a combined clinical endpoint, and were single 
centre studies. Furthermore, infarct size is intuitively an independent predictor of out-
come, and there is conflicting evidence to support this (26) (19).
We performed a collaborative patient pooled analysis to evaluate the prognostic value 
of infarct size, MO and LVEF. We performed a meta-analysis to evaluate the hypotheses 
that MO and infarct size, expressed as a percentage of LV mass are independent predic-
tors of major adverse cardiovascular events and cardiac death in patients with STEMI un-
dergoing pPCI (27). The results of this study, as a consequence of collaboration between 
Dutch, German, French, Spanish, Norwegian, Austrian and U.S. sites, are described in 
chapter 7-8. The main findings - and important part of this thesis - of this study were 
that: 1) MO was present in > 50% of patients; 2) MO, IS%LV and LVEF were predictors for 
MACE, with value added to clinical risk factors; 3) MO was associated with cardiac death 
when adjusted for age and LVEF; and 4) IS%LV, adjusted for MO and LVEF was not an 
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independent predictor for MACE or cardiac death. The cause of the detrimental effect re-
mains unknown. Baks et al. (28) demonstrated that the presence of MO in dysfunctional 
myocardial segments was associated with significant thinning of the myocardium com-
pared with normal segments. Nijveldt et al. (29) demonstrated that a significant portion 
of patients with MO developed a significant increase in LV end-diastolic volume, with no 
improvement of LVEF. Both studies suggest that MO is involved in adverse ventricular 
remodeling of the heart after STEMI. Our finding that IS%LV is secondary to MO and 
LVEF is remarkable. It is important to realise that IS%LV is correlated with LVEF and MO. 
However, due to its univariate association with outcome (i.e. myocardial infarction, heart 
failure and cardiac death), its correlation with LVEF and its contribution to the model, as 
shown as an improvement in the c-index, suggest that IS%LV is an attractive option as 
an endpoint in IHD trials. Importantly, MO seems to be an important predictor of cardiac 
death, which might be a game changer, as the focus of current studies is on infarct size. 
As shown by Ito (30) patients with no-reflow more often had malignant arrhythmias, 
cardiac tamponade and early congestive heart failure compared with patients without 
no-reflow. In addition, according to a study previously performed by Ndrepepa et al., 
there is a clear relationship between infarct size and no-reflow. Infarct size, as estimated 
by single-photon emission computed tomography (SPECT), was larger in the no-reflow 
group (percentage of the LV affected: 15% versus 8%, p <0.001) (31). Of the current 
variables, MO is still the best predictor and probably indicates which patients should be 
investigated further. The results are in line with the studies of de Waha (32), Eitel (33) and 
Stone et al. (34). Stone et al. performed a similar pooled patient-level analysis from 10 
randomised pPCI trials (total of 2,632 patients) in which infarct size was assessed within 
one month after randomisation by either CMR imaging or technetium-99m sestamibi 
SPECT, with clinical follow-up for ≥ six months. Infarct size measured by CMR or tc-99m 
sestamibi SPECT within one month after primary PCI was strongly associated with all-
cause mortality and hospitalisation for HF within one year, even after adjustment for 
multiple clinical, angiographic and treatment parameters (35). 
The findings of our study are important in the design of IHD trials for the evaluation of 
new treatment options. Secondly, although it is clear that CMR offers valuable informa-
tion in infarct size characterisation, a compelling case for routine clinical use is lacking. 
In patients with a typical presentation of ACS, there is currently no role in the diagnostic 
work-up and patient triage (36). To complicate clinical matters further, as highlighted 
in the editorial of JACC Cardiovascular Imaging by Nathaniel Reichek dedicated to this 
study, MRI is costly and time consuming (37). Unfortunately we did not take myocardial 
salvage index and a hypointense infarct core into account in our regression analysis (38, 
39). In chapter 9, the authors described in detail how to setup a trial to reduce infarct 
size in patients with STEMI. Postconditioning Rotterdam Trial tested the hypothesis that 
adding ischaemic postconditioning to routine thrombus aspiration could prevent MO. 
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In that study a strategy was used in which controlled, brief, intermittent episodes of 
re-occlusions in the first few minutes of reperfusion were determined to protect the 
myocardium from lethal reperfusion injury. Unfortunately that study was withdrawn. In 
this study, MRI was performed early (3-5 days) after STEMI and after three months using 
a 1.5 or 3 Tesla MRI scanner. In essence, this trial was set up to limit infarct size in patients 
with STEMI undergoing pPCI. 
oUTCoMe sTUDIes IN CoNGeNITAL HeART DIseAse
Part 4 describes the application of MRI in patients with CHD. Magnetic resonance imag-
ing provides excellent information for establishing the diagnosis and image-guided 
treatment of CHD. The enormous possibilities in imaging might be overwhelming. 
Therefore, a specific question has to be formulated by the referring physician for the ra-
diologist and MRI technicians to tailor the protocol, as the different pulse sequences may 
provide overlapping information about cardiac anatomy and function. Preferably, data 
should be checked during or after examination, when the patient is still in the MRI bore. 
In chapters 10-11 we aimed to investigate the indication and complications of perma-
nent cardiac pacing in adults with CHD. In this large multicentre study, which included 
the department of cardiology of Erasmus Medical Center, Rotterdam, the Netherlands, 
Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands, University 
Hospitals Leuven, Leuven, Belgium and Leiden University Medical Center, Leiden, the 
Netherlands, the authors retrospectively identified all adults with CHD and a history of 
pacemaker implantation using a nationwide CONgenital CORvitia (CONCOR) registry in 
the Netherlands and a Belgian tertiary care centre adult CHD database. In chapter 10 
we demonstrated that atrial-based pacing was not associated with a lower incidence 
of atrial arrhythmias (41). In chapter 11, our study showed that the incidence of per 
procedural complications in patients with CHD seems higher than in the general popu-
lation (10.6% versus 5.2%), suggesting that placement of a pacemaker device might be 
challenging in this group of patients. Patients with complex CHD more often received an 
epicardial pacemaker system. Furthermore, more than one-third of our cohort (34.6%) 
experienced a late pacemaker-related complication during a median follow-up of 12 
years. The most common late complication was lead failure necessitating intervention 
(42).
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CoNCLUsIoNs 
In this thesis we showed that cardiac MRI is an excellent tool for the evaluation of 
atherosclerotic and congenital cardiovascular disease. It is an excellent tool in predict-
ing outcome after STEMI in patients undergoing pPCI. Microvascular obstruction and 
infarct size were predictors of adverse outcomes. Microvascular obstruction was an in-
dependent predictor for cardiac death in patients with STEMI. In patients with resistant 
hypertension, referred for renal denervation, the renal arteries can be accurately mea-
sured with high correlation with invasive measurements and in a reproducible manner. 
With emerging sequences, such as CMR 4D flow imaging, MRI is an attractive option for 
establishing a diagnosis and follow-up compared to echocardiography in patients with 
CHD. The incidence of per procedural complications in patients with CHD seems higher 
than in the general population suggesting that placement of a pacemaker device might 
be challenging in this group of patients.
FUTURe PeRsPeCTIVes
As experienced as a researcher, ambitious projects with highly valued objectives, like the 
promised bivalirudine CMR study and PORT study which were a main objective of this 
thesis, will not always take place. Project management and expectation management 
are essential to maintain good relationships with the stakeholders, like financial stake-
holders. Mechanical reperfusion in acute myocardial infarction does not always result in 
desirable optimal myocardial perfusion (43). As studied in this thesis, the no-reflow phe-
nomenon is an ominous sign beyond its association with infarct size. Prevention of so-
called no-reflow is a crucial step in improving the prognosis of patients with STEMI (44). 
Several strategies including pharmacological and mechanical strategies, and perhaps a 
combination have been proposed, and despite negative studies (45-49), doubt and dis-
cord, the search for the holy grail to limit infarct size and reperfusion injury will continue 
(50). A better understanding of the no-reflow phenomenon and the visualisation by MRI 
should enable us to modify the disease process, resulting in a better outcome. Magnetic 
resonance imaging might play a pivotal role in these experimental studies as a surrogate 
endpoint, as nowadays the survival of patients with myocardial infarction is good with 
less than 5% mortality per year. The essential feature of a surrogate endpoint is its sensi-
tivity. Clinical events are generally insensitive markers of disease activity because clinical 
events are generally rare, and therefore typically require large numbers of individuals 
to be followed for protracted periods. Surrogate endpoints are more sensitive markers 
of disease presence, severity or activity, are usually continuous variables, and therefore 
are ‘common’ and reduce the sample sizes required to have a certain power to detect 
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an effect of given clinical and statistical significance. These reductions in sample size 
can often be translated into reduced cost and duration of a trial compared with a study 
based on clinical endpoints or trials using less precise surrogates (51) (52). As noted 
earlier, project and people management are essential to finish these complex projects 
between multiple departments and stakeholders. Interesting developments are in the 
field of CHD with advances in 4D flow imaging and echocardiographic techniques such 
as speckle tracking echocardiography. With the use of speckle tracking, ventricular 
dysfunction may be detected (53). The application of MRI is increasing in the field of 
risk stratification in structural and acquired genetic heart disease such as hypertrofic 
cardiomyopathy , non-compaction cardiomyopathy and ARVC. Beyond the scope of this 
thesis, one might oversee things from an insurance company perspective, and therefore 
it is important to evaluate costs and downstream testing in the interesting field of CAD 
detection (54). Secondly, sudden out of hospital cardiac arrest is an important public 
health problem with survival rates of less than 10%. An interesting project created by 
Momont et al. is a collaboration between the Technical University of Delft and University 
Hospital Leuven to improve the outcome of patients with cardiac arrest due to ven-
tricular fibrillation with a network of drones (55). Their objective is to improve current 
infrastructure to create a network of drones equipped with an onboard AED, capable 
of saving lives. This might increase the survival rate of patients with cardiac arrest from 
8% to 80%. Furthermore text message alert systems and research into S-ICD’s are an 
interesting development, this might result in a marked increase of survival chances in 
patients with cardiac arrest (56). We hope our efforts and results may eventually lead to 
improvement of the prognosis of patients with IHD and CHD.
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Chapter 13
Samenvatting en discussie
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NeDeRLANDse sAMeNVATTING
Studies in dit proefschrift omschrijven de toepassing van magnetische resonantie 
imaging (MRI) in patiënten met ischemische en aangeboren hartziekten. Nieuwe pulse 
sequenties werden toegepast in zowel patiënten als in experimentele modellen. De 
resultaten die beschreven zijn in dit proefschrift kunnen worden gebruikt in studies om 
het effect van nieuwe therapieën tijdens een acuut hart infarct te beoordelen. Verder kan 
een MRI scan worden gebruikt voor het stellen van een diagnose bij patiënten verdacht 
voor een aangeboren hartaandoening. MRI is een unieke niet-invasieve beeldvormende 
technologie waarmee de linker en rechter kamer functie kan worden bestudeerd. Het 
biedt gedetailleerde en reproduceerbare informatie om de grootte van een hartinfarct 
te meten. Helaas zijn we er niet in geslaagd om het hoofddoel; het beperken van infarct 
grootte met bivalirudine te bereiken. In de discussie worden de resultaten van de studies 
uitgezet tegen de reeds bestaande literatuur.
VALIDATIe eN MeTHoDoLoGIe 
Magnetische resonantie imaging is een gebruikelijk diagnosticum om nierslagader 
vernauwing te meten. In hoofdstuk 2 hebben we MRI toegepast in patiënten met 
therapie resistente hypertensie; ofwel hoge bloeddruk. Renale denervatie is een 
experimentele behandeling en nieuwkomer om therapie resistente hypertensie te 
behandelen. Het doel van de studie was om de reproduceerbaarheid van de dikte van 
een nierslagader te meten, en om deze meting te valideren met een invasieve meting 
(Intravasculaire ultrasound - IVUS). In deze studie gebruikte we een MRI sequentie met 
een hoge spatiele resolutie. Voxel grootte was 0.89 x 0.89 x 1.66 mm. Onze studie toonde 
aan dat met MRI de dimensies van een nierslagader met goede reproduceerbaarheid 
gemeten kunnen worden. De software was eenvoudig te gebruiken. Voor zover onze 
kennis reikt, is dit de eerste studie die de MRI meting van de nierslagader met invasieve 
echotechnieken heeft vergeleken. In hoofdstuk 3, beschrijven we de resultaten van 
renale denervatie bij patiënten met therapie resistente hypertensie. Ondanks veelbe-
lovende niet gerandomiseerde studies is er in 2014 een negatieve studie gepubliceerd. 
Data wat betreft veiligheid is echter schaars en howel er case reports van nier-arterie 
stenose na denervatie zijn gepubliceerd ontbreekt een kwanitatieve analyse in de 
wetenschappelijke literatuur. In dit hoofdstuk wordt de veiligheid van deze nieuwe 
behandeling beschreven. In de laatste tien jaar, is er veel onderzoek verricht naar het 
in beeld brengen van bloedstromen in het hart. In tien minuten tijd is het mogelijk om 
doorstroming van het bloed over de hartkleppen zichtbaar te maken. In hoofdstuk 4, 
evalueerde de auteurs een cload-based applicatie om aorta-klep lekkage te meten. MRI 
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4D flow beelden en daaruit volgende gemeten variabelen werden gevalideerd ten op 
zichte van doppler echocardiografie. De metingen kwamen redelijk met elkaar overeen 
met een kappa waarde (een maat die correlatie meet) van 0.73. Aortaklep lekkage kan 
goed in beeld worden gebracht met een uitstekende sensitiviteit en specificiteit. Dit 
was een kleine studie, en als een proof of concept zijn de analyses beperkt gebleven tot 
aortaklep lekkage. 
MRI sURRoGAAT eINDPUNTeN IN sTUDIes oM HARTINFARCT beHANDeLING 
Te oPTIMALIseReN
In hoofdstuk 5, hebben de auteurs de effecten van groeifactoren bestudeerd na een 
infarct in een experimenteel model. Er wordt aangenomen dat groeifactoren de wond-
heling gunstig beinvloedt en daarmee de schade kan worden beperkt. Deze groeifacto-
ren, vessel endothelial growth factor (VEGF), waren verpakt in kleine polymeerbolletjes. 
Deze bolletjes zijn via een catheter in een opgewekt infarct (linker kransslagader) bij 
varkens ingespoten. Dit is gedaan in totaal 32 varkens verdeeld over 3 groepen. Na een 
periode van 2 uur waarin een kransslagader werd afgesloten werden in 3 behandel-
groepen (placebo, lage dosis VEGF en hoge dosis VEGF) deze bolletjes ingebracht. Na 
1 en 5 weken werd infarct grootte en linker ventrikel functie beoordeeld. Verder zijn 
er met histologische technieken vaatdichtheden bekeken. Helaas verbeterde de linker 
ventrikel functie van de behandelde dieren niet, er werden verder geen significante 
verschillen gevonden in de grootte van het hartinfarct tussen de verschillende groepen. 
In hoofdstuk 6 werd hartfalen onderzocht in een varkensmodel. Meer dan 50% van 
de patiënten met hartfalen heeft een behouden linker ventrikel ejectie fractie (HFpEF). 
Patiënten met HFpEF hebben een hoge mortaliteit en worden vaak opgenomen in een 
ziekenhuis. Op dit moment is er geen effectieve therapie voor deze groep patiënten. 
Waarschijnlijk ligt er een metabole aandoening of cardiale risicofactoren aan de aan-
doening aan ten grondslag. In hoofdstuk 6 werden varkens aan diabetes (geïnduceerd 
door streptozotocin), een hoog cholesterol en hypertensie (hoge bloeddruk) bloot 
gesteld en wilden we weten of ze daarmee HFpEF kunnen ontwikkelen. Concluderend 
zagen we dat de combinatie kan leiden tot verstijving van de linker ventrikel en ont-
stond er diastolische dysfunctie. Het voorspellen van prognose na een hartinfarct; een 
goede of slechte uitkomst na een hartinfarct is belangrijk onderwerp van onderzoek 
en discussie. Een van de doelen van dit proefschrift was om te beoordelen of met MRI 
de prognose na een hartinfarct kan worden voorspeld. We hebben een internationale 
meta-analyse opgezet om de prognostische waarde van infarct grootte, obstructie van 
de kleine bloedvaten in het infarct gebied en linker ventrikel ejectie fractie (een maat 
om de knijpkracht van de linker kamer te meten), te onderzoeken. Onze hypothese was, 
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dat infarct grootte een onafhankelijke voorspeller voor het optreden van hartfalen, een 
volgend hartinfarct en cardiale dood zou zijn in patiënten met een acuut hartinfarct. 
De resultaten van een internationale samenwerking van Nederlandse, Duitse, Franse, 
Spaanse, Noorse, Oostenrijkse en Amerikaanse onderzoekers worden beschreven in 
hoofdstuk 7 en 8. De belangrijkste resultaten worden opgesomd: 1) obstructie van de 
kleine bloedvaten in het infarct gebied komt in meer dan 50% van de patiënten met 
een hartinfarct voor; 2) obstructie van de kleine bloedvaten, de grootte van het infarct 
en linker ventrikel ejectie fractie zijn voorspellers voor het optreden van een volgend 
hartinfarct, hartfalen of zelfs overlijden; 3) obstructie van de kleine bloedvaten is ge-
associeerd met overlijden wanneer dat ook wordt gecorrigeerd voor leeftijd en linker 
ventrikel ejectie fractie; 4) Infarct grootte, gecorrigeerd voor obstructie van de kleine 
bloedvaten en linker ventrikel ejectie fractie was geen onafhankelijke voorspeller voor 
een slechte prognose. De oorzaak hiervan blijft speculatief. Baks et al. toonde aan dat de 
aanwezigheid van obstructie van de kleine bloedvaten in segmenten van de hartspier 
geassocieerd zijn met het dunner worden van deze segmenten. Nijveldt et al. toonde 
aan dat een significant deel van de patiënten met obstructie van de kleine bloedvaten 
dilatatie en afname van de linker ventrikel functie vertoonde. Beide studies toonden aan 
dat obstructie van de kleine bloedvaten geassocieerd is met negatieve remodelering 
van de linker ventrikel. Het is opmerkelijk om te zien dat de grootte van het infarct van 
secundair belang is. Men moet zich realiseren dat infarct grootte en obstructie van 
de kleine bloedvaten en linker ventrikel functie nauw met elkaar zijn verbonden. Een 
groot infarct is geassocieerd met obstructie van de kleine bloedvaten en een slechte 
linker ventrikel ejectie fractie. In lijn met de studie is een recent gepubliceerde meta-
analyse van Stone et al. Op een vergelijkbare manier werden 10 individuele studies 
samen gevoegd. In deze studie werd ook een SPECT scan gebruikt om infarct grootte 
te bestuderen. De conclusie van deze studie was, dat infarct grootte een onafhankelijke 
voorspeller was voor het optreden van hartfalen en overlijden na een hartinfarct. De 
resultaten zijn relevant voor het opzetten van nieuwe studies. Routine gebruik van een 
MRI na infarct is echter op het moment een brug te ver. Op dit moment is er nog geen 
plaats in de diagnostische work-up van patiënten met een acuut coronair syndroom. In 
hoofdstuk 9 beschrijven de auteurs in detail hoe je een onderzoek kan opzetten om 
infarct grootte te beperken in patiënten met een hartinfarct. PORT (Post-conditioning 
Rotterdam Trial) testte de hypothese dat een catheterballon welke een aantal maal werd 
opgeblazen tijdens een dotterbehandeling, de infarct grootte zou kunnen beperken. 
Helaas werd deze studie teruggetrokken.
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sTUDIes IN PATIeNTeN MeT AANGeboReN HARTZIeKTeN 
MRI is een uitstekend diagnosticum om een aangeboren hartaandoening vast te stellen 
en om de behandeling te optimaliseren. De mogelijkheden van MRI kunnen overwel-
digend zijn, daarom moet er een specifieke vraag gesteld worden door de verwijzend 
specialist aan de radioloog en de laboranten om het juiste protocol in gebruik te nemen, 
aangezien verschillende puls sequenties overlappende informatie kunnen bevatten. Bij 
voorkeur moet de data worden gecheckt wanneer de patiënt in de MRI scanner bevind. 
In hoofdstuk 10 en 11 onderzochten we indicaties en complicaties van pacemaker 
therapie bij patiënten met een aangeboren hartaandoening. In deze grote multicenter 
studie, deelnemers: Erasmus MC, Rotterdam, Radboud Universiteit Nijmegen, Leiden 
Universitair Medisch Centrum en Universiteit ziekenhuis Leven, onderzochten de auteurs 
retrospectief naar complicaties. In hoofdstuk 10 demonstreerden we dat een atriaal 
gepaced systeem niet geassocieerd is met met een lage incidentie van ritmestoornis-
sen. In hoofdstuk 11 toonden we aan dat het per-procedurele complicatie cijfer van 
pacemaker implantaties hoger lag in vergelijking met de ‘algemene patiënten populatie’ 
(10.6% versus 5.2%). Dit suggereert dat het lastige procedure is bij patiënten met een 
aangeboren hartaandoening. Patiënten met een aangeboren complexe hartaandoe-
ning kregen vaker een epicardiaal (op het hart geplaatste leads) lead systeem, via een 
thoracotomie. Ongeveer een derde van de populatie ervaarde een pacemaker gerela-
teerde complicatie gedurende een mediaan follow-up van twaalf jaar. Een bekende late 
complicatie was lead-falen, welke een indicatie was tot interventie. 
CoNCLUsIes 
In dit proefschrift hebben we aangetoond dat met een cardiale MRI een prognose kan 
worden gegeven na een hartinfarct en na een dotterbehandeling. Obstructie van de 
kleine bloedvaten en de grootte van het hartinfarct waren voorspellers voor een slechte 
uitkomst. Verder was obstructie van de kleine bloedvaten een onafhankelijke voorspel-
ler voor overlijden in patiënten met een hartinfarct. In patiënten met therapie resistente 
hypertensie, verwezen voor renale denervatie, kan MRI uitstekend de grootte van de 
niervaten beoordelen. Dit kan met hoge accuraatheid en met hoge reproduceerbaar-
heid in vergelijking met IVUS. Met nieuwe MRI pulse sequenties in aantocht, is MRI een 
aantrekkelijke manier in de diagnostische work-up bij een vermoeden van een aange-
boren hartaandoening. Het optreden van per-procedurele complicaties in patiënten 
met een aangeboren hartaandoening was hoger dan in de ‘’algemene populatie’’, wat 
suggereert dat het een uitdagende ingreep is. 
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ToeKoMsTPeRsPeCTIeF
Een dotterbehandeling tijdens een hartinfarct leid niet altijd tot een optimale doorbloe-
ding van de hartspier. Gezien het onderzoek in dit proefschrift is het zogenoemde no-
reflow fenomeen een prognostisch ongunstig teken. Preventie van dit fenomeen is een 
cruciale stap om de prognose van een hartinfarct positief te beinvloeden. Verschillende 
strategieën worden geopperd, zowel mechanisch als medicamenteus, om dit te behan-
delen. Verder zou er onderzoek gedaan kunnen worden naar het succesvol opvolgen 
van leefstijl adviezen zoals roken, gezien dat het naast longkanker ook hart en vaatziek-
ten kan veroorzaken. Met MRI kan uitstekend obstructie van de kleine bloedvaten in 
beeld worden gebracht en waarschijnlijk gaat MRI een belangrijke rol spelen in experi-
mentele studies. Interessante ontwikkelingen zijn er in de diagnostiek van aangeboren 
hartaandoeningen in de vorm van speckle tracking echocardiografie en 4D flow MRI. 
Mogelijk kan er met speckle tracking hartfalen eerder worden gedetecteerd. Ook neemt 
de toepassing van MRI toe in het veld van structurele en/of verworven genetische hart-
afwijkingen zoals hypertrofische cardiomyopathie, non-compaction cardiomyopathie, 
gedilateerde cardiomyopathie en ARVC in de risicostratificatie en behandeling. Buiten 
beschouwing van dit proefschrift, blijft het interessant om te kijken vanuit een verzeke-
ringsoogpunt. Gezien de toename van gezondheidskosten voor de samenleving, denk 
alleen al aan atriumfibrilleren en ischemiedetectie, is onderzoek naar kosten-effectiviteit 
van behandelingen en ‘down-stream testen’ wellicht noodzakelijk. Het optreden van een 
hartstilstand is een belangrijk maatschappelijk probleem met een overlevingskans van 
ongeveer 10% wanneer een hartstilstand buiten het ziekenhuis optreed. Een boeiend 
project van Moment en collega’s is het inzetten van drones met AED’s om de uitkomst 
te verbeteren. Verder is een tekst message alert systeem en onderzoek naar subcutane 
ICD’s een kans om de prognose te verbeteren. Project management is essentieel om 
deze complexe projecten tussen meerdere afdelingen en belanghebbende succesvol 
af te sluiten. We hopen dat met onze inspanning uiteindelijk de diagnostiek, prognose 
en levenskwaliteit van patiënten met ischemische en congenitale aandoeningen zal 
verbeteren. 
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He was involved in detection of myocardial ischemia as measured by cardiac magnetic 
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AbbReVIATIoNs
Part 1: PReFACe
Chapter 1: Introduction
ACS = acute coronary syndrome
CMR = cardiac magnetic resonance
CT = computed tomography
STEMI = ST-elevation myocardial infarction
pPCI = primary percutaneous coronary intervention
MO = microvascular obstruction
IS%LV = infarct size expressed as percentage of left ventricle
LVEF = left ventricular ejection fraction
ECG = electrocardiogram
IHD = ischemic heart disease
CAD = coronary artery disease
GUCH = grown up population with congenital heart disease
RDN = renal denervation
MRA = magnetic resonance angiography
MACE = major adverse cardiovascular events
CHD = congenital heart disease
VSD = ventricular septal defect
ASD = atrial septal defect
TOF = tetralogy of fallot
CoA = coarctation of aorta
TGA = transposition of the great arteries
GRE = gradient echo
Part 2: VALIDATIoN oF MAGNeTIC ResoNANCe ANGIoGRAPHY AND CMR 4D 
FLoW IN PATIeNTs WITH ResIsTeNT HYPeRTeNsIoN AND CoNGeNITAL HeART 
DIseAse
Chapter 2: Validation of renal artery dimensions measured by magnetic resonance 
angiography in patients referred for renal sympathetic denervation.
RDN = renal sympathetic denervation 
CTA = computed tomography angiography 
MRA = magnetic resonance angiography
IVUS = intravascular ultrasound
3D = three-dimensional
TOF = time of flight
POC = polygon of confluence
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SD = standard deviation
OCT = optical coherence tomography
RAS = renal artery stenosis
2D = two dimensional
Chapter 3: Serial quantitative magnetic resonance angiography follow-up of renal artery 
dimensions following treatment by four different renal denervation systems.
MRA = magnetic resonance angiography
RDN = percutaneous renal sympathetic denervation
CTA = computed tomography angiography
MRI = magnetic resonance imaging
IVUS = intravascular ultrasound
OCT = optical coherence tomography
Chapter 4: Qualitative grading of aortic regurgitation: a pilot study comparing CMR 4D 
flow and echocardiography. 
CMR = cardiac magnetic resonance
4D = four dimensional
CMP = cardiomyopathy
Part 3: CARDIAC MAGNeTIC ResoNANCe IMAGING IN IsCHeMIC HeART DIseAse 
TRIALs 
ANIMAL sTUDIes 
Chapter 5: VEGF165A microsphere therapy for myocardial infarction suppresses acute 
cytokine release and increases microvascular density but does not improve cardiac 
function.
AMI = acute myocardial infarction
PEG-PBT = polyethylene-glycol/polybutylene terephthalate 
MSP = microsphere
TTC = tirphenyltetrazolium chloride
LCx = left circumflex coronary artery
DE-MRI = delayed enhancement MRI
MSPA = MSP treated area
Chapter 6: Multiple common co-morbidities produce left ventricular diastolic dysfunc-
tion associated with coronary microvascular dysfunction, cardiac oxidative stress and 
myocardial stiffening. 
HFpEF = heart failure with preserved ejection fraction
HT = hypertension
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HC = hypercholesterolemia
DM = diabetes mellitus
LV = left ventricular
MAP = mean aortic pressure
PAP = pulmonary artery pressure
PCWP = pulmonary capillary wedge pressure
CO = cardiac output
EDPVR = end-diastolic pressure volume relation
ESPVR = end-systolic pressure volume relation
IR-SPGR = inversion recovery spoiled gradient echo
LDL = low-density lipoprotein
HDL = high-density lipoprotein (HDL
ASAT = aspartate aminotransferase (ASAT)
ROS = reactive oxygen species 
NO = nitric oxide
NOS = nitric oxide synthase 
HUMAN sTUDIes
Chapter 7 and 8: Prognostic value of microvascular obstruction and infarct size, as mea-
sured by CMR in STEMI patients.
STEMI = ST-segment elevation myocardial infarction
pPCI = primary percutaneous coronary intervention
MO = microvascular obstruction
CE-CMR = contrast-enhanced cardiac magnetic resonance
LVEF = left ventricular ejection fraction
MACE = major adverse cardiovascular events
LV = left ventricular
IS%LV = infarct size expressed as left ventricular mass
TIMI = thrombolysis in myocardial infarction
CMR = cardiac magnetic resonance
IQR = interquartile range
HR = hazard ratio
aHR = adjusted hazard ratio
CI = confidence interval
AMI = acute myocardial infarction 
ICD = implantable cardioverter defibrillator
NSTEMI = non ST-elevation myocardial infarction
IS = infarct size
BMI = body mass index
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CABG = coronary artery bypass graft
CK = creatine kinase
CV = cardiovascular
LAD = left anterior descending
LCA = left circumflex artery
LVEDV = left ventricular end-diastolic volume
LVESV = left ventricular end-systolic volume
MI = myocardial infarction
PCI = percutaneous coronary intervention
RCA = right coronary artery
CE-CMR = contrast-enhanced cardiac magnetic resonance
Chapter 9: Ischemic postconditioning after routine thrombus aspiration during primary 
percutaneous coronary intervention: rationale and design of the POstconditioning Rot-
terdam Trial. 
IPOC = ischemic postconditioning
TA = thrombus aspiration
PORT = Postconditioning Rotterdam Trial
IRA = infarct related artery
MVO = microvascular obstruction
CK-MB = creatine kinase myocardial bound
AAR = area at risk
FFR = fractional flow reserve
IMR = index microcirculatory resistance
Part 4: oUTCoMe sTUDIes IN CoNGeNITAL HeART DIseAse
Chapter 10: Atrial-based pacing has no benefit over ventricular pacing in preventing 
atrial arrhythmias in adults with congenital heart disease. 
CHD = congenital heart disease
Ao valve = aortic valve
ASD = atrial septal defect
AVSD = atrioventricular septal defect
cc-TGA = congenitally corrected transposition of the great arteries
Ebstein = ebstein anomaly
PAPVR/TAPVR =  partial anomalous pulmonary venous return, total anomalous pul-
monary venous return
Pul Valve = pulmonary valve
SV = single ventricle
TGA = transposition of the great arteries
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ToF = tetralogy of fallot
VSD = ventricular septal defect
Chapter 11: Complications of pacemaker therapy in adults with congenital heart disease: 
A multicenter study. 
CHD = congenital heart disease
AV = atrialventricular
IQR = interquartile range
ASD = atrial septal defect
SSS = sick sinus syndrome
TGA = transposition of the great arteries
Ao valve = aortic valve
AVSD = atrioventricular septal defect
cc-TGA = congenitally corrected transposition of the great arteries
CoA = coarctation aortae
Ebstein = Ebsteins anomaly
PAPVR/TAPVR =  partial anomalous pulmonary venous return, total anomalous pul-
monary venous return
Pul valve = pulmonary valve
Single ventricle = single ventricle physiology (fontan)
ToF = tetralogy of Fallot
VSD = ventricular septal defect

